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Children with end stage liver disease are thought to have reduced lean mass and higher energy 
requirements. The aim of the study was to assess how body composition and energy 
requirements of children with end stage liver disease differ from those of healthy children and 
how they change after liver transplantation as well as to study for metabolic pathways that may 
be influencing the body composition. 
Body composition was assessed by various methods including basic anthropometry, stable 
isotopes, dual-energy X-ray absorptiometry (DXA) and air displacement plethysmography (BOD 
POD). Resting energy expenditure was assessed by indirect calorimetry. The patients were 
compared to age and sex matched healthy controls and were re-assessed at least 6 months 
after they received their liver transplant. Liver, muscle and fat tissue obtained at the time of 
transplant was assessed by microarray analysis of gene expression and validated with qPCR 
with a focus on metabolic pathways of glycolysis, lipolysis, insulin resistance and muscle 
atrophy and in particular the AMPK pathway (a cellular catabolic pathway). 
Seventeen patients and 14 healthy controls were recruited. Basic anthropometry showed that 
the patients had significantly lower weight and height. The deuterium, BOD POD and DXA 
measurements showed that whereas some children had lower lean mass, fat mass (FM) was 
preserved and remained within the normal range. Body mass index, mid upper arm 
circumference and FM indices were negatively correlated with stay in hospital post liver 
transplant. The presence of hypermetabolism was not different between patients and controls. 
The tissue studies distinguished a subgroup of patients with significant differences in their 
muscle and fat tissue. These differences were not related to catabolic pathways including 
AMPK, but were related to a pathway linked to inflammatory mediated insulin resistance 
involving interleukin-6. 
In this cohort of patients, in spite of lean mass reduction, fat mass was preserved and correlated 
with a shorter stay in hospital after liver transplantation. This is relevant information when 
deciding on appropriate nutritional management prior to transplantation. Some patients may 
develop insulin resistance as a mechanism of fat mass preservation during their chronic illness. 
This is the first time a possible mechanism for the insulin resistance described in these patients 
is identified. Further work would be required to confirm this finding and to link it with clinical 
evidence of insulin resistance.  
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Chapter 1 INTRODUCTION 
End stage chronic liver disease (ESCLD) has been defined as “the consequence of many 
chronic liver diseases, leading to irreversible impairment of liver function, architecture (cirrhosis) 
and blood supply” (Sokal et al., 2008). Liver transplantation is the only realistic treatment option 
for ESCLD. The liver is the most metabolically active organ which interacts with muscle and fat 
tissue via processes like gluconeogenesis, glycogenolysis, fatty acid oxidation, synthesis of 
lipoproteins, protein synthesis and protein degradation.  In spite of being only 1.5-2% of adult 
body weight, 20%-25% of our resting energy expenditure can be attributed to the liver (Muller, 
1998). ESCLD is known to affect body composition (Sinclair et al., 2016, Maharshi et al., 2015, 
Peng et al., 2007). 
 
Body composition in end stage chronic liver disease. 
1.1.1 Body composition of adults with ESCLD 
Patients with chronic liver disease and cirrhosis are known to suffer from protein- energy 
malnutrition (Lautz et al., 1992, Maharshi et al., 2015, Thandassery and Montano-Loza, 2016). 
This comes as a consequence of various factors. The most important are anorexia and fat 
malabsorption (Romiti et al., 1990, Beckett et al., 1980) due to cholestasis. Additional factors 
are prescribed low salt diets and micronutrient deficiencies contributing to dysgeusia (Reifen et 
al., 1998, Heckmann et al., 2005). The presence of organomegaly and ascites further contribute 
to feelings of fullness and discomfort whilst eating. 
Multiple studies in adults with cirrhosis have shown significant changes to body composition 
when compared to healthy controls (Peng et al., 2007, Vulcano et al., 2013, Riggio et al., 1997). 
These changes are reduction of lean mass (mainly skeletal muscle), reduction of total body fat, 
reduction of bone mineral density and an increase in extra cellular water. In addition these 
patients have been shown to have abnormal metabolic profiles with hypermetabolism, insulin 
resistance and abnormal protein metabolism (Kondrup and Muller, 1997, Selberg et al., 1993, 
Muller et al., 1999, Petrides et al., 1991). 
The reduction of skeletal mass is called sarcopenia. Sarcopenia has been described in male 
and female patients with cirrhosis, but tends to be more common in males (Riggio et al., 1997, 
Kim and Jang, 2015, Montano-Loza et al., 2012). Sarcopenia has been linked to worse 
outcomes both before (Montano-Loza et al., 2012, Selberg et al., 1997) and after liver 
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transplantation (Dimartini et al., 2013, Montano-Loza, 2014). Studies have shown that the 
presence of sarcopenia does not necessarily correlate with the disease severity (Figueiredo et 
al., 2005, Riggio et al., 2003, Hara et al., 2016) and may be present from the early stages of 
cirrhosis. 
Sarcopenic obesity is the term used to describe the presence of sarcopenia in an obese 
individual (Roubenoff, 2004). Two patients with the same body mass index (BMI) may have 
significantly different body composition. As obesity becomes more prevalent in our society, the 
risk of not identifying sarcopenia in patients with liver disease who could be obese increases. 
One study reported 56% of obese (BMI ≥ 30) cirrhotic patients to fulfil the criteria of muscle 
wasting on computed tomography (CT) as per established definitions for cancer patients (Cruz 
et al., 2013). 
Sarcopenia is important because it has been repeatedly shown to be associated with an 
increase in morbidity and mortality both before (Selberg and Selberg, 2002, Tandon et al., 2012, 
Montano-Loza et al., 2012) and after (Hamaguchi et al., 2014, Masuda et al., 2014, Kaido et al., 
2013, Englesbe et al., 2010, Tsien et al., 2014) liver transplantation. Montano-Loza et al 
(Montano-Loza et al., 2012) demonstrated that the presence of sarcopenia significantly reduces 
the median survival time before liver transplant from 34 months to 19 months and the presence 
of sarcopenia did not correlate with the severity of the liver disease. Further to this Tsien et al 
showed that after liver transplantation in a cohort of 53 patients sarcopenia increased from 
66.2% to 88.6% and was associated with an increase in mortality. The patients in this study 
were male and a significant proportion were receiving the transplant for hepatocellular 
carcinoma (HCC), nevertheless the study does raise awareness of the potential increase of 
sarcopenia post liver transplant. 
Loss of body fat is observed in patients with cirrhosis. Some studies report a more pronounced 
loss of body fat in the initial stages of the liver disease which is then followed by an increase in 
loss of body cell mass in the later stages regardless of the patient’s gender (Figueiredo et al., 
2005). Other studies claim that body fat is reduced in women with cirrhosis and that lean tissue 
is preserved, whereas men show a reduction in both lean and fat tissue (Riggio et al., 2003). 
These differences between the genders may reflect the different body composition make up of 
men and women; men naturally have more muscle and women have more fat. The variation in 
findings also has to do with the different study populations. In Riggio’s study, patients with HCC 
were excluded, so the study population suffered purely from cirrhosis. The patients were stable 
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cirrhotics, which was defined as patients with less than 5% of weight loss in the preceding 6 
months. In the Figueiredo study the patients had various diagnoses and were at different stages 
of disease. 
Liver disease is known to affect bone health. Patients with liver disease may suffer from hepatic 
osteodystrophy, a term used to describe the clinical manifestations of the metabolic bone 
disease. Pathogenesis appears to be diverse e.g. deficiency in 25-hydroxylation of vitamin D by 
the liver resulting in secondary hyperparathyroidism, deficiency of vitamin K required for making 
bone matrix protein, insulin growth factor 1 (IGF-1) deficiency or insensitivity (which is involved 
in osteoblast differentiation and proliferation), hypogonadism, medications particularly steroids, 
a sedentary lifestyle and poor nutrition (Lopez-Larramona et al., 2011, Stokes et al., 2013, 
Soylu et al., 2012). The prevalence of osteoporosis in adults with advanced liver disease is 
reported at 12-55% (Gatta et al., 2014) and again there is variation in the patterns of bone 
density loss reported. Some studies report a loss in bone mineral content (BMC) in females, but 
not in males (Figueiredo et al., 2005), whereas others report loss in bone mineral density (BMD) 
and BMC in male and females (Riggio et al., 1997). One cross sectional study that has looked 
at BMC before and after liver transplant, found no changes overall (Meys et al., 1994), but when 
they followed the same patients before and after transplant they found a 3.5% reduction in BMC 
after liver transplantation, as also reported by Gatta et al (Gatta et al., 2014). 
Fluid retention presenting as ascites or as whole body fluid retention and oedema is a common 
complication of ESCLD. Cirrhosis results in portal hypertension and splachnic vascular and 
peripheral arterial vasodilation thought to be due to an overproduction of nitric oxide. This then 
results in a reduction of effective cardiac output and an increase in antidiuretic hormone, 
stimulation of the sympathetic nervous system (SNS) and the renin- angiotensin-aldosterone 
system, all leading to sodium and water retention (Kashani et al., 2008).  Water retention is the 
main reason that makes basic anthropometry very difficult to use in these patients. Apart from 
an increase in their total body water, patients with cirrhosis exhibit a redistribution of their body 
water, with an increase in extracellular water (ECW) and a reduction in intracellular water (ICW) 
even before oedema is clinically evident (Figueiredo et al., 2005, Lehnert et al., 2001).  
Hypermetabolism has frequently been described in patients with cirrhosis. It is usually defined 
as an increase of the resting energy expenditure (REE) of the patient to over 120% of the 
predicted REE, as calculated by relevant equations or when compared to appropriately matched 
controls (Muller et al., 1999, Ferreira et al., 2013).  Basic metabolic rate (BMR) is the heat 
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production of the individual in a state of complete muscular repose 12-24 hours after the last 
meal, i.e. in the post-absorptive condition. Resting energy expenditure is the energy required by 
the body at rest, as measured in less strict conditions to BMR e.g. less hours of fasting. Only 
about 15-31% of patients are hypermetabolic (Muller et al., 1994b, Selberg et al., 1997) and 
some patients are in fact hypometabolic. Hypermetabolism does not seem to be associated with 
particular clinical or biochemical measures, but it has been linked to worse outcomes mainly 
before liver transplantation. Fewer studies have looked at hypermetabolism after transplantation 
particularly after the first 6 months. The studies that have looked into it show a persistence of 
hypermetabolism after liver transplantation and an association with poorer liver function (Muller 
et al., 1994b).  
Not all studies confirm the presence of hypermetabolism and some argue that, because total 
energy expenditure in cirrhotic patients is either normal or reduced (Riggio et al., 2003), 
possibly because of reduced physical activity, even if there was an increase in REE it would not 
be of clinical significance. Studies that have looked at energy intake and energy balance in 
patients with cirrhosis show that these patients do balance their expenditure with their intake, 
but that their expenditure is reduced in comparison to the healthy population allowing therefore 
for nutritional rehabilitation (Nielsen et al., 1993). Patients with HCC are generally accepted to 
be hypermetabolic (Chen and Chung, 1994) and therefore care needs to be taken when 
reviewing the literature that studies looking into energy expenditure take this into account. 
The reason hypermetabolism is interesting in cirrhosis, and indeed in other patients with chronic 
disease, is because it represents a maladaptation of the body to the reduction in caloric intake/ 
caloric absorption. In starvation and in anorexia nervosa people tend to reduce their REE, 
something which is not the case in these chronically ill patients (Muller et al., 1994a).This 
hypermetabolism, or even surprisingly ‘normal’ REE implies that there are other metabolic 
disturbances inherent to the disease process influencing the metabolic rate. The variance in 
REE is influenced by body cell mass, age, sex and genetic make-up (Ravussin and Bogardus, 
1989). There is some experimental evidence to show that as portal venous flow to the liver 
reduces, hepatic energy expenditure reduces as well, but at the same time whole body energy 
expenditure increases (Muller et al., 1994a). Linking this to what was previously mentioned 
when discussing fluid retention in chronic liver disease, it may be that the increase in cardiac 
output and sympathetic nervous system (SNS) stimulation may explain the increase in whole 
body energy expenditure. 
21 
 
Apart from aberrations in energy metabolism, aberrations are noted in substrate metabolism. 
Cirrhotic patients have been shown consistently to be insulin resistant (Selberg et al., 1993, 
Petrides et al., 1991). The insulin resistance has been shown to be a reflection of reduced 
glycogen synthesis and reduced insulin dependent glucose transport into the muscle cells 
(Selberg et al., 1993, Petrides et al., 1991) and not due to hepatic insulin resistance. Even 
though fat intestinal absorption, particularly in cholestatic patients, is reduced, fat metabolism 
has been shown to be normal (Kondrup and Muller, 1997). The patients rely on fat oxidation for 
energy, most likely because glycogen levels in the liver are depleted (Muller et al., 1992a, 
Greco et al., 1998). Protein requirements for patients with liver disease are at least that of 
normal individuals or higher, in contrast to malnourished people without underlying disease, 
who have reduced protein requirements (Nielsen et al., 1995). To try and understand the reason 
for this, one study compared cirrhotic patients with an increased protein requirement to those 
with a normal protein requirement. It found that the patients with the increased protein 
requirements had an increase in protein degradation, perhaps due to reduced insulin-like 
growth factor 1 (IGF-1) levels (Kondrup et al., 1997). 
IGF-1 is the main mediator of the effects of growth hormone (GH) and is exclusively made in the 
liver. It is therefore not surprising that circulating IGF-1 levels are low in liver disease (De Palo 
et al., 2001, Yoshida et al., 2003). Whereas the liver and fat cells only have insulin receptors, 
muscle cells have insulin and IGF-1 receptors. IGF-1 in muscle increases the uptake of amino 
acids and protein synthesis in muscle. Therefore low IGF-1 levels could contribute to the 
mechanism of muscle wasting seen in chronic liver disease. In recent years many more 
hormones and their role have been studied in liver disease. Particular interest has been aimed 
at adipokines like leptin and adiponectin. Leptin has been noted to be reduced in end stage liver 
disease and serum levels of adiponectin have consistently been noted to correlate with severity 
of liver fibrosis (Kalafateli et al., 2015, Roberts et al., 1998, Dornelles et al., 2013). 
End stage chronic liver disease can be effectively managed with liver transplantation. This 
comes with its own complexities, but it does achieve excellent outcomes for the patients with 
very good post-transplant survival rates. Increasingly studies are looking into the effect of liver 
transplantation on body composition of patients. One study demonstrated, at a median of 2 
years post liver transplant, a prevalence of sarcopenic obesity at 88% with half of the patients 
fulfilling the criteria of metabolic syndrome (Choudhary et al., 2015) and, as mentioned earlier, 
sarcopenia seems to remain a feature post liver transplant as well. Another study measured 
22 
 
with dual-energy X-ray absorptiometry (DXA) an increase of 4.75% in fat mass a year after liver 
transplant (Meys et al., 1994). These are all important findings. Previously it was thought that as 
the liver disease is ‘removed’ with the change of the native liver, the nutritional and metabolic 
issues would also resolve. As liver transplant recipients enjoy an increase in survival, it 
becomes more important to know how their body composition is affected and what implication 
this has for their long term health and well-being. 
1.1.2 Body composition of children with ESCLD 
Studies in children with liver disease are limited, but they also indicate alterations in body 
composition. Studying body composition in children is challenging as the various measurements 
have to be adjusted for age and the availability of normal data for comparison is not always 
possible. Particularly in the context of liver disease it has long been established that due to 
organomegaly and the possible presence of fluid retention and ascites, as with adults so with 
children, basic anthropometry measures like weight underestimate the presence of malnutrition 
(Trocki et al., 2000).  
Greer et al (Greer et al., 2003) studied 21 children with end stage liver disease awaiting liver 
transplantation and compared them to 15 age and sex matched controls. These children were 
found to have a reduction in total body fat, an increase in extracellular water, but no significant 
difference in body cell mass (muscle and solid organ mass), as measured by total body 
potassium. The percentage of body cell mass per body weight was increased. REE, when 
expressed per body weight, was higher than in controls by 27%, presumably because a higher 
percentage of this body weight was now active muscle and solid organ mass rather than fat 
tissue. When REE was expressed per body cell mass it was again increased in comparison to 
healthy controls by 16%. This could be explained if there was a reduction in the body cell mass 
(BCM), but this was not seen in this study. Alternatively the increase in REE/BCM could be 
because of a change in energy metabolism related to the disease itself. In Greer’s study only 
average REE between the two groups is reported, but looking at the range of the values for 
REE there is overlap between the patients and the controls. This implies that even though on 
average the patients had a higher REE than the controls, this is not necessarily the case at an 
individual level for all the patients. The study of Chin et al of 27 children with end stage liver 
disease did demonstrate a reduction in body cell mass, as total body potassium of the patients 
was 63% of the expected for age and sex (Chin et al., 1992). An older study of 11 infants with 
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extra hepatic biliary atresia by Pierro et al has demonstrated a 29% higher REE than expected 
for weight (Pierro et al., 1989). 
At this point a particular group of patients with chronic liver disease needs to be mentioned, it is 
that of children with Alagille syndrome. This syndrome is genetically inherited and growth 
faltering has been described even when these patients are compared to patients with biliary 
atresia. They tend to be stunted with lower weight and lower fat and muscle mass (Arvay et al., 
2005). They have not been shown to be hypermetabolic (Rovner et al., 2006). 
After paediatric liver transplantation it has been shown that weight gain and appropriate growth 
is usually achieved, even though it may take a few years before height standard deviation (sd, 
or otherwise known as z) scores catch up (Holt et al., 1997, van Mourik et al., 2000). Poor graft 
function is associated with poor growth post-transplant (Holt et al., 1997), but it is not known 
how this relates to pre transplant body composition and energy metabolism. Increasingly 
studies are showing that after transplantation some patients accumulate fat e.g. after 
haematopoietic stem cell transplant (HSCT) in childhood 15.6% of patients develop insulin 
resistance and central fat adiposity in adulthood (Bizzarri et al., 2015). A recent study that has 
looked at BCM of children before and after liver transplantation (median time post-transplant 
7.23 years) found that even though weight had increased and was now in the normal range, 
there was no increase in BCM (Ee et al., 2014), indicating that the catch up in weight was due 
to an increase in fat mass. To our knowledge, no studies so far have looked at REE after liver 
transplant in children. 
In summary, faltering of growth has been described in children with chronic liver disease with 
various changes in fat tissue and lean mass. Most previous studies have suggested that 
children with chronic liver disease are hypermetabolic. There have been some data to suggest 




1.1.3 Definition of cachexia 
This change in body composition, as previously indicated, can be explained to a degree by 
malnutrition. Malnutrition implies that by correcting the caloric and nutrient insufficiency body 
composition will return to normal. It is now known from observations and studies in a variety of 
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chronic diseases that there is another process occurring, frequently with malnutrition, a process 
termed cachexia. Cachexia, is “a complex metabolic syndrome associated with underlying 
illness and characterized by loss of muscle with or without loss of fat mass. The prominent 
clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure 
in children (excluding endocrine disorders). Anorexia, inflammation, insulin resistance and 
increased muscle protein breakdown are frequently associated with wasting disease. Wasting 
disease is distinct from starvation, age-related loss of muscle mass, primary depression, 
malabsorption and hyperthyroidism, and is associated with increased morbidity” (Evans et al., 
2008). The hallmark of cachexia is that the muscle wasting cannot be fully reversed by 
supplementation of calories (Casaer, 2015, Ries et al., 2012, Fearon et al., 2011). Cachexia, in 
the context of cancer, has been further classified as pre-cachexia (weight loss ≤ 5%), cachexia 
(weight loss > 5%) and refractory cachexia (Fearon et al., 2011). It may be that pre- cachexia is 
the stage where most interventions would be most effective.  
A more practical consensus definition of cachexia has been reached to help physicians 
diagnose the condition and also to help for recruitment to studies. In adults, cachexia can be 
diagnosed if there has been at least 5% weight loss in the last 12 months or less (or the BMI < 
20 kg/m2) and at least 3 of the following 5 conditions are met: presence of decreased muscle 
strength, fatigue, anorexia, low fat free mass index (mid upper arm circumference (MUAC) < 
10th centile for age and sex, appendicle skeletal mass index by DXA in kg/m2 under 5.45 in 
females and 7.25 in males)  and/or abnormal biochemistry e.g. increased inflammatory markers 
like C-reactive protein (CRP) and interleukin 6  (IL6), anaemia (haemoglobin (Hb) < 12 g/dL) 
and low serum albumin (< 32 g/dL) (Evans et al., 2008). In addition various studies have helped 
create cut offs for what can be considered normal lean mass on imaging for men and women 
(Kazemi-Bajestani et al., 2016). Unfortunately for children there are no established criteria. 
Growth is an essential consideration in defining cachexia for children. Growth parameters in 
children are usually expressed in centiles or standard deviation scores (known as sd or z 
scores) to allow comparison between different age groups. Looking in the literature various cut 
offs have been used for children e.g. failure of linear growth, BMI < 5th centile, body fat % less 
than 10% or a minimum 5% weight loss from the highest previous weight or an ideal weight for 
height equal or under 90% (Cuvelier et al., 2014, Mak et al., 2012). 
Defining cachexia is important for its diagnosis in the clinical setting and for deciding inclusion 
criteria of patients in the research setting. A plethora of studies have shown the presence of 
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cachexia to be linked to worse outcomes for many chronic diseases (Narumi et al., 2015, Celli 
et al., 2008, Fearon et al., 2006) and because of this cachexia is being studied in cancer, 
chronic heart failure, end stage renal disease, chronic obstructive pulmonary disease and many 
other diseases. A lot of effort has been dedicated to delineating the molecular mechanisms of 
cachexia the last two decades. 
1.1.4 Molecular mechanisms of cachexia 
The molecular mechanisms of cachexia are complex and not fully understood. These 
mechanisms involve the central nervous system (CNS) and in particular the hypothalamus, the 
muscle tissue, the fat tissue and the communications between these systems with the 
autonomic nervous system, the hormones and the cytokines of the inflammatory cascade 
(Mendes et al., 2015, Schiaffino et al., 2013, Bing and Trayhurn, 2009, Onesti and Guttridge, 
2014). 
1.1.4.1 The Central Nervous System (CNS) in cachexia 
The brain controls body homeostasis mainly through the hypothalamic melanocortin system 
(Garfield et al., 2009). Anorexia, reduced appetite, is one of the hallmarks of cachexia. In the 
hypothalamus reside neurons that directly affect appetite. Pro-opiomelanocortin (POMC) and 
cocaine and amphetamine regulated transcript expressing (CART) neurons decrease appetite 
whilst Agouti related peptide expressing (AgRP) and neuropeptide Y (NPY) neurons increase 
appetite. Proopiomelanocortin (POMC) neurons produce -melanocyte-stimulating hormone (-
MSH) which stimulates the type 4 melanocortin receptors (MC4R) (Tao, 2010) with anorexigenic 
actions whilst AgRP acts as an inverse agonist of the MC4R (Tolle and Low, 2008). This system 
integrates local and systemic signals of energy status in health and illness. During illness the 
body has to adjust its metabolic processes to meet the energy demand of the acute phase 
response. As part of this adjustment, particularly when it is dealing with chronic inflammatory 
conditions, it may end up in a catabolic state with lipolysis of adipose tissue and muscle break 
down. The pro-inflammatory cytokines tumour necrosis factor α (TNFα) and interleukin 1β (IL-
1β) have been shown to have increased levels of expression in the hypothalamus in models of 
cachexia. When given via intra-cerebroventricular (ICV) injection they can induce skeletal 
muscle wasting (DeBoer et al., 2009, Arruda et al., 2010). Other cytokines have been less 
studied and e.g. IL6 seems to have a more elusive role. IL6 expression increases in the 
hypothalamus during inflammation, but it is not known how it affects muscle mass at the same 
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time particularly as in the periphery it has been shown to be involved in muscle wasting as well 
as muscle recovery and regeneration (Fuchs et al., 2013, He et al., 2009, Toth et al., 2011). 
The neuroendocrine system is another way the brain participates in whole body energy balance 
and metabolism. The hypothalamus, in response to stress, produces corticotrophin releasing 
hormone (CRH), which then increases production of adrenocorticotrophic hormone (ACTH) 
leading to release of cortisol by the adrenals. Increased cortisol levels have been described in 
cachexia (Tzanis et al., 2014) and cortisol can directly affect muscle break down and lipolysis. 
The hypothalamus also controls release of the thyroid hormones via the release of thyrotropin 
releasing hormone (TRH). TRH increases in the hypothalamus after injection of TNFα in the 
hypothalamus (Arruda et al., 2010), but peripheral increase of thyroid hormones have not been 
confirmed in patients with cachexia (Creutzberg and Casaburi, 2003). The hypothalamus also 
participates in the GH/IGF-1 axis by producing growth hormone releasing hormone (GHRH). 
Most studies report low IGF-1 levels in cachexia and a peripheral resistance to GH (Anker et al., 
2001, Jenkins and Ross, 1996). Last but not least of the hormones controlled by the 
hypothalamus are the sex hormones and as previously mentioned hypogonadism is a key 
feature of cachexia for both men and women and in men could be one of the contributing 
factors to muscle loss (Vigano et al., 2010). Other hormones that feed into the hypothalamus 
are leptin and ghrelin. In cachectic patients leptin levels have been found to be decreased and 
ghrelin levels increased. However energy intake does not increase as one would expect, 
suggesting an altered hypothalamic response to these hormones (Itoh et al., 2004, Xin et al., 
2009). 
The melanocortin system also mediates the anorexigenic effects of serotonin. Serotonin-
induced hypophagia requires MC4R, with no effect seen in MC4R knockout mice (Heisler et al., 
2006). Increased levels of tryptophan, the precursor of serotonin, have been found in the 
plasma and cerebrospinal fluid of patients with anorexia, cancer cachexia and liver cirrhosis 
(Cangiano et al., 1990, Laviano et al., 1997). Tryptophan metabolism is profoundly affected by 
inflammatory mediators (Freitas et al., 2001). 
In more recent years interest has shifted to how these inflammatory signals are communicated 
to the hypothalamus and how signals of acute inflammation transition to chronic inflammation 
with the involvement of non-neuronal cells. Microglia, the macrophages of the CNS, are now 
thought to be activated by the cytokines and then in turn produce more cytokines and 
chemokines that then affect the neurons. In a similar way, the endothelial cells of the CNS 
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vessels, in response to peripheral cytokines, produce more cytokines and also cell adhesion 
molecules (selectins) for the binding of leucocytes (via their integrins), as well as chemokines 
like C-C motif chemokine ligand 2 (CCL2) for the attraction of leucocytes. This process further 
generates cytokines that bind to neuronal receptors (Molfino et al., 2015, Burfeind et al., 2016) 
The other way the CNS communicates with the periphery is with the autonomic nervous system 
(ANS). Through vagal afferents to the brainstem (Appleyard et al., 2005), in a rat model of 
cancer-induced anorexia, autonomic relay brainstem regions are activated independently of any 
increase in systemic cytokines (Ruud and Blomqvist, 2007). Intraperitoneal lipopolysaccharide 
administration activates adrenergic and noradrenergic neurons of the nucleus tractus solitarius 
(Gaykema et al., 2009), suggesting vagal input perhaps secondary to local inflammation 
(Laviano et al., 2008, Tracey, 2007). Via the SNS it can directly affect substrate metabolism and 
influence triglyceride synthesis and white adipose tissue fat accumulation, as well as glucose 
homeostasis (Rossi et al., 2011, Parton et al., 2007). It also regulates the activity of brown 
adipose tissue (BAT), which has an important role in thermogenesis (Cypess et al., 2009). BAT 
is now thought to have a functional role in adults and not just in neonates as previously thought. 
Retrograde tracers have demonstrated connections between BAT and nuclei involved in energy 
homeostasis many of which express MC4R (Voss-Andreae et al., 2007).  ICV administration of 
melanocortin agonists increases BAT thermogenesis and lipolysis of white adipose tissue (Brito 
et al., 2007). BAT is emerging as a key player not only for the development of cachexia and 
hypermetabolism, but also as a counter balance and potential therapeutic target for the 
overcoming of obesity. 
In summary, the hypothalamus is key to whole body energy and metabolic control. It is affected 
by acute and chronic inflammatory signals from the periphery during illness and it orchestrates 
its response via the ANS and the endocrine system. In this way it instigates skeletal muscle 
proteolysis and adipose tissue lipolysis in an effort to provide for the body a valuable source of 
amino acids and energy respectively to fuel the acute phase response and the expansion of the 
immune system required in these situations.  
1.1.4.2 Muscle wasting and cachexia 
Muscle wasting is one of the hall marks of cachexia (Bowen et al., 2015, Fearon et al., 2011). 
Muscle wasting results from a change in the balance between protein synthesis/ muscle 
hypertrophy and protein degradation/ muscle atrophy. Two major pathways are implicated in 
muscle hypertrophy: the IGF-1/P13K/Akt/mTOR pathway and the myostatin pathway, whilst 
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three major pathways are implicated in muscle atrophy: the proteasomal pathway (responsible 
for the degradation of extracellular proteins and cell receptors), the calcium activated pathway 
(involved in tissue injury, necrosis and autolysis) and the autophagic- lysosomal pathway (which 
degrades the majority of cellular proteins) (Tisdale, 2009, Lecker et al., 1999, Schiaffino et al., 
2013).  Each of these pathways are implicated in cachexia (Figure 1.1). 
In the IGF-1/PI3K/Akt/mTOR pathway (Egerman and Glass, 2014), IGF-1 binds to the IGF-1 
receptor which then binds with insulin receptor substrate -1 (IRS-1). Once IGF-1 has activated 
IRS-1, phosphoinositide 3-kinase/ protein kinase B (PI3K/Akt) is activated. (IGF-1 also activates 
the mitogen activated protein kinase / extracellular signal regulated kinase MAPK/ERK, but this 
relates more with muscle differentiation than muscle hypertrophy (Keren et al., 2006)). PI3K/Akt 
activation results in the activation of the mechanistic target of rapamycin (mTOR) pathway and 
also in the inhibition of glycogen synthase kinase β (GSK3β). mTOR is part of two complexes: 
the rapamycin sensitive mTOR complex 1 (mTORC1) containing raptor and the rapamycin 
insensitive mTOR complex 2 (mTORC2) containing rictor. mTORC2 mostly works by activating 
Akt. mTORC1 exerts its downstream actions by activating S6 kinase 1 (S6K1) and inhibiting 
eukaryotic translation initiation factor 4E- binding protein 1 (4E-BP1) leading to the activation of 
eukaryotic initiation factor 4E (eIF4E), a key initiator of translation (Shah et al., 2000). It is very 
important to note here that amino acids, and in particular leucine, are also able to independently 
activate S6K1 and therefore promote muscle growth (Duan et al., 2015). The inhibition of 
GSK3β mentioned previously also has the net effect of activating translation initiator eukaryotic 
initiation factor 2B (eIF2B) (Rommel et al., 2001) and promoting muscle growth.  
IRS-1 is key in mediating the effects of IGF-1 (Bohni et al., 1999). Without IRS-1 the 
downstream effects of IGF-1 cannot happen. After IRS-1 activation, the subsequent activation 
of PI3K results in inactivation of IRS-1 and helps regulate the pathway (Zhande et al., 2002). 
Various proteins are known to ‘mark’ IRS-1 for degradation. Suppressor of cytokine signalling 1 
and 3 (SOCS1 and SOCS3) are two of them and they are thought to mediate inflammatory 
related insulin resistance (Rui et al., 2002) whereas in conditions of protein scarcity, IRS-1 is 
degraded by F-box protein 40 (Fbxo40) (Shi et al., 2011). 
Myostatin is a skeletal muscle specific member of the Transforming Growth Factor β (TGF-β) 
superfamily, also known as growth differentiation factor 8 (GDF 8), and is a negative regulator 
of muscle growth. Myostatin, together with similar acting activin-A and growth differentiation 
factor 11, act through the activin receptor IIB (ActRIIB). Experiments in tumor bearing mice have 
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shown reversal of muscle wasting by blocking ActRIIB activation (Zhou et al., 2010, Benny 
Klimek et al., 2010). Myostatin released into the circulation by the heart in chronic heart failure 
is implicated in muscle wasting (Breitbart et al., 2011). Not all studies though in humans confirm 
higher levels of circulating myostatin in cachexia (Loumaye et al., 2015). Binding of myostatin to 
its receptor leads to activation of SMAD 2 and 3 signalling mediators which translocate to the 
nucleus to regulate pro-atrophy gene expression (Sartori et al., 2009). Myostatin stimulation 
also leads to inhibition of PI3K/Akt and mTOR (Trendelenburg et al., 2009).  
From the three systems of protein degradation in skeletal muscle, the ubiquitin-proteasome 
system (UPS) which degrades the majority of cellular proteins is thought to be the most involved 
in cachexia. The UPS system involves an adenosine triphosphate (ATP) dependent process of 
tagging protein substrates with molecules of ubiquitin. Proteins called E3 ubiquitin protein 
ligases are important for this ‘tagging’. The polyubiquinated substrate protein is then recognised 
by the proteasome and degraded (Dahlmann, 2007).Two E3 ubiquitin protein ligases have been 
identified to be highly expressed in animal models of muscle atrophy in catabolic conditions 
(fasting, diabetes mellitus, renal failure and tumor implantation): muscle atrophy F box (MAFbx) 
(or atrogin-1) and muscle RING finger 1 (MURF1) (Lecker et al., 2004). MURF-1 has been 
shown to bind and ubiquitinate myosin filaments whereas MAFbx proteolyses the transcription 
factor eukaryotic initiation factor 3f (eIF3f). Inhibition of MAFbx activity attenuated muscle loss in 
fasting mice (Cong et al., 2011) as did MURF1 inhibition in cellular models (Eddins et al., 2011). 
Stimulation of Akt inhibits the upregulation of MAFbx and MURF 1 by the forkhead box O 
(FOXO) transcription factors, thus Akt has a role in inhibiting proteolysis, as well as facilitating 
protein synthesis (Glass, 2005). 
The ubiquitin-proteasome system is the system considered responsible for mediating most of 
the muscle atrophy in cachexia. There is though evidence to suggest that calcium dependent 
proteolysis via e.g. calpains also has a role (Costelli et al., 2001), as does lysosomal protein 
degradation via autophagy. Even though defects in autophagy have been linked to muscular 
dystrophies for many years, only recently has autophagy been studied in muscle atrophy. The 
lysosomal-autophagy system is controlled by the FoxO transcription factors, particularly FoxO1, 
3 and 4. The absence of nutrients ignites autophagy, and the formation of the autophagosome, 
but in FoxO 1, 3, 4 -/- mice this does not happen (Milan et al., 2015). In addition, Akt 
dephosphorylates FoxOs causing them to translocate from the nucleus to the cytoplasm, 
whereas when Akt is reduced, FoxOs remain in the nucleus causing upregulation of the 
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proteasome related atrogenes as well as autophagy related genes (Zhao et al., 2008). FoxOs 
are important in regulating both pathways of protein degradation. 
In regards to the muscle atrophy associated with cachexia, we know that anorexia can be 
associated with reduced protein synthesis through reduced food intake. Nevertheless anorexia 
cannot explain the muscle wasting in isolation. In mouse models of cachexia there is more 
muscle wasting in the diseased mice than in the pair fed healthy control group (Baracos et al., 
1995). Other mechanisms thought to be triggering muscle atrophy are reduced activity, potential 
treatment with steroids (mainly via reduced mTOR activity) and of course the presence of 
inflammation. Pro-inflammatory cytokines e.g. TNFα mediate muscle wasting via the activation 
of the transcription factor nuclear factor κβ (NFκβ) (Peterson et al., 2011), which leads to an 
increase in the expression of MuRF1. Pro-inflammatory cytokines also result in insulin 
resistance (Hirosumi et al., 2002) and therefore suppression of protein synthesis via 
suppressing the IGF-1/P13K/Akt pathway previously described. 
The presence of muscle wasting is one of the key predictors of outcomes in chronic disease. 
Understanding the molecular pathways underpinning muscle wasting in cachexia is very 
important for the development of therapeutic targets. Potential treatments under development 
aiming to increase muscle mass and function include myostatin inhibitors, nutritional 
supplements like leucine, selective androgen receptor modulators and of course exercise. An 
important area of emerging research though is also the cross talk between muscle and other 




Figure 1.1 The main mechanisms of muscle atrophy in cachexia.  
There are four mechanisms contributing to muscle atrophy; reduced protein synthesis, 
increased proteolysis by the ubiquitin proteasome system, increased autophagy and an 
upregulation of the negative muscle growth factor, myostatin. 
IGF-1 insulin growth factor-1, IRS-1 insulin receptor substrate-1, PI3K phosphoinositide 3 
kinase, Akt protein kinase B, UPS ubiquitin proteasome system, MuRF1 muscle RING 
finger 1, MAFbx muscle atrophy F box, FoxO 1,3,4 forkhead box 1,3,4. 
 
1.1.4.3 Adipose tissue in cachexia 
Depletion of fat mass is common in cachexia and frequently precedes the muscle loss. Adipose 
tissue is well known as the energy store of the body, with fat percentage ranging from 5-70% 
(Hausman et al., 2001). In the last couple of decades though far more interesting roles for 
adipose tissue in influencing energy balance are emerging. Two processes control adipose 
tissue mass: formation of stored fats with triacylglycerol (TAG) synthesised from dietary and 
endogenous non-esterified fatty acids (NEFAs), and breakdown of these stores through 
lipolysis, generating NEFAs and glycerol to be used as energy substrates. The main 
mechanism thought to be implicated in cachexia is increased lipolysis rather than decreased 
lipogenesis or adipocyte cell death (Ryden et al., 2008). Lipolysis is controlled by several 
enzymes: adipocyte triglyceride lipase (ATGL) removes the first fatty acid (FA) from 
triacylglycerol, and then the rate-limiting enzyme in lipolysis, hormone-sensitive lipase (HSL), 
removes the second. A third enzyme, monoacylglycerol (MAG) lipase removes the final fatty 
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acid to produce in total 3 NEFAs and 1 glycerol per triacylglycerol molecule. Lipolysis is 
stimulated by the sympathetic nervous system and is also influenced by hormones e.g. insulin 
down regulates the lipases (Blaszkiewicz and Townsend, 2016). 
Inflammation is again key in generating lipolysis in the context of cachexia. Raised levels of IL-6 
and its downstream products have been seen in mouse models of cancer cachexia. One study 
on humans showed that lipolysis was responsible for the weight loss in cancer, but that the 
raised levels of IL-6 in the circulation were not matched with raised IL-6 in the adipocytes 
(Ryden et al., 2008). TNF-α also increases lipolysis by downregulating perilipin (PLIN) (Ryden 
et al., 2004); PLIN is a protein that coats the fat droplets, binds to the lipolytic enzymes and 
prevents them from being activated. Particularly in cancer cachexia, lipolysis has also been 
strongly linked to the lipid mobilising factors e.g. zinc alpha-2 glycoprotein (increased in cancer 
cachexia) (Todorov et al., 1998). 
In the more recent years research has focused on understanding the role of brown adipose 
tissue and also the process of ‘browning’ of white adipose tissue (WAT).  WAT is what we 
mostly know as adipose tissue. WAT is known either as visceral or subcutaneous depending on 
its location. White adipocytes contain one large droplet of fat. BAT in adult humans is mostly 
found in the neck. Brown adipocytes contain multiple small fat droplets and are rich in 
mitochondria. They are stimulated by the SNS to generate heat as a response to cold exposure. 
This is done via uncoupling protein 1 (UCP1). UCP1 is located in the inner mitochondrial 
membrane and it can dissipate the proton gradient generated by the reactions of the citric acid 
cycle before it can be used to provide the energy for oxidative phosphorylation, thus releasing 
energy as heat. Whereas white adipocytes originate from endothelial cells, brown adipocytes 
have a completely different lineage and originate from mesenchymal cells that are also 
precursors for skeletal muscle (Sanchez-Gurmaches and Guertin, 2014). In addition, it has 
become apparent that some white adipocytes also share precursors similar to brown adipocytes 
and these are now called ‘brite’ adipocytes. They tend to increase in numbers when the body is 
exposed to cold or to β-adrenergic agonists (Sanchez-Gurmaches and Guertin, 2014). We also 
need to mention the presence of adipocytes in the muscle, a feature of various muscular 
dystrophies. In mouse models these have been shown to express high levels of UCP1 when 
induced by bone morphogenetic protein 7 (BMP7) (Almind et al., 2007). 
Adipose tissue is no longer thought to be a passive store of energy for the body and is now 
considered a very active and important endocrine organ. The two most studied adipokines 
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produced by adipose tissue are leptin and adiponectin. Leptin reduces food intake via its 
receptors in the hypothalamus, increases glucose metabolism in the body whist decreasing 
glycogen content in the liver without an increase in insulin and it stimulates fatty acid oxidation 
in skeletal muscle (Harwood, 2012). Low leptin levels are associated with increased fat mass in 
healthy individuals, but in cachexia leptin levels are low in spite of reduced fat mass 
(Smiechowska et al., 2010). Adiponectin has a strong negative correlation with the amount of fat 
mass and low levels of adiponectin are linked to insulin resistance. There are two receptors for 
adiponectin, one expressed in the liver and one in skeletal muscle. Adiponectin is able to 
increase insulin sensitivity by reducing glucose production by the liver and by increasing fatty 
acid oxidation in the liver and muscle (Harwood, 2012). Paradoxically though high adiponectin 
levels are associated with cardiac cachexia (McAloon et al., 2016). 
In summary, fat loss is an important feature of cachexia with a prognostic significance for 
cachexia inducing diseases. The primary mechanism involved is lipolysis, but adipose tissue 
also has an important role in cachexia because of its role in energy balance and because of the 
cross talk between adipose tissue, the brain, the skeletal muscle and the liver. 
1.1.4.4 The role of the liver in cachexia 
The liver is key to many metabolic processes of the body. Less is known about the role of the 
liver in the development of cachexia when compared to other tissues like skeletal muscle and 
adipose tissue. The liver is responsible for the acute phase response. This means that, when 
there is inflammation in the body, the liver has to shift to synthesizing acute phase proteins like 
CRP, serum amyloid A (SAA) etc. In fact amino acids like alanine from muscle proteolysis are 
diverted to the liver for gluconeogenesis and protein synthesis (Argiles et al., 1997). The liver, 
as previously mentioned, contributes significantly to the whole body energy expenditure and 
increases in resting energy expenditure have been reported in cachexia. There is experimental 
evidence to indicate that adenosine triphosphate (ATP) synthesis in liver mitochondria is 
inefficient in cancer cachexia (Tsuburaya et al., 1995, Hochwald et al., 1996) and this seems to 
be related to cardiolipin content of the hepatic mitochondria and is affected by stimulation by 
TNFα (Peyta et al., 2015, Julienne et al., 2014). 
Insulin resistance has been frequently described with chronic disease and is therefore 
associated with cachexia, but not a defining feature of cachexia. The insulin resistance noted 
may be hepatic (e.g. in sarcopenic obesity) (Bhanji et al., 2017) or may be peripheral (muscles) 
(Cleasby et al., 2016). Most commonly in the context of cachexia it is peripheral and in cirrhosis 
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it has been well described that the insulin resistance is peripheral and not hepatic (Selberg et 
al., 1993). 
In summary, as pictured in Figure 1.2, inflammation is a key process driving catabolism in 
cachexia. Chronic disease with chronic inflammation results in neuroinflammation and this in 
turn results in muscle wasting, because of accelerated proteolysis and reduced protein 
synthesis, fat loss, because of lipolysis and an increase in energy expenditure. One of the key 
metabolic pathways controlling energy balance in our cells is that of AMPK. 
 
 
Figure 1.2 The multiple interactions leading to cachexia.  
A variety of chronic diseases like cancer, COPD, CHF etc. can trigger the development of 
cachexia through an increase in cytokines, in ROS and by causing an endocrine imbalance. 
These in turn can mediate signals to the hypothalamus either directly or via the vagus nerve 
and directly to peripheral organs like the liver, the muscle and the adipose tissue. In addition, 
the hypothalamus communicates changes to the periphery via the SNS. The net result is 
anorexia and perturbations of metabolism consistent with catabolism. 
COPD chronic obstructive pulmonary disease, CHF chronic heart failure, CRF chronic 
renal failure, CLD chronic liver disease, RA rheumatoid arthritis, ROS reactive oxygen 
species, SNS sympathetic nervous system, APR acute phase response, REE resting 
energy expenditure. 
 
The pathway of AMP-activated kinase (AMPK) 
AMPK is considered the master switch for the cell’s energy control (Carling et al., 2011). AMPK 
is activated via phosphorylation when AMP levels rise in the cell indicating a shortage of ATP, 
the cell’s energy unit. Once AMPK is activated cell proliferation stops and the cell shifts to 
catabolic rather than anabolic processes. AMPK, as pictured in Figure 1.3, facilitates better 
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glucose utilisation and lipid break down whereas discourages gluconeogenesis, lipogenesis etc. 
and therefore plays a crucial role in controlling cellular energy balance (Viollet et al., 2010, 
Steinberg and Kemp, 2009). AMPK interacts with other important pathways of substrate 
metabolism in the cell e.g. it inhibits phosphatidylinositol-3-kinase/ protein kinase b (PI3K/Akt) 
and mammalian target of rapamycin/ ribosomal protein S6 kinase beta-1 (mTOR/S6K1) (Aguilar 
et al., 2007, Yang et al., 2010b) in an effort to stop protein synthesis and reduce energy 
expenditure. AMPK also integrates stress responses, nutrient and hormonal signals to control 
food intake, energy expenditure and substrate utilisation at whole body level (Viollet et al., 2010, 
Steinberg and Kemp, 2009, Woods et al., 2005). Apart from effects in the short term, AMPK 
also exerts control in the long term by regulating gene transcription (Viollet et al., 2006). 
AMPK is a serine/threonine protein kinase. It is a heterotrimeric complex consisting of a catalytic 
subunit α and two regulatory subunits β and γ. Each subunit has two or three isoforms encoded 
by different genes (α1, α2, β1, β2, γ1, γ2, γ3) and as a result a large variety of heterotrimeric 
complexes (Viollet et al., 2006, Viollet et al., 2010, Steinberg and Kemp, 2009) exist. The AMPK 
complexes found in the liver contain α1 and α2 subunits equally and then mainly β1 and γ1 
subunits (Viollet et al., 2006). 
When the cell’s unit of energy, adenosine triphosphate (ATP), is depleted, adenosine 
monophosphate (AMP) increases, as does the AMP: ATP ratio. This results in activation of 
AMPK. AMPK is allosterically activated by AMP binding to its γ subunit (Xiao et al., 2007). AMP 
also makes AMPK more susceptible to phosphorylation by its upstream kinases and also less 
susceptible to dephosphorylation (Hardie, 2004). Two upstream kinases that activate AMPK 
have been identified in humans, liver kinase B-1 (LKB1) (Woods et al., 2003) and calmodulin-
dependent protein kinase β (Woods et al., 2005). The major AMPK kinase activity in the liver 
though is LKB1. If LKB1 is depleted, AMPK’s sensitivity to stimuli, that normally activate it, is 
reduced (Steinberg and Kemp, 2009, Viollet et al., 2006, Viollet et al., 2010). 
Once activated AMPK has multiple roles in the liver. Its main aim is to switch on catabolic 
pathways and to switch off anabolic pathways. In regards to lipid metabolism, AMPK 
phosphorylates acetyl-CoA carboxylase (ACC) and 3-hydroxy- 3- methyglutaryl-coenzyme A 
reductase (HMG-CoA reductase). These two enzymes are key respectively in fatty acid and 
cholesterol synthesis; both ATP consuming pathways. AMPK also increases mitochondrial 
density (Steinberg and Kemp, 2009). 
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In regards to glucose metabolism, AMPK has a role in increasing glucose tolerance, reducing 
blood glucose levels and inhibiting hepatic gluconeogenesis. This is done in multiple ways, e.g. 
by activating protein AS160 (with or without insulin dependent pathways), by activating insulin 
receptor substrate-1 (IRS-1), by transcriptional regulation of the transmembrane protein glucose 
transporter 4 (GLUT4) and the enzyme hexokinase. AMPK also activates glycogen 
phosphorylase and inhibits glycogen synthase, therefore favouring glycogen breakdown; the 
long term effect of AMPK on glycogen stores is not clear (Steinberg and Kemp, 2009, Halse et 
al., 2003). 
AMPK also has a role in inhibiting pathways of protein synthesis and cell proliferation. AMPK 
can inhibit the mTOR/S6K1 pathway which drives cell growth and proliferation, but can also be 
inhibited by S6K1 (Aguilar et al., 2007). Plus AMPK is activated by two known tumour 
suppressor genes: LKB1 (associated with Peutz-Jeghers syndrome) and TSC2 (associated with 
tuberous sclerosis). Evidence is also emerging that AMPK is also associated with muscle 
atrophy (Krawiec et al., 2007). 
AMPK has been extensively studied in cancer cells and in obesity and diabetes type 2 (Jeon, 
2016, Weikel et al., 2016). Cancer cells have ways of suppressing AMPK activation and 
therefore continuing to exploit the cell’s energy producing mechanisms for the benefit of their 
own growth and proliferation (Swinnen et al., 2005). Interest in AMPK has further expanded as it 
has been found that metformin and the thiazolidinediones, medications used to treat diabetes 
type 2, activate AMPK (Coughlan et al., 2014). AMPK is therefore being recognised as a 
potential target for treatment of obesity, diabetes type 2 and glucose intolerance. 
The role of AMPK in end stage liver disease has not been studied per se. As previously 
described, patients with liver disease, when compared to healthy controls, exhibit a metabolic 
syndrome characterised by hypermetabolism, insulin resistance and increased lipid utilisation, 
as well as loss of muscle mass.  AMPK is key in controlling glucose and lipid metabolism in the 
body particularly in the liver and muscle. One could hypothesize that AMPK is activated in 
catabolic patients with ESCLD. AMPK activation though promotes insulin sensitivity, so it is not 
clear how AMPK activation interplays with the development of insulin resistance in catabolism. 
Thus, establishing how AMPK and related pathways react in end stage liver disease would be a 
further step in understanding how disease affects organ and subsequently whole body 
metabolism and may help develop new therapeutic interventions. 
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In summary, end stage chronic liver disease in adults and in children has a significant effect on 
their body composition mainly with weight loss, fluid retention, and loss of fat mass, loss of lean 
mass and with perturbations of the energy balance. This metabolic syndrome is what is now 
described in the context of many other chronic diseases as cachexia. Cachexia is a catabolic 
process involving many different integrating pathways. One of these major catabolic pathways 
is the AMPK pathway. AMPK has been directly and indirectly implicated in muscle atrophy, 
lipolysis in cachexia and it has a role in insulin sensitivity. The role of AMPK in cachexia of end 
stage liver disease is still to be elucidated. 
 
Figure 1.3 Effects of AMPK on human metabolism 
AMPK AMP-activated kinase, CaMMKβ calmodulin dependent protein kinase-β, LKB1 
liver kinase β-1 
 
Hypothesis and Aims 
As described in the previous section, adult patients with end stage liver disease are likely to 
have weight loss, fat loss and muscle loss and a proportion of them are hypermetabolic. This 
cachectic phenotype of weight loss, sarcopenia and hypermetabolism does not necessarily 
relate to disease severity. It may persist after the liver transplant and influence long term 
outcomes. Similar issues have been described in children, but there is often an assumption that 
all children of their cohort are hypermetabolic rather than a percentage of them. In addition, 













Body composition studies in children with liver disease are few for a number of reasons. 
Studying body composition in children has two main challenges; one the inherent difficulty in 
measuring a small child, who may find it difficult to comply with instructions and two the need for 
appropriate reference data per method of body composition which is not always available. In 
addition, as previously described, liver disease comes with changes in body composition like 
water retention, disproportionate abdominal distention due to organomegaly or ascites 
rendering many methods of body composition assessment problematic and inaccurate, 
particularly when used in isolation. Finally, liver disease in children is rare.  
For all the above reasons, studying body composition systematically in children with end stage 
liver disease and their energy requirements before and after liver transplantation and attempting 
to add to the body of knowledge in this field becomes imperative. 
1.1.5 Clinical Questions 
i. What is the body composition and resting energy expenditure of children with 
end stage chronic liver disease pre and post liver transplant? 
ii. Do children with a higher resting energy expenditure per weight have  more 
complications and worse outcome post liver transplant and does the increase in 
resting energy expenditure persist 6 months post liver transplant? 
iii. How are metabolic pathways, that control cell energy metabolism, affected in 
children with end stage chronic liver disease and how do they relate to body 
composition, resting energy expenditure and outcome? 
1.1.6 Hypothesis 
A proportion of children with end stage liver disease are hypermetabolic and cachectic. These 
children suffer more complications after their liver transplant. Cell energy controlling metabolic 
pathways are likely to be disturbed and contribute to the disease state. 
1.1.7 Aims 
Primary aims: 
 To study the role of cell energy controlling pathways in children with end stage liver 
disease. 





 To measure and describe body composition and resting energy expenditure in children 
with end stage liver disease and how they influence outcome post liver transplant. 
 To study how body composition and resting energy expenditure change at least 6 




Chapter 2 MATERIALS AND METHODS 
 
Research Protocol 
Children were prospectively enrolled as they came for their liver transplant assessment. This 
meant that they had end stage liver disease including one or all of the following: liver synthetic 
failure, development of portal hypertension, persistent jaundice, growth failure resistant to 
nutritional management, refractory episodes of cholangitis/ bacterial peritonitis and poor quality 
of life. 
The study was comprised of two arms. 
The first arm involved detailed assessment of body composition and resting energy 
expenditure of the patients before and after liver transplant. The first arm also involved 
recruiting healthy participants that were age and sex matched to the patients.  
Inclusion criteria:  
Children with end stage liver disease coming for their liver transplant assessment. 
Age 6 months-18 years 
Consent to participate 
Exclusion criteria:  
Children with acute liver failure (children without a previously known liver disease 
presenting with liver failure of a relatively short history and requiring a liver transplant) 
Children with liver tumours e.g. hepatoblastoma, without evidence of chronic liver 
disease 
 
Healthy controls were recruited from siblings of patients with liver disease or other healthy 
children. The aim was to recruit healthy children that were age and sex matched to the patients 
so that the two groups could be comparable. Siblings were matched to other patients in the 
study for which they were an age and sex match. 
Pre liver transplantation body composition assessment for the patient participants  
(Figure 2.1) 
Clinical review and examination 
Liver ultrasound (performed by the radiology department as part of their clinical review) 
Weight and height measurement (details in section 2.1.1 page 46). 
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BMI calculation  
Mid upper arm circumference 
Multiple skin fold thicknesses 
Multifrequency bioelectrical impedance for all ages (details in section 2.1.6 page 54). 
Indirect calorimetry to measure resting energy expenditure (details in section 2.1.5 page 52). 
For the over 4 years of age:  4 component model of body composition. 
Air displacement plethysmography (BOD POD) to measure body volume (details in section 
2.1.2 page 47). 
Whole body DXA scan to determine bone mineral content (BMC) (details in section 2.1.3 page 
48). 
Bromide dilution studies to measure extra cellular water (ECW) (details in section 2.1.4 page 
50). 
3D photonic scanning to assess body shape (details in section 2.1.7 page 57). 
For the under 4 years of age: 2 component model of body composition. 
Deuterium dilution studies (details in section 2.1.4 page 50). 
Bromide dilution studies (details in section 2.1.4 page 50). 
The under 4 year olds could not have a 4 component model, because of the technical difficulties 
and lack of reference data when using the BOD POD and the DXA scan in this age group. 
Blood sampling included full blood count (FBC), urea and electrolytes (U+Es), liver function 
tests (LFTs), albumin, international normalised ratio (INR), vitamin A, E and D levels, lipid 
profile, thyroid function tests, cortisol and baseline samples for the dilution studies. Two more 
blood tests were required for the dilution studies and these were taken from an intravenous 
cannula inserted for the first blood test. 
Body composition assessment post liver transplant. 
This assessment was identical to the initial assessment and was undertaken at 6 months post 
liver transplant, for the patients that were well enough, or anytime thereafter.  
Body composition for the healthy participants: 
The healthy participants had one assessment which included anthropometry, indirect 
calorimetry, BOD POD (if they were over 4 years of age), deuterium dilution studies and 
multifrequency bioelectrical impedance. They did not have a DXA scan and bromide dilution 
studies. No blood samples were taken from the healthy participants, urine samples were 
obtained for the deuterium dilution studies. 
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Other data collection: 
During the whole study period for each patient i.e. from the time of initial assessment till the post 
liver transplant assessment the following were recorded: 
Length of stay in hospital (PICU/ HDU/ total) 
Infection episodes (bacterial and viral) 
Graft function (episodes of acute cellular rejection, biliary complications, vascular complications, 
liver function tests) 
Final outcome (alive, re-transplanted, death). 
All the anthropometrics were obtained by the same operator. 
 
For the second arm of the study: 
Inclusion criteria: 
Children undergoing a liver transplant with end stage liver disease with consent to participate 
(the patients from the first arm of the study) and children undergoing a liver transplant without 
end stage liver disease e.g. with Crigler-Najjar type 1 syndrome. 
Age from 6 months-18years 
Consent to participate 
Exclusion criteria:  
Children with acute liver failure or tumours undergoing a liver transplant (as previously stated). 
 
Liver tissue from the explanted liver, muscle tissue (e.g. from the rectus abdominis) and adipose 
tissue (e.g. from the subcutaneous fat) was collected during the liver transplant operation to be 
used for assessment of cell energy controlling metabolic pathways. In particular, levels of 
expression and activation of precursor activators of the AMPK pathway, like LKB-1 were 
studied, as well as relevant subunits of AMPK and of course downstream to AMPK enzymes, 
like ACC1, ACC2.  Pathways interacting with the AMPK pathway with a particular interest in 
pathways involved in muscle wasting and lipolysis were also studied. 
Tissue from the children without end stage liver disease undergoing liver transplant were used 





Figure 2.1: Pathway for the body composition assessment of the patient participants 
The children would start the body composition assessment at King’s College Hospital where 
they also they had their clinical review. After the stable isotopes were given, the assessment 
would continue at the Institute of Child Health before the final samples for the dilution studies 
were taken back at King’s College Hospital. 
DXA dual-energy X-ray absorptiometry, BOD POD air displacement plethysmography 
 
Ethical Approval and Amendments 
Ethical approval was obtained from the NRES Committee London – Central (11/LO/1146). Two 
amendments to the protocol have also received ethical approval. The first one was in regards to 
the number of samples required for the stable isotope studies (from two samples the protocol 
was changed to three). This change was necessary, because we changed provider for the 
stable isotope studies. The second one was in regards to using plasma instead of saliva 
samples for the deuterium measurements for the patients and urine samples instead of saliva 
samples for the controls. This change was necessary because the smaller children could not 
provide adequate saliva samples. 
 
Methods of Body Composition 
There is no gold standard of measuring body composition in vivo in humans. Various methods 
of body composition have been developed that can be used in isolation or in combination as 
explained later on. Each method has its own advantages and disadvantages. When measuring 
children, one needs to keep in mind that the less cooperation needed from the child the more 
accurate the measurements, In addition, because children grow, there need to be normative to 
compare their measurements. If a method can also be applied by the bedside, then it could be 
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more helpful for sick children. The following table summarises the advantages and 
disadvantages of the methods used in this study. 
Table 2-1: Advantages and disadvantages of body composition methods used 
 
Method What it measures Advantages Disadvantages 









Body volume Safe High degree of 
cooperation required 
Normative data only 
for over 5 year olds 
and under 6 month 
olds 
Whole body DXA  Bone mineral density Easy method 
Children enjoy the 
result 
Low dose radiation 
Normative data only 




Total body water Established method 
Normative data exist 
Method has many 




Requires saliva, urine 





Established method Method has many 






Indirect calorimetry Energy expenditure Simple 
Safe 
Requires a fasting 
period 













Body shape Children enjoy this 
scan 
A degree of 
cooperation required 
Not an established 
method of body 
composition 
DXA dual X-ray absorptiometry, 3D 3 dimensional 
As there is no gold standard of measuring body composition in vivo in humans, various models 
exist that attempt to estimate the various body compartments based on a combination of 
measurements and on assumptions. The more assumptions one makes the less potentially 
accurate the estimations. 
The 2 component (2C) model (Wells and Fewtrell, 2006, Wells et al., 1999) divides body mass 
into fat mass (FM) and fat free mass (FFM). Body weight (BW) is the sum of FM and FFM.  
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BW= FM + FFM 
Once we measure BW, by estimating FM we can estimate FFM or the other way round. FM can 
be estimated using various equations, one very well- known one being Siri’s equation where BD 
is body density (Siri, 1993): 
FM% = [(4.95/BD) – 4.5] * 100  
The body density (BD) in Siri’s equation can be estimated either by measuring skin fold 
thickness or by measuring body volume (BV). 
With skin fold thickness (4 measurements: subscapular, biceps, triceps and suprailiac) there are 
various equations that can be used. For example, Johnston’s equations for children (Johnston 
et al., 1988): 
For boys: BD= 1.166- 0.070 x, where x is the log of the sum of the 4 skinfold measurements 
For girls: BD= 1.144- 0.060 x. 
FM in children can also be estimated using the equations of Slaughter et al that require just 
triceps and subscapular skinfold measurements (Slaughter et al., 1988). 
BV can be measured by hydrodensitometry or by air displacement plethysmography (BOD 
POD) and BD= BW/BV (kg/litres). In addition, if one has BD from BV, they can use the modified 
Siri’s equation (Siri, 1956): 
Ff= [(DFFM/BD)-1]/ [(DFFM/0.9007)-1] 
In this equation Ff is the fraction of body weight that is fat mass, DFFM is the density of the fat 
free mass, which particularly in children is not constant and 0.9007 is the density of fat which is 
constant. DFFM can be estimated for children of various ages from the equations of Weststrate 
and Deurenberg (Weststrate and Deurenberg, 1989) which require just age to be solved. 
Alternatively we can estimate the FFM by measuring TBW and by assuming hydration of FFM is 
constant. For adults this is assumed to be 73% (Wang et al., 1999) i.e. TBW= 73% FFM. In 
children, we know hydration is not constant. Two hallmark papers can be used when converting 
TBW estimates to FFM, one is that of Lohman (Hewitt et al., 1993) that provides hydration 
factors for male and female children from their first year of life till the age of 16 years and the 
other is that of Wells et al (Wells et al., 2010b). In this more recent paper, hydration factors are 
provided for children of both sexes from the age of 4 years to 23 years, based on body 
composition analysis of 533 healthy children. 
With the 3 component (3C) model (Wells and Fewtrell, 2006, Wells et al., 1999) the body is 
divided into fat, water and fat free dry mass; assuming that the protein: mineral ratio is constant. 
46 
 
By measuring body volume (BV) in litres, total body water (TBW) in litres and body weight (BW) 
in kg, we can estimate fat mass. 
FM kg= [(2.22 * BV)- (0.764 * TBW)] – (1.465 * BW) 
With the 4 component model (Wells and Fewtrell, 2006, Wells et al., 1999) the body is divided 
into fat, water, protein and mineral. This model does not assume that the ratio of protein to 
mineral in fat free mass is constant. The ratio of bone mineral to total body mineral is still 
assumed to be constant. 
FM (kg)= [( 2.747 * BV) – (0.710 * TBW)] + [( 1.460 * A) – ( 2.050 * BW)] 
In this equation: BV is body volume from displacement plethysmography in litres, TBW is total 
body water in litres, A is total body mineral content (BMC) from the DXA scan in kg and BW is 
body weight in kg. 
This study uses the 2C, 3C and 4C models for the children over 4 years of age and the 2C 
model for the children under the age of 4 years. The reason for the difference is that the 
techniques available to us for the 4C model are not all applicable to younger children either from 
a practical point of view e.g. a 2 year old cannot stay still for the air displacement 
plethysmography for the required amount of time or because of lack of reference data e.g. with 
DXA. In addition, because in chronic liver disease it is well known that there is an increase in 
extracellular water (ECW), we are estimating TBW and ECW. In a study comparing a 4C model 
of body composition of 20 cirrhotic patients without overt oedema to 20 healthy individuals, 
Morgan et al were able to show that the density of the FFM in the patients was in fact lower and 
with a higher hydration factor (Morgan et al., 2006) than in the controls, indicating that 2C 
models are not accurate to use on patients with cirrhosis. On the other hand being able to 
compare 4C with 2C models can give us some insight as to which 2C method would be the 
most appropriate to use in our daily practice where of course the 4C cannot be used. 
2.1.1 Anthropometry 
Weight was measured for the over 4 year olds in swim wear to the nearest 0.01 kg. The 
measurement was repeated and recorded twice after excluding any erroneous values. The 
younger children were weighed with no clothes. Height was measured on a wall mounted 
stadiometer to the nearest 0.1 cm for the over 4 year olds. The measurement was repeated and 
recorded twice after excluding any erroneous values. For the younger children length was 
measured on a horizontal stadiometer. BMI was calculated as weight/ height2, with weight in 
kilograms and height in metres. The raw weight, height and BMI measurements were converted 
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to sd scores (standard deviation scores otherwise known as z scores) using the 1990 reference 
data (Cole et al., 1995).  
Mid-upper arm circumference (MUAC) was measured according to the Institute of Child Health 
standard operating procedure with appropriate tape and on the left arm. The circumference was 
measured at the half point between the acromion tip and the point of the elbow. The half point 
was identified with the left arm at the side and the elbow bent at 90º whereas the circumference 
was measured with the arm hanging loosely by the side of the body. The measurement was 
recorded to the nearest 0.1 cm and was repeated three times. 
Skinfold thickness was measured for biceps, triceps and subscapular skinfolds on the left side 
with Holtain callipers according to the Institute of Child Health standard operating procedure. 
For the biceps skinfold the point of measurement was on the anterior aspect of the arm, on a 
line perpendicular to the line drawn for the MUAC and directly over the humerus. For the triceps 
it was on the posterior aspect of the arm and on a line perpendicular to the line drawn for MUAC 
and directly over the humerus. The subscapular skinfold was measured just below the inferior 
angle at the lower margin of the scapula with the skinfold inclined 45º to the horizontal and in 
the natural cleavage line of the skin. Measurements were repeated and recorded 3 times and to 
the nearest 0.2 cm after excluding any erroneous values. 
All patient participants and all healthy controls had their anthropometry done. 
2.1.2 Air displacement plethysmography (BOD POD) 
Body volume (BV) is required for the 3C model (done for the healthy controls over 4 years of 
age) and for the 4C model (done for the patients over the age of 4 years). As we previously 
discussed, body volume BV can also be used together with weight in estimating fat and fat free 
mass as a 2C model. BV can be measured by hydrodensitometry (a technique also known as 
hydrostatic weighing or underwater densitometry) or by air displacement plethysmography using 
the BOD POD (Model Siri 1961, Life Measurement Instruments, Concord, CA). The latter 
method was developed as an easier quicker, more appealing method, particularly as it does not 
require submersion in water. Indeed it has been shown in children that percentage of body fat 
(%BF) estimated by BOD POD has a high correlation with %BF estimated by DXA and by 
hydrodensitometry (Lockner et al., 2000, Nunez et al., 1999).  
This technique is used for the children over 4 years of age as it requires a certain degree of co-
operation from them. The machine has an anterior and a posterior chamber with an oscillating 
diaphragm between the two chambers creating volume perturbations that lead to small pressure 
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fluctuations. The machine operates on the basis of Boyle’s Law which states that at a constant 
temperature (isothermal conditions), the product of pressure (P) and volume (V) is constant i.e. 
P1V1= P2V2. It makes measurements of volume by calculating the difference in volume in the 
anterior chamber with and without the patient sitting in it. 
The participants have their measurements taken wearing a tight fitting swimming costume and a 
swimming cap. Two complete tests are performed on each child; these provide at least 4 raw 
volumes of total body volume (in litres). The raw body volume needs to then be converted to 
actual body volume. This is done by correcting for thoracic gas volume and the surface area 
artefact by using appropriate equations for children that take into account their age, sex, weight 
and height (Dewit et al., 2000). Lung volume was therefore predicted using age and sex specific 
equations (Wells and Fuller, 2001), as actually measuring lung volume particularly in young 
children is quite challenging. 
 
Figure 2.2: The BOD POD 
 
2.1.3 Whole body dual-energy X-ray absorptiometry (DXA) 
DXA was originally designed to measure bone mineral content (BMC) expressed in grams (g) 
and bone mineral density (BMD) expressed in grams per square centimetre (g/cm2), but it has 
also been applied for body composition assessment. DXA machines use a source of X-rays at 
two energies, low and high energy, a detector and a computer system that converts the data 
into an image. Depending on the path of the X-ray beam DXA machines can be pencil beam, 
fan beam or narrow fan beam. The first scanners were pencil beam. Subsequently the fan beam 
ones allowed for better resolution and faster scanning times at the cost of higher radiation 
doses and magnification of scanned areas closest to the source of X-ray. The narrow fan beam 
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scanners like the Lunar Prodigy used in this study use a wider beam than the pencil beam, but 
narrower than the fan beams and therefore are still quick with a reduced magnification effect 
(Laskey, 1996, Toombs et al., 2012).  
DXA assumes the body is of two components; bone mineral and soft tissue. As the X-ray beam 
travels through the body its two different energies are attenuated. By using the two energies of 
the un-attenuated and the attenuated beam the computer is able to conclude if the pixel can be 
assumed to contain bone or soft tissue. In an average subject about one third of pixels are over 
bone and 2/3 are over soft tissue (Toombs et al., 2012, Laskey, 1996).  
DXA is used in the 4 component model to measure body mineral content (Wells and Fewtrell, 
2006). DXA is also used in studies as a stand-alone tool for body composition. The advantages 
of DXA are that it is a very easy to perform technique as long as the subject can lie still on their 
back for a few minutes, this may of course be a challenge for young children, and that it can 
provide regional body composition measurements, which are very important in individuals with 
altered distribution of body fat and loss of lean mass. The disadvantages of DXA are that it 
involves low radiation doses (estimated radiation exposure per scan with the Lunar Prodigy 2.2 
μSv) and that it assumes a constant hydration factor for the fat free mass of 73%. This means 
that in individuals with a higher hydration factor, as may be the case in patients with liver 
disease, DXA will overestimate fat mass (Laskey, 1996). In addition hydration of lean mass in 
children varies with age and sex (Wells et al., 1999). DXA measurements have not been 
compared to cadaveric body composition data and not all DXA systems have been compared to 
gold standard in vivo methods like the 4 component model (Toombs et al., 2012). Furthermore 
differences have been consistently noted in measurements between different DXA systems 
(Toombs et al., 2012, Laskey, 1996). Where DXA has been compared to the 4 component 
model it has been mostly found to underestimate fat mass (Toombs et al., 2012). A study 
though comparing the Lunar Prodigy scanner, used in this study, with the 4 component model in 
healthy individuals showed that it overestimated fat mass (Williams et al., 2006). The same 
group has compared DXA body composition data to the 4 component model in anorexic and 
obese young people compared to healthy controls and has found that in both cases DXA 
overestimated fat mass and underestimated fat free mass (Wells et al., 2010a, Wells et al., 
2015a).  
Therefore DXA has, in spite of significant advantages, significant limitations when applied to 
assess body composition in individuals expected to have altered hydration of fat free mass 
50 
 
and/or excessive loss of fat free mass. As previously mentioned, in this study, the Lunar Prodigy 
Advance PA+ 303999 whole body scanner was used (GE Medical Systems, Madison, WI, with 
software Encore 2002). For the DXA scan the patients wear loose fitting clothes and lie down on 
their back for about 5-10 minutes. Only patients that were over 4 years of age had the DXA, as 
part of the 4C model. From the DXA scan we were able to obtain values for bone mineral 
content, fat mass, and bone free fat free mass both regional and for the whole body. 
 
Figure 2.3: The DXA scanner 
 
2.1.4 Deuterium and bromide stable isotope dilution studies. 
Stable isotopes are atoms whose nuclei contain the same number of protons, but different 
numbers of neutrons. Isotopes occupy the same position on the periodic table. Isotopes can be 
radioactive or stable. Radioactive isotopes can spontaneously disintegrate to form an atom of 
another element sometimes omitting radiation in the process, whereas stable isotopes have 
stable nuclei and pose no physiological risk. For example deuterium (2H) is the stable isotope of 
hydrogen. Hydrogen has one proton in its nucleus whereas deuterium has one proton and one 
neutron.  
Deuterium dilution studies are used for the estimation of TBW (Schloerb et al., 1950). TBW 
measurements can be used as part of the 2C model and are also needed for the 3C and 4C 
models. Bromide dilution studies are used for the estimation of the ECW. TBW is ECW plus 
intracellular water (ICW). ECW includes interstitial fluid, plasma volume and fluid compartments 
like cerebrospinal fluid and joint fluid. The basic principle of dilution studies is that we give a 
certain dose of a tracer and after it has reached the equilibrium phase of its distribution in the 
fluid compartment of interest, we measure its concentration in that compartment. The volume of 
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the fluid compartment of interest will equal the mass given (the dose) divided by the 
concentration of the tracer (Dou et al., 2012). 
Deuterium labelled water (D2O) is handled by the body just like water. The dose of deuterium 
used in children is 0.05 gr/kg BW of patient (99.8% D2O, Cambridge Isotope Laboratories) 
(Chomtho et al., 2006). Our patient participants had their deuterium measured with the 
equilibrium (or plateau) method, whereas the healthy participants had the deuterium measured 
by the back extrapolation method. After the dose administration one has to wait for the dose to 
equilibrate with the total body water pool. For deuterium this is 4 hours. The dilution space (N) is 
calculated from the following equation: 
N = TA/a * (Ea- ET)/ (Es  - Ep) 
where A is the isotope dose in grams, a is the isotope dose in grams retained by the machine 
for the analysis, T is the amount of tap water in which a is diluted in before analysis and Ea, ET, 
Es, Ep are the isotopic enrichments in delta units in the dose retained by the machine, in the tap 
water, in the sample of plasma post equilibrium and in the sample of plasma before the dose is 
given (Wells et al., 2005). Delta units express isotopic enrichment relative to a standard, in this 
case Vienna-Standard Mean Ocean Water. 
For the equilibrium method, first a blood sample was obtained from the patient and then the 
dose was administered. The administering vessel (cup or bottle) was first weighed empty, then 
with 10 mls of water and then with the deuterium. The individual weights and volumes were 
recorded. A 1 ml sample of the solution was removed and the vessel was weighed again. If a 
straw was added, an additional weight with the straw was obtained. The solution was then given 
to the participant to drink. The time of drink was recorded and the vessel was weighed again 
after the participant has finished drinking. At 4 hours and 6 hours after the drinking time, blood 
samples were obtained and the exact time of the sampling was recorded. The plasma from the 
blood samples was stored in -80°C and was analysed in batches at the Cambridge MRC- HNR 
centre by Dr L Bluck’s team with IR-MS (isotope ratio mass spectrometry). 
For the back extrapolation method, a urine sample was collected from the child prior to giving 
the dose of deuterium. The dose was given just like the previous method and the same times 
and measurements were recorded. A further 5 samples of urine were collected by the parents 
starting the following day and for 5 days and the date and time of the urine collection was 
recorded.  For the infants that were still in nappies any urine sample at any time was 
acceptable, but the continent children had to give us urine samples after the first one of the day. 
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Es with this method was calculated from the washout kinetics of the isotope as indicated from 
these 5 samples (Wells and Strickland, 1996). The equilibrium method overestimates TBW in 
infants under the age of 2 years, but in children over the age of 2 years the two methods yield 
similar results (Wells et al., 2005). The patients under the age of 2 years had the equilibrium, 
because the sampling could be combined with the samples for the bromide dilution. 
With the bromide dilution method the corrected bromide space (CBS) is measured and we are 
assuming that after some adjustments this equals ECW. Bromide has good oral absorption, 
tends to not penetrate in cells and has a slow excretion, therefore the bromide space represents 
the extracellular fluid well (Sergi et al., 2003). 
CBS= [Br dose in mg/ Br dose in plasma in mg/L] * 0.9 * 0.95 * 0.94 
Where 0.9 is the correction for the amount thought to be distributed in non-extracellular sites, 
like the erythrocytes, 0.95 is the Donnan equilibrium factor and 0.94 is the concentration of 
water in serum (Bell et al., 1984). 
The dose of bromide used was 25 mg Br/kg BW of patient (3.22% NaBr, Tayside 
Pharmaceuticals) (Prelack et al., 2005). This was given to the patient to drink after the pre-
dosing baseline blood sample had been taken. The time the dose was taken was recorded. The 
administering vessel (cup) was first weighed empty and then with the bromide solution. A 1 ml 
sample of the solution was then taken out and the cup was weighed again. All weights and the 
volume of the bromide solution were recorded. The patient drank the solution, the exact time 
was recorded and the vessel was weighed again. Blood samples were taken at 4 and 6 hours 
after drinking the solution. The exact time of the sampling was recorded. The samples were 
centrifuged and plasma from the pre-dose sample as well as the 4 and 6 hour post dose blood 
samples were stored at -80ºC together with the sample of the solution. These were later 
analysed in batches at the Department of Biomineral Research at the MRC- Human Nutrition 
Research, Elsie Widdowson Laboratory. The method used for the analysis is ICP-MS 
(inductively coupled plasma mass spectrometry) and with this the average of 78Br and 81Br 
concentration in mg/L was measured for each sample. 
2.1.5 Indirect Calorimetry 
REE was quantified by indirect calorimetry using the Deltatrac II metabolic monitor (Datex-
Ohmeda). The Deltatrac II is considered the most accurate open- system indirect calorimeter 
and has been evaluated in many studies (Wells and Fuller, 1998). It requires a 30 minute warm-
up and calibration of the gas analysers using a known standard gas mixture of 95% O2and 5% 
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CO2. The participants were measured at least 2 hours after any oral/ enteral intake. They were 
asked to lie down and the mixed expired gas was collected via a canopy hood for up to 30 
minutes. All our participants were spontaneously breathing. All the patients and all the healthy 
controls had indirect calorimetry. 
The machine measures the O2 and CO2 gas fractions via gas sensors and then transforms 
these values to VO2 and VCO2. It was calibrated before each use. The machine requires to 
measure the patient in a respiratory and metabolic steady state; where the equilibrium of 
variation of VO2 and VCO2 must be less than <10% for five consecutive minutes (McClave et 
al., 2003b) or alternatively one can take measurements over 30 minutes and then discard the 
measurements of the first 10 minutes (Matarese, 1997, Weissman et al., 1986). 
The calorimeter then uses the Weir equation (Weir, 1949) to transform VO2 and VCO2 into 
energy expenditure per minute with a correction for the metabolism of protein.  
M = (3.941* VO2) + (1.106* VCO2) - (2.17 *uN2) 
M is the metabolic energy expenditure in kcal/min and uN2 is urinary nitrogen in g per day. The 
equation applies to the fasting state and the error of omitting the effect of protein metabolism is 
small (1% for each 12.3% of total calories arising from protein metabolism) (Wells, 1998). 
M (kcal/min) * 1440 min/day = REE (kcal/day). 
The Weir equation is based on knowing the primary caloric value for the metabolism of a 
mixture of 1 g of carbohydrate, lipid and protein with the consumption of x litres of O2 (VO2) and 
the production of y litres of CO2 (VCO2). In addition the values of VO2 and VCO2 can be used 
to derive equations for determining the endogenous metabolic rate of carbohydrate, lipid and 
protein.  
The respiratory quotient RQ is the ratio of VCO2 and VO2. RQ varies from 0.67 (ketone body 
metabolism in the fasting state) to 1.3 reflecting lipogenesis from glucose or hyperventilation 
(Holdy, 2004). Below 0.67 it suggests there may be a leak in the gas collecting system, but 
investigators have reported RQ below 0.67 in patients with liver disease (Glass et al., 2013). 
The current opinion is that using the RQ to guide the macronutrient choice of nutritional support 
is inadequate (McClave et al., 2003a). 
In bed ridden patients REE is comparable to total energy expenditure (TEE), but in active 
patients TEE is made up of REE plus physical activity energy expenditure (PAEE) plus 
thermogenesis. PAEE is the component of TEE with the greatest variability, but has not been 
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evaluated in most disease states. TEE can be evaluated with double-labelled water (Levine, 
2005). 
 
Figure 2.4: Indirect calorimetry 
 
2.1.6 Bioelectrical Impedance (BIA) 
All our patient and healthy control participants had BIA. BIA is a way of estimating body 
composition in humans. The technique involves passing an electrical current between 2 points 
of the subject’s body; usually these are the wrist and the ankle on the same side. It relies on the 
electrical properties of human tissue. It aims to measure the impedance (Z) of the current as it 
passes through the body. Electrical impedance consists of 2 components in human tissue; 
resistance (R) and reactance (Xc). 
When a current passes through a cylinder of homogeneous conductive material the resistance 
(R) is the opposition offered by the material to its flow. This is proportional to the cylinder’s 
length (L) and inversely proportional to its area (A) (Figure 2.5). The human body of course is 
not a cylinder and is not made of homogeneous material, nevertheless a relationship can be 
established between the impedance quotient (L2/R) and the body water, which contains the 
electrolytes that conduct the current. Instead of using the length between the 2 electrodes, 
height of the individual can be used. As lean mass contains the water (e.g. 73% in adults), the 




Figure 2.5: Principles of BIA. Adapted from (Kyle et al., 2004) 
 
Reactance is related to the capacitance (i.e. the ability of a system to store electric charge) and 
variations in capacitance can occur depending on the integrity, function and composition of the 
cell membrane. At zero frequency the current cannot penetrate the cell membrane, so it passes 
through the extra cellular water (ECW) and the resistance it meets is R0. At infinite frequency, 
the cell membrane is a perfect capacitor and so the current passes through intra and extra 
cellular water and the resistance it meets is R∞. 
Phase angle (PA) is derived from resistance and reactance. It is the arc tangent of the ratio of 
reactance/ resistance converted to degrees.  
 
Figure 2.6: Representation of phase angle. 
Adapted from (Kyle et al., 2004) 
 
The relationship between reactance and resistance reflects different properties of tissues that 
are affected by disease, nutritional status and hydration. Phase angle has been interpreted as 
an indicator of cell membrane integrity and water distribution between the intra and extra 
cellular space. Another index of this type is the ratio R0/R∞. Total body phase angle has been 
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shown to be mostly determined by arm and leg phase angle (Selberg and Selberg, 2002). This 
is of particular relevance for patients with liver disease. Phase angle has been shown to 
correlate with total body potassium (body cell mass) and with muscle mass (Selberg and 
Selberg, 2002). 
The illness marker (IM) or impedance ratio is the ratio of impedance at 200 kHz and 5 kHz. 
Impedance at 200 kHz reflects TBW and at 5 kHz ECW. The greater the variance between 
these 2 impedance values the healthier the cells. IM closer to 1 indicates poor cellular health or 
fluid overload. 
BIA measures properties of fat free mass and therefore should not be used to predict fat mass. 
Hydration of fat free mass varies between populations depending on age and other parameters. 
Equations exist to convert the impedance measurements to clinically relevant data, but one 
needs to be aware of the characteristics of these populations when applying the equations to 
different individuals (Wells and Fewtrell, 2006). 
BIA can be single frequency, usually 50 kHz or multi-frequency, deriving measurements at a 
range of frequencies usually from 5 kHz to 200 kHz. Multifrequency BIA is usually better at 
detecting changes in ECW (Patel et al., 1996). We performed BIA with a multi-frequency 
bioelectrical impedance meter (Quadscan4000). Two electrodes were placed over the dorsal 
aspect of the left hand and foot of the child whilst it was lying down. The readings took about 20 
seconds and we did 2 measurements for each participant. 
Bioelectrical impedance vector analysis (BIVA) is an attractive technique that may be used 
without the need for equations. The patient’s R and Xc standardised for height are plotted in the 
R-Xc plane. An individual vector can then be compared with the 50%, 75% and 95% tolerance 
ellipses calculated in the same population of the same gender and race. Clinical validation 
studies have shown that patients falling outside the 75% tolerance ellipse have abnormal tissue 
impedance. These abnormalities may be related to hydration, either dehydration or over 
hydration or they may be related to body cell mass content (visceral/ muscle protein and 
intracellular water) in the lean mass (Kyle et al., 2004, Walter-Kroker et al., 2011). This a 
particularly exciting application of BIA, because it does not rely on equations for the data to be 
interpreted and it can be of direct benefit to the patient. For e.g. one can adjust the dose of 
diuretics so that the patient is not dehydrated or over-hydrated and one can also compare 
consecutive measurements of the same person and can picture how their body composition 
changes (Piccoli et al., 2014). 
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2.1.7 3D Photonic scanning (3D-PS) 
3D-PS is a technique that has been used for many years in the clothing industry and has only 
relatively recently been used to study body composition and in particular to study body shape, 
body volume and to obtain various diameters, girths and volumes of the body and its segments 
that may be of interest.  
Only the patients over 5 years of age had the 3D-PS. They had the scan in their underwear, 
which had to be tight fitting and light in colour, to provide contrast against the scanning booth 
walls which are black. The scanner projects strips of white light onto the body and records the 
distortion induced by the body’s body surface. The scanner uses 6 fixed cameras and records 
over a period of about 8 seconds. Subsequently it takes this raw photonic data and reconstructs 
the skin topography using computer algorithms. We used the NX16 scanner ([TC]2, Cary, North 
Carolina) and the software used is Body Measurement System version 5.3. 3D-PS 
measurements have shown high correlation with manual measurements, but the 3D-PS 
measurements have consistently been shown to be slightly but systematically higher in both 
adults and children (Wells et al., 2015b) 
The advantage of 3D-PS is that it is a safe and quick method with which one can obtain multiple 
measurements and can also track or project changes in body shape. It is though (Wells et al., 
2015b) a technique that is still under evaluation in regards to its application in body composition 
sciences. 
 
Other data collection 
For each patient we recorded the date of liver transplantation, the amount of days they were 
intubated after the transplant in PICU, the total of days they were in PICU/HDU and the days to 
discharge. We also recorded all major complications (infections, acute cellular rejection, surgical 
complications, post-transplant lymphoproliferative disease (PTLD)) and other reasons for re-
admission to hospital. 
 
Tissue Studies- Gene Expression Analysis 
Liver tissue was collected at the time of transplant by wedge biopsy. Samples were immediately 
frozen in liquid nitrogen and stored at -80⁰C. At the same time of transplant samples of muscle 
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and fat tissue were taken from the abdominis rectus and its subcutaneous fat respectively. 
These samples were stored in the same way at -80⁰C. 
The aim was to process the samples and look at gene expression by microarray analysis. For 
this to happen, total RNA needed to be extracted from the tissue and converted to amplified 
cDNA (complementary DNA) with was hybridized onto the microarray chips. Following this we 
performed relative quantification real time polymerase chain reaction (qRT-PCR) in order to 
validate the microarray findings.  
2.1.8 Isolation of Total RNA 
Total RNA was extracted from the tissue samples using the MagMAX™-96 for Microarrays Total 
RNA Isolation Kit by Thermofisher Scientific. In particular the spin procedure was used, which is 
suitable for tissue samples that have been snap frozen and are potentially high in fat content 
and/ or high in cellular content. It has fewer steps than the no-spin procedure and more tissue 
can be processed per sample. The procedure protocol can be found on the company’s website 
(https://tools.thermofisher.com/content/sfs/manuals/cms_055599.pdf).  
Procedure Overview: 
1. Sample homogenized in TRI Reagent (1 mL TRI Reagent per 50–100 mg tissue)  
-the homogenate was incubated at room temperature for 5 minutes 
2. Spin Procedure 
a. Separation of aqueous and organic phase  
- Homogenate mixed with 0.1 volumes BCP and left at room temp for 5 min 
- Centrifuged at 12,000 x g for 10 min at 4°C 
- 100 μL of aqueous phase transferred to the Processing Plate 
b. RNA purification using RNA binding beads 
- 50 μL of 100% isopropanol added and shaken for 1 min  
- 10 μL of RNA Binding Beads added and shaken for 3 min  
- RNA Binding Beads captured magnetically and supernatant discarded 
- Washed twice with 150 μL Wash Solution 2 each time  
- Beads dried by shaking for 2 min  
- RNA eluted in 50 μL of Elution Buffer 
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2.1.9 Formation of cDNA 
From the total RNA isolated, amplified cDNA was made following the Ovation® Pico WTA 
Systems V2 protocol by NuGEN (http://www.nugen.com/products/microarray-qpcr/ovation-pico-
and-picosl-wta-systems-v2).  
Procedure overview:  
1. First strand cDNA synthesis 
a. 2 μL of First Strand Primer Mix and 5 μL of total RNA were mixed in a 0.2 ml PCR 
tube 
b. The tube was placed in a thermal cycler running Programme 1 (65 °C, 2 minutes; 
finally held at 4 °C) 
c. First Strand Mastemix was prepared and 3 μL added to each tube 
d. The tubes were placed in the thermal cycler running Programme 2 (4°C , 2 min; 
25°C, 30 min; 42°C , 15 min; 70°C , 15 min; finally held at 4°C) 
2. Second strand cDNA synthesis 
a. Second Strand Mastermix was prepared and 10 μL was added to each tube 
b. The tubes were placed  in a thermal cycler running Program 3 (4°C, 1 min; 25°C, 10 
min; 50°C,  30 min; 80°C, 20 min; finally held at 4°C). 
3. Purification of Double-Stranded cDNA 
a. RNAClean® XP beads were re-suspended and brought to room temperature.  
b. 32 μL of beads was added to each tube and mixed. They were then left to incubate 
at room temperature for 10 minutes. The tubes were placed on the magnet for 5 
minutes to completely clear the beads. Only 45 μL of Binding Buffer was removed 
before the first wash step. The beads were washed while still on the magnet for 30 
seconds with 200 μL of freshly prepared 70% ethanol. The wash was repeated 2 
more times. Beads were left to dry completely, at least for 15 to 20 minutes.  
4. SPIA Amplification 
a. The SPIA Master Mix was prepared by combining SPIA amplification reagents C1 
(25 μL/ sample, C2 (50 μL/ sample) and C3 (25 μL/ sample) 
b. 100 μL of the SPIA Master Mix was added to each tube containing the dried beads 
c. The tubes were placed  in a thermal cycler running Program 4 (4°C, 1 min; 47°C, 75 
min; 95°C, 5 min; finally held at 4ºC) 
5. Purification of Amplified SPIA cDNA 
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2.1.10 Microarray analysis 
A microarray is a glass slide with many spots on it where each spot contains thousands of 
copies of a DNA sequence that uniquely corresponds to a particular gene. The extracted RNA 
was coloured by different dyes whilst converted to cDNA. This cDNA of the tissue being tested 
was hybridized onto the slide and each cDNA part of it that represents a gene will bind to its 
complementary oligonucleotide sequence on the slide. The slide was then excited by laser able 
to detect the different dyes and the final image was stored for final analysis (http://www.mrc-
lmb.cam.ac.uk/genomes/madanm/publications.html).  
The isolation of the total RNA, the formation of the cDNA and the analysis of gene expression 
by microarray was done at the Genomics Centre at King’s College London. The candidate was 
trained in these methods, but only observed work at the Genomics Centre. The microarray was 
done using the Affymetrix GCS3000 microarray system which uses GeneChip arrays. 
The microarray data is MIAME (minimal information about a microarray experiment) compliant 
and has been deposited in the GEO repository (accession number GSE84954). 
The microarray results were analysed using the software Qlucore Omics Explorer version 3.2 
and GeneGO MetacoreTM (Thomson Reuters).  
2.1.11 Relative Quantification Real-Time PCR  
Relative quantification real-time PCR was undertaken for the samples of amplified cDNA 
derived from the tissue samples. 
Thirty seven samples of cDNA from 13 participants: 11 liver, 13 muscle and 13 adipose tissue. 














Table 2-2: The list of genes of the gene expression assays used for the validation of the 
microarray 
 
Name of Gene 
CTGF- Connective tissue growth factor 
RGS1- Regulator of G-protein signalling 1 
FNDC5- Fibronectin type III domain-containing 
protein 5 
RGS2- Regulator of G-protein signalling 
JUN- JUN proto-oncogene 
DUSP1- Dual specificity protein phosphatase 1 
TGF1- Transforming growth factor 1 
JUNB- JUN B proto-oncogene 
USF2- Upstream transcription factor 2 
ATF3- Activating transcription factor 3 
CCL2- C-C Motif Chemokine Ligand 2 
EGR1- Early Growth Response 1 
PPARA- Peroxisome Proliferator Activated 
Receptor Alpha 
PPARG- Peroxisome Proliferator Activated 
Receptor Gamma 
IL8- Interleukin 8 
SOCS3- Suppressor of cytokine signalling 3 
IL6- Interleukin 6 
LEP- Leptin 
GAPDH- Glyceraldehyde 3-P dehydrogenase 
 
For the real time PCR a 384 well plate was used.  
Each well had 11 µl of the probe solution (1 µl of gene probe and 10 µl of Taqman® Universal 
Master Mix II with UNG) and 9 µl of the sample solution (10 ng of cDNA made up to 9 µl of 
solution by adding RNAse free water). 
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The plate was sealed and centrifuged at 2000 rpm at 20˚C for 2 minutes and was then placed in 
the real time machine analyser QuantStudioTM 12K Flex Real-Time PCR System (Applied 
BiosystemsTM). The reactions were carried out using the cycles shown in Table 2-3. 
 
Table 2-3: Real-time PCR cycles 
 
Stage Cycles  Holding 
Temp. 
Holding Time Ramp Rate 
Hold   50˚C 2 minutes  
 40  95˚C 10 minutes Automatic 
PCR Stage   95˚C 15 seconds  
   60˚C 1 minute  
 
PCR is used to amplify the cDNA. By knowing how much cDNA one has after each cycle of 
PCR one can calculate how much material there was in the first place, as long as it can be 
compared to a known standard. The amount after each cycle is measured by using fluorescent 
coloured dyes that are attached to the PCR products during amplification. 
Real time PCR involves 3 steps that are run for 40 cycles and they are: 
1: Denaturation- this is done at 95˚C and results in the separation of the 2 DNA strands and 
therefore ssDNA. 
2. Annealing- this is where complementary sequences between the primer and the ssDNA bind- 
this is done 5˚C below the melting point of the primer. 
3. Extension- this done at 70-72 ˚C which is the optimal temperature for the DNA polymerase 
and the primer extension happens as fast as 100 bases per second. 
In relative quantification real-time PCR the expression of the genes of interest are compared 
between the various samples and the results are expressed as fold change. A ‘housekeeping’ 
gene is used as a control for experimental variability- in our experiment this was GAPDH. 




Figure 2.7: Real-time PCR output: calculation of Ct. 
Ct threshold cycle, the cyan line is the threshold and the black arrow points to the Ct value. 
 
The real-time PCR output curve (Figure 2.7) has certain important features. 
1) The baseline is the signal level, usually during cycles 3-15, where there is little change 
to the fluorescent signal. 
2) The threshold is where the signal is now increased at a statistically significant level 
above the baseline. 
3) The threshold cycle (Ct) is the cycle number during which the reaction signal exceeds 
the threshold.  The higher the template amount the smaller the threshold cycle and vice 
versa. 
In its basic form, in comparative quantification, one takes the Ct values obtained from 
expression of a gene from the sample of interest and from a control sample- the difference 
between these 2 values is ΔCt and the fold difference is 2 to the power of ΔCt. 
Fold difference = 2 ΔCt. 
This basic form though does not take into account differences in sample quality, quantity and 
reaction efficiency. To address these issues the ΔΔCt algorithm is used. 
ΔCt sample- ΔCt control sample= ΔΔCt 
Where: 




ΔCt control sample= Ct of the gene of interest in the control sample – Ct of the ‘housekeeping’ 
gene in the control sample. 
For the PCR analysis in this study, Ct of the housekeeping gene was Ct of GAPDH and Ct of 
the gene of interest in the control sample was the average Ct for that particular gene in the 2 
samples from the subjects with Crigler-Najjar type 1 syndrome. The relative quantification real-




Measurements were reported as mean sd scores (standard deviation scores; otherwise known 
as z scores) and their SD (standard deviation). Comparisons were made between the patients 
and the healthy controls by performing an independent t-test, or where appropriate, between the 
measurements of the patients before and after liver transplantation by performing a paired t-
test. Linear correlations between variables were tested using the Pearson’s correlation 
coefficient r. 
A p value of less than 0.5 was the cut off for statistical significance. 
The statistical software used was IBM SPSS Statistics version 22 and for some of the statistical 
figures GraphPad Prism 7. 
For the microarray analysis Qlucore Omics Explorer version 3.2 was used. This software uses p 
and q values, where “q” is the smallest false discovery rate for which a particular gene would 
remain on the list of differentially expressed genes. GeneGO MetacoreTM software was also 
used to generate significant networks. These networks have a p value, a z-score and a g- 
score. The p-value for both software represents the probability of a particular arrangement 
arising by chance. The z-score ranks the networks according to their saturation in genes coming 
from the experiment submitted and then the g-score downgrades the z-score depending on if 
important genes- nodes in the network are not present from the experiment submitted. 







Chapter 3 RESULTS- “BODY COMPOSITION” 
 
Timeline of Study 
The study received R&D approval from King’s College Hospital in February 2013 and has been 
ongoing since. Seventeen children with end stage liver disease undergoing the process of 
assessment for liver transplantation have been recruited and have had their body composition 
measured. Two of these children have been removed from the waiting list for a liver transplant 
whereas 14 of the remaining 15 have now had their liver transplant. Tissue has been collected 
from thirteen of them and repeat body composition has been performed in nine of them. To date 
fourteen healthy children have had their body composition measured as controls. Tissue has 
also been collected from 2 children who were having a liver transplant for Crigler-Najjar type 1 




Seventeen patients with ESCLD being assessed for a liver transplant or already waiting for a 
liver transplant were recruited and they had their body composition measurements. Ten of these 
children were female and 7 were male. Age varied form 0.6 years to 17.2 years (mean age 7.4 
years and median age 5 years). The diagnoses (Figure 3.1) were biliary atresia (8), Alagille 
syndrome (2), neonatal sclerosing cholangitis (NSC) (1), a1-antitrypsin deficiency (1), primary 
sclerosing cholangitis (PSC) (1), cryptogenic cirrhosis (1) and hepatitis C virus (HCV) related 
cirrhosis (1) as well as two patients who were being assessed for a second transplant (one of 
these had been originally transplanted for biliary atresia and the other for neonatal 
haemochromatosis). In terms of ethnic background, 2 patients were Black-African, one was 
Asian, 1 was mixed race, 1 was white-Greek and the rest were white-British. 
Fourteen of the 17 patients who had their body composition measured were transplanted. The 
age at transplant ranged from 0.65 years to 17.73 years (mean 6.54 years and median 5.3 
years). The time that had lapsed from their body composition assessment to the time of their 
liver transplant ranged from 7 days to almost 2 years (mean 5.3 months and median 6.9 
months). As previously mentioned, 2 of the children have been removed from the waiting list. 
66 
 
One of them was a boy with previous biliary atresia, who had already been transplanted, but 
was being considered for a second liver transplant due to considerable graft dysfunction. The 
other patient removed was the one with the HCV related cirrhosis. She was treated for the HCV 
infection and she achieved a sustained viral response after the treatment. As she has been 
stable from a cirrhosis point of view, she was removed from the liver transplant waiting list. One 
child from the original 17 is currently still awaiting liver transplant. 
 
 
Figure 3.1: Diagnoses of Patients 
NSC neonatal sclerosing cholangitis, PSC primary sclerosing cholangitis, HCV hepatitis C virus 
 
Of the 14 patients that have had their liver transplant, 9 have had their second body 
composition assessment. For these 9 patients the post liver transplant body composition 
assessment was on average 11.4 months after their liver transplant (range 5.2 to 20 months 
and median 10.8 months) and on average 15.6 months after their pre liver transplantation body 
composition assessment (range 10.8 to 21.6 months, median 15.6 months). The child with the 
HCV related cirrhosis also had a second body composition assessment, 12 months after 








Table 3-1: Blood results of patients at their pre liver transplant body composition 
assessment 
 
 Mean (SD) Range  Median 
Hb g/L 115.3 (16.7) 81 – 152 116 
MCV fL 87.4 (5.8) 75.6 – 95.5 88.7 
MCH pg 28.6 (2.6) 23.4 - 33 28.4 
MCHC g/L 327.3 (14.6) 306 - 361 327 
WCC 109/L 6.3 (4.7) 1 – 14.3 4.1 
Neutrophils 109/L 2.4 (1.6) 0.5 – 6.2 1.8 
Lymphocytes 109/L 3.3 (3.3) 0.4 – 11.4 1.6 
PLTs 109/L 106.1 (57.3) 15 - 199 84 
Na mmol/L 138.5 (2.6) 133 - 142 139 
Urea mmol/L 3.7 (1.7) 1.9 – 8.1 3.2 
Creatinine umol/L 25.1 (17.3) 1 - 62 18 
Albumin g/L 35 (6.3) 23 - 51 35 
Total Protein g/L 64.5 (9.6) 51 - 83 60 
INR 1.4 (0.2) 1.03 – 1.85 1.38 
Bilirubin umol/L 113.6 (138.2) 16 - 522 57 
AST IU/L 154.7 (105.4) 36 – 327 96 
ALT IU/L 98.7 (45.7) 33 - 173 100 
ALP IU/L 690.6 (488) 229 - 2227 463 
GGT IU/L 241.2 (334.9) 15 - 1369 174 
TBA mg/dL 117.6 (92.1) 92 - 335 135 
SD standard deviation, Hb haemoglobin, MCV mean corpuscular volume, MCH mean corpuscular 
haemoglobin, MCHC mean corpuscular haemoglobin concentration, WCC white cell count, PLTs platelets, 
Na sodium, INR international normalised ratio, AST aspartate aminotransferase, ALT alanine 
transaminase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, TBA total bile acids. 
 
 
Out of the 17 patients, 9 were anaemic with a haemoglobin below the lowest normal range for 
their age, and two of the patients had a low MCV and MCH. Nine patients had a higher than 
normal MCV (3 of which with a higher MCH as well), but only 2 of these also had a low 
haemoglobin. Nine patients had a lower than normal white cell count and all patients had a 
below normal platelet count. In terms of liver synthetic function, 7 of the patients had below 
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normal albumin levels with 1 patient having higher than the normal range levels (the one with 
Alagille syndrome). INR was prolonged in 14 patients. All the patients were cholestatic. All of 
the patients had splenomegaly with evidence of hypersplenism. Three patients had experienced 
a variceal GI bleed prior to being transplanted. Two of the patients were diagnosed with 
hepatopulmonary syndrome. One of them requiring oxygen in the final stages prior to her liver 
transplant (this was the patient with the NSC). In addition, one of the patients being assessed 
for her second liver transplant had adrenal insufficiency. 
All children received dietetic input as part of their ongoing management. The child with the NSC 
was prescribed oral high calorie supplements, but with poor compliance and the family refused 
nasogastric feeding. One of the children with Alagille syndrome was on overnight feeds via 
gastrostomy and one of the young girls with biliary atresia was supplementing her oral intake 
with nasogastric feeds. 
As mentioned earlier 14 healthy controls (8F: 6M) also had body composition measurements. 
Their ages varied from 8 months to 18 years old (mean 7.35 years, median 5.5 years). These 
children had no medical issues. 
 
Results by body composition method 
The following 2 tables summarise the body composition methods performed on the patients. 
The results are in the first instance reported as per method. 
Table 3-2: Body composition methods for the patients under 4 years of age 
 
Body composition methods for the patients under 4 years of age 
1. Basic anthropometry; weight, height and BMI 
2. MUAC and Skinfold thicknesses :triceps, biceps and subscapular 
3. Deuterium dilution studies 
4. Bromide dilution studies 
5. Bioelectrical impedance 
6. Indirect calorimetry 














Table 3-3: Body composition methods for the patients over 4 years of age 
 
Body composition methods for the patients over 4 years of age 
1. Basic anthropometry; weight, height and BMI 
2. MUAC and Skinfold thicknesses :triceps, biceps and subscapular 
3. Deuterium dilution studies 
4. Bromide dilution studies 
5. Whole body DXA 
6. Air displacement plethysmography (BOD POD) 
7. 3D photonic scanning 
8. Bioelectrical impedance 
9. Indirect calorimetry 
BMI body mass index, MUAC mid upper arm circumference, DXA dual energy X-ray absorptiometry 
 
 
Table 3-4: Body composition methods for the healthy controls under 4 years of age 
 
Body composition methods for the healthy controls under 4 years of age 
1. Basic anthropometry; weight, height and BMI 
2. MUAC and Skinfold thicknesses :triceps, biceps and subscapular 
3. Deuterium dilution studies 
4. Bioelectrical impedance 
5. Indirect calorimetry 
BMI body mass index, MUAC mid upper arm circumference 
 
 
Table 3-5: Body composition methods for the healthy controls over 4 years of age 
 
Body composition methods for the healthy controls over 4 years of age 
1. Basic anthropometry; weight, height and BMI 
2. MUAC and Skinfold thicknesses :triceps, biceps and subscapular 
3. Deuterium dilution studies 
4. Air displacement plethysmography (BOD POD) 
5. Bioelectrical impedance 
6. Indirect calorimetry 
BMI body mass index, MUAC mid upper arm circumference 
 
The following 2 tables show the number of patients and healthy controls that were recruited and 











Table 3-6: Number of patients participating in body composition studies 
 
Patients 
 11 were > 4 years old 6 were < 4 years old Total 
Basic anthropometry 11 6 17 
MUAC/skinfolds 10 5 15 
Deuterium 11 6 17 
Bromide 8 4 12 
DXA 11 N/A 11 
BOD POD 10 N/A 10 
3D photonic scanning 4 N/A 4 
BIA 11 6 17 
Indirect calorimetry 11 6 17 
BIA bioelectrical impedance, BOD POD air displacement plethysmography, DXA dual energy X-ray 
absorptiometry, MUAC mid upper arm circumference 
 
Table 3-7: Number of healthy controls participating in body composition studies 
 
Healthy Controls 
 10 were > 4 years old 4 were < 4 years old Total 
Basic anthropometry 10 4 14 
MUAC/skinfolds 10 4 14 
Deuterium 10 4 14 
Bromide N/A N/A N/A 
DXA N/A N/A N/A 
BOD POD 10 N/A 10 
3D photonic scanning N/A N/A N/A 
BIA 10 4 14 
Indirect calorimetry 10 3 13 
BIA bioelectrical impedance, BOD POD air displacement plethysmography, DXA dual energy X-ray 
absorptiometry, MUAC mid upper arm circumference 
 
The healthy controls had only one body composition assessment. The patients however were 
also assessed at least 6 months after their liver transplant. Out of the 17 patients, 14 were 
transplanted, 2 were taken off the transplant list and one is still awaiting transplant. Of the 14 
transplanted ones, 2 were lost to follow up as they lived abroad. 9 of the 12 remaining patients 
had a post transplantation body composition assessment at the time of this thesis. Out of the 2 
who were taken off the waiting list, one had a second assessment after completing treatment for 






Table 3-8: Number of patients participating in body composition studies after transplant 
or treatment 
 
Patients after transplant or after treatment 
 10 were > 4 years old 4 were < 4 years old Total 
Basic anthropometry 5 5 10 
MUAC/skinfolds 5 3 8 
Deuterium 5 5 10 
Bromide 5 3 8 
DXA 6 N/A 6 
BOD POD 5 N/A 5 
3D photonic scanning 4 N/A 4 
BIA 5 5 10 
Indirect calorimetry 5 5 10 
BIA bioelectrical impedance, BOD POD air displacement plethysmography, DXA dual energy X-ray 
absorptiometry, MUAC mid upper arm circumference 
 
3.1.1 Anthropometry 
The weight, height and BMI measurements were converted to sd scores using the UK WHO 
data in ImsGrowth program© (Cole, 1990). The database is a combination of WHO and UK 1990 
to age 4 years and UK 1990 from 4 years to 20 years of age (full term children) (Freeman et al., 
1995, de Onis et al., 2006). We have weight, height and BMI sd.scores on 17 patients (7M:10F) 
and 14 healthy controls (6M:8F). Six of the patients and 4 of the healthy controls were under the 
age of 4 years. 
Looking at the table below we see that when the patient and the control group are compared as 
a whole, the patients have significantly lower sd scores for weight and height, but when the 
comparison takes sex into account these differences diminish. 
 
Table 3-9: Mean weight, height and BMI sd scores for patients and controls 
 






Patients 17 7.39 (6.0) -0.88 (0.85) -1.15 (1.54) -0.21 (0.9) 
Controls 14 7.35 (5.4) 0.23 (1.31) 0.18 (1.29) 0.14 (1.12) 
*the difference of mean weight s.ds between the 2 groups reached statistical significance at p <0.01 
**the difference of mean height s.ds between the 2 groups reached statistical significance at p <0.05 






Table 3-10: Mean weight, height and BMI sd scores for patients and controls according to 
sex 
 
Patients Mean Weight sds 
(SD) 
Mean Height sds 
(SD) 
Mean BMI sds  
(SD) 
Male -0.88 (1.05) -1.42 (1.22) 0.79 (0.83) 
Female -0.87 (0.74) -0.96 (1.77) -0.42 (0.93) 
Controls    
Male -0.53 (1.27) -0.39 (0.98) -0.5 (1.15) 
Female 0.81 (1.08) 0.61 (1.38) 0.62 (0.89) 
BMI body mass index, sds standard deviation score, SD standard deviation 
 
The difference of the mean weight, height and BMI sd score between patients and controls for 
male and female participants tested separately with a 2-tailed independent t-test did not achieve 
statistical significance in any group. 
 
Table 3-11: Mean weight, height and BMI sd scores for patients and controls divided by 
age 
 
Patients Mean Weight sds 
(SD) 
Mean Height sds 
(SD) 
Mean BMI sds  
(SD) 
Under 4 years old -1.12 (0.55)* -1.45 (0.83)** -0.36 (0.81) 
Over 4 years old -0.74 (0.97) -0.99 (1.84) -0.13 (0.97) 
Controls    
Under 4 years old 0.895 (1.42)* 1.13 (1.4)** 0.4 (1.24) 
Over 4 years old -0.03 (1.24) -0.2 (1.08) 0.04 (1.12) 
*The difference of the mean weight sd score between patients and controls under the age of 4 years was 
statistically significant p < 0.05 
** The difference of the mean height sd.score between patients and controls under the age of 4 years was 
statistically significant p <0.01. 
The other comparisons did not reach statistical significance. 
BMI body mass index, sds standard deviation score, SD standard deviation 
 
 
When comparing the mean sd scores of our patients to an sd score of 0, the difference reaches 
statistical significance for weight at p < 0.001 and for height at p < 0.01, but not for BMI. When 
the same is done for our healthy controls none of the differences are statistically significant. 
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In summary, overall the patients are significantly underweight and short, with this being more 
significant in the under 4 years of age children. 
 
The average of 3 measurements of MUAC and skinfold thickness measurements recorded for 
each patient and each healthy control was converted to the corresponding sd score. For the 
under 4 year olds this was done using the WHO database and for the over 4 year olds this was 
done using the study population previously measured by Wells et al. The WHO database does 
not include reference values for biceps skinfold thickness for the young children. 
 
Table 3-12: Mean sd score for MUAC, triceps and subscapular skinfold for the children 
under 4 years of age 
 
 Patients (5) Controls (4) P value 
MUAC -1.1340 (0.49) 1.2 (0.51) 0.0002 
Triceps -1.34 (1.12) 0.11 (0.93) NS 
Subscapular -1.68 (1.73) 1.49 (2.29) NS (0.06) 
MUAC mid upper arm circumference, in brackets the standard deviation 
 
Table 3-13: Mean sd scores for MUAC, triceps, biceps and subscapular skinfolds for 
children over 4 years of age 
 
 Patients (10) Controls (10) P value 
MUAC -1.13 (0.69) 0.02 (0.86) 0.0048 
Triceps -0.32 (0.89) -0.14 (1.19) NS 
Biceps -0.45 (0.54) 0.47 (0.81) 0.0085 
Subscapular 0.07 (0.79) 0.21 (1.1) NS 
MUAC mid upper arm circumference, in brackets the standard deviation 
 
For nine of the patients that have had their liver transplant we have anthropometry 







Table 3-14: Mean weight, height and BMI sd scores before and after liver transplantation. 
 
 Mean Weight sds 
(SD) 
Mean Height sds 
(SD) 
Mean BMI sds  
(SD) 
Pre-transplant -0.84 (0.88) -1.26 (0.97) -0.14 (0.82) 
Post-transplant -0.25 (1.29) -0.9 (1.13) 0.46 (0.93) 
BMI body mass index, sds standard deviation score, SD standard deviation 
 
There was an increase in weight, height and BMI sd scores for these 9 patients, but this 
difference in sd scores before and after transplant did not reach statistical significance when 
applying a paired t-test.  
Height after transplant correlated strongly with height before transplant (r=0.84, p <0.05), this 
was not the case for weight and BMI. 
 
Table 3-15: Mean MUAC, triceps, biceps and subscapular skinfolds before and after liver 
transplantation for children over 4 years of age 
 
 Pre-transplant Post-transplant P value 
MUAC -1.07 (0.75) -0.12 (0.66) 0.000 
Triceps 0.32 (0.56) 1.0 (0.49) 0.099 
Biceps -0.45 (0.82) 0.9 (0.75) 0.057 
Subscapular -0.11 (0.53) 0.68 (0.55) 0.014 
MUAC mid upper arm circumference 
 
We have anthropometry data for 4 children who were older than 4 years of age before and after 
liver transplantation. MUAC, biceps, triceps and subscapular skinfolds all increased after the 
transplant. This increase reached statistical significance for MUAC and subscapular skinfold. 
The younger children did not cooperate consistently with the skinfold measurements post liver 
transplant, so we can only compare MUAC before and after transplant in this age group. Even 
though there was an increase in mean MUAC sd score from -1.7 to -0.9, this did not reach 
statistical significance. 
In summary, the patients under 4 years of age had an MUAC sd score significantly less than 
the controls, whereas for the older children it was MUAC and biceps skinfold that was less. After 
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transplant, all indices increased for the older children, but only the MUAC and subscapular 
skinfolds sd scores increased significantly. Height after transplantation correlated with height 
before transplantation. 
 
3.1.2 Deuterium Dilution Studies 
All participants had deuterium dilution studies as part of their body composition assessment in 
order to assess TBW. The patients had TBW measured by the equilibrium or plateau method 
and the healthy controls by the back extrapolation method. The samples as previously 
mentioned were analysed in batches. 
TBW is mostly found in fat free mass. By using the Lohman hydration factor, TBW can be 
converted to FFM, where TBW (kg) = hydration factor X FFM (kg) (Hewitt et al., 1993). The 
results were assigned the appropriate sd score using data from a reference population of 
healthy children (Wells et al., 2012, Wells et al., 2010b) 
All 17 patients have had their deuterium analysed for the before liver transplant body 
composition and subsequently their TBW calculated. Looking at the first 9 patients, we can see 
that for 3 of the younger ones, the results generated are not plausible (numbers in italics). FM 
takes a negative value and therefore the results are invalid. This was thought to be due to the 
infants’ reluctance to drink the solution, resulting in a degree of drooling making it difficult to 
assess the exact amount of dose taken by the children. Further to this, 2 of the older children, 
(results underlined) also most likely have inaccurate results, this was thought to be due to 
suboptimal mixing of the solution. At the time the deuterium and bromide solutions were given 
together as one to the children. Because of these issues, for all subsequent measurements, the 
deuterium was given separately to the bromide solution and extra care was taken to mix the 
solutions well, particularly prior to taking out the sample of the solution. After these measures, 










Table 3-16: TBW results for the patients prior to liver transplantation 
 
ID Age Sex Wt TBW sds HF 
% 
LM LM % FM FM % 
1 118 F 31.8 20.9 0.61 77 27.14 85.35 4.7 14.65 
2 20 M 11.04 5.79 -2.88 78.6 7.37 66.72 3.7 33.28 
3 62 M 21.7 8.33 -3.6 77 10.82 49.85 10.9 50.15 
4 7 F 7.14 7.04 4.79 78.8 8.93 125.13 -1.8 -25.13 
6 58 M 15.2 8.2 -3.42 77.8 10.54 69.34 4.7 30.66 
7 57 F 15.45 9.22 -1.14 78.3 11.78 76.22 3.7 23.78 
8 10 M 8.08 6.55 1.2 79 8.29 102.61 -0.2 -2.61 
9 36 F 11.4 2.22 -8.67 78.3 2.84 24.87 8.6 75.13 
10 8 F 6.98 0 n/a 78.8     
11 126 F 33.3 20.11 -0.17 77 26.12 78.43 7.2 21.57 
12 12 F 7.06 4.9 0.92 78.5 6.24 88.41 0.8 11.59 
13 181 F 42.4 21.34 -2.52 77 27.71 65.36 14.7 34.64 
14 112 M 21.8 12.45 -3.2 76.2 16.34 74.95 5.5 25.05 
15 206 M 54.26 32.04 -1.53 74.2 43.18 79.58 11.1 20.42 
16 200 F 59.01 30.76 -0.16 75 41.01 69.50 18.0 30.50 
17 104 F 24.53 14.48 -0.83 77.6 18.66 76.07 5.9 23.93 
18 188 M 53.62 35.23 -0.47 74.2 47.48 88.55 6.1 11.45 
Age in months, Wt weight in kilograms, TBW total body water in kilograms, sds standard deviation score, 
HF hydration factor, LM lean mass in kilograms, FM fat mass in kilograms 
 
 
Fourteen of the healthy children that had their body composition also had deuterium studies. 
For 2 of these their results have not been analysed yet. The results of the remaining 12 can be 
seen in the following table. The second child had invalid results due to the solution not being 








Table 3-17: TBW results for the healthy controls 
 
ID Age Sex Wt TBW SDS HF % LM LM % FM FM % 
C1 39 M 13.2 7.99 -1.52 77.8 10.27 77.80 2.93 22.20 
C2 55 M 19.25 0.04 n/a 77.8     
C6 9.5 F 9.2 5.06 1.14 78.8 6.42 69.80 2.78 30.20 
C5 54 M 17.68 11.7 0.5 78.3 14.94 84.52 2.74 15.48 
C7 120 M 29 16.77 -1.25 76.2 22.01 75.89 6.99 24.11 
C8 162 F 38.85 22.02 -1.03 75.5 29.17 75.07 9.68 24.93 
C9 116 M 32.33 14.09 -2.36 76.2 18.49 57.19 13.84 42.81 
C10 216 F 69.14 32.42 0.15 75 43.23 62.52 25.91 37.48 
C11 190 M 38.76 27.01 -2.06 74.2 36.40 93.92 2.36 6.08 
C12 52 F 19.78 12.63 1.72 78.3 16.13 81.55 3.65 18.45 
C13 78 F 25.15 13.98 0.55 78 17.92 71.26 7.23 28.74 
C14 115 F 26.36 13.1 -2.3 77 17.01 64.54 9.35 35.46 
Age in months, Wt weight in kilograms, TBW total body water in kilograms, Sds standard deviation score, 
HF% hydration factor %, LM lean mass in kilograms, FM fat mass in kilograms 
 
Nine children had deuterium dilution studies post liver transplantation, as did the child who was 
taken off the transplantation list and was treated for HCV infection. For the child with the HCV 
infection and for 1 of the post liver transplant children, their deuterium samples have not been 














Table 3-18: Results of TBW post liver transplant 
 
ID Age Sex Wt TBW sds HF % LM LM % FM FM % 
3 84 M 26.13 14.81 0.1 76.8 19.28 73.80 6.85 26.20 
4 19 F 13.56 0 n/a      
8 21 M 12.12 8.68 1.06 78.6 11.04 91.12 1.08 8.88 
9 52 F 17.06 8.78 -1.15 78.3 11.21 65.73 5.85 34.27 
10 24 F 10.7 7.62 0.34 78.5 9.71 90.72 0.99 9.28 
12 28 F 9.68 6.17 -1.89 78.5 7.86 81.20 1.82 18.80 
15 219 M 53.8 29.26 -2.22 74.2 39.43 73.30 14.37 26.70 
17 115 F 25.29 13.4 -2.15 77 17.40 68.81 7.89 31.19 
Age in months, Wt weight in kilograms, TBW total body water in kilograms, Sds standard deviation score, 
HF% hydration factor %, LM lean mass in kilograms, FM fat mass in kilograms 
 
 
Figure 3.2: TBW (in kg) versus Age in Months 
TBW total body water 
 





























Figure 3.3: Box plots of sd scores for measured TBW of patients before liver transplant 
and of healthy controls 








Figure 3.4: Box plots of sd scores for TBW of patients before and after liver 
transplantation.  
TBW total body water, sd standard deviation 
 
 
The difference in mean sd score for TBW between the patients and the healthy controls (Figure 
3.3) did not achieve statistical significance. When the mean sd scores for TBW of these 2 
populations were tested individually against an sd score of zero with a paired t-test, the patients 
did have a significant difference (-1.41 ± 1.56, p <0.05) whereas the healthy children did not (-
0.59 ± 1.45, p= 0.2). 
After liver transplantation there was a reduction in the mean sd score for TBW, but the 
difference in mean sd score between the patients before liver transplant and after liver 
transplant did not achieve statistical significance ( 1.24 ± 1.15, p=0.12). 
Various prediction equations exist to predict TBW for healthy children. Wells et al (Wells et al., 
2005) have published a set of these equations for boys and girls, taking into account age, 
weight and height and based on a UK population. These equations are: 
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For the boys: 
Ln(TBW)= -2.952 + 0.551*Ln(Wt) +0.796*Ln(Ht) +0.008(Age), 
Where Ln(TBW) in the natural logarithm of the total body water in litres, Wt is weight in 
kilograms, Ht is height in centimetres and age is in years. 
For the girls, in a similar way: 
Ln(TBW)= -2.952 + 0.551*Ln(Wt) +0.796*Ln(Ht) -0.047 +0.008(Age). 
Using the above equations, the predicted TBW for each participant was calculated as was the 
average TBW (the average of the measured and the predicted TBW) and the values were 
plotted against the percent difference of the measured TBW minus the predicted TBW. One can 
see that there is agreement between measured and predicted TBW for the healthy children, but 
not for the patients either before or after liver transplantation. 
 
 
Figure 3.5: Percent difference in TBW using the Wells equations for patients before and 
after liver transplant and healthy children 
TBW total body water 
 
In summary, from the 12 patients with valid deuterium results, 4 of them had an sd score < 
1.96 (<5th centile) for TBW. None of the children had a FM <10%. From the 11 healthy children, 
3 had an sd score < 1.96 and one of them also had a FM <10%. After the transplant, for 7 of the 








































TBW sds scores were not different between patients and healthy controls. TBW may be an 
indirect measure of lean mass, but this would include organomegaly in the patients and of 
course the TBW would also include water retention or oedema the patients may have. TBW sds 
scores reduced post liver transplant, but this reduction did not achieve statistical significance. 
The prediction equation for TBW by Wells et al (Wells et al., 2005) worked well for the healthy 
children, but not for the patients. 
 
3.1.3 Bromide Dilution Studies 
According to the protocol, only the patients and not the healthy children had bromide dilution 
studies. The bromide solution was of a larger volume to the deuterium and therefore more 
children refused to drink it. It also has a salty taste, which some of the children disliked. 
Of the 17 patients, 5 did not have bromide dilution studies and of the 12 remaining, 7 had valid 
results. The children with the invalid results (results in italics) were the same as the ones with 
the problematic results from the deuterium studies. 
Post liver transplant, of the 9 patients eligible to have the test, 2 refused and therefore 7 of them 
completed the test. In addition the child treated with HCV infection also had the bromide dilution 
study. Her samples, as well as for 2 of the patients are still to be analysed. We therefore have 
results from 5 patients that were post their liver transplant, all valid.  
Unfortunately the 7 patients with valid results pre liver transplant and the 5 with results so far 















Table 3-19: ECW estimated by bromide dilution before and after liver transplantation. 
 
ID PreTx-Age Wt (kg) ECW (kg) ECW%/Wt 
1 118 31.8 9.23 29.04 
2 20 11.04 3.07 27.77 
3 62 21.7 11.64 53.62 
4 7 7.14 0.50 6.96 
6 58 15.2 8.75 57.57 
7 57 15.45 3.71 24.02 
8 10 8.08 7.57 93.69 
10 8 6.98 0 0 
11 126 33.3 9.58 28.77 
14 112 21.8 5.47 25.08 
15 206 54.26 6.18 25.18 
18 188 53.62 16.31 30.42 
ID PostTx-Age Wt (kg) ECW (kg) ECW%/Wt 
3 84 26.13 6.18 23.65 
9 52 17.06 3.95 23.13 
10 24 10.7 2.57 24.06 
12 28 9.68 2.64 27.27 
15 219 53.8 12.28 22.82 
PreTx before transplant, PostTx after transplant, Wt weight, kg kilograms, ECW extra cellular water 
The difference between the mean ECW% per kg of BW before liver transplant (27.18% +/- 2.42) 
was significantly different to the mean post liver transplant (24.19% +/- 1.79 kg) when compared 




Figure 3.6: Percentage of ECW per kilogram of body weight before and after liver 
transplant 
ECW extra cellular water, kg kilograms 
 
 
Figure 3.7: ECW versus age before and after liver transplantation 
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The measurement of TBW and ECW allows as to calculate intracellular water (ICW), which is 
TBW minus ECW. 
Table 3-20: ICW and ECW:ICW before and after liver transplantation 
 
Pre Tx- ID TBW (lit) ECW (lit) ICW (lit) ECW:ICW 
1 21.03 9.29 11.74 0.79 
2 5.83 3.08 2.74 1.13 
6 8.25 3.73 5.54 0.67 
11 20.11 9.64 10.6 0.91 
14 12.45 5.5 7.03 0.78 
17 14.48 6.2 8.36 0.74 
18 35.23 16.42 19.04 0.86 
Post Tx- ID TBW (lit) ECW (lit) ICW (lit) ECW:ICW 
3 14.9 6.22 8.68 0.72 
9 8.84 3.97 4.86 0.82 
10 7.67 2.59 5.08 0.51 
12 6.21 2.66 3.55 0.75 
15 29.45 12.28 17.09 0.72 
PreTx before transplant, PostTx after transplant, TBW total body water, ECW extracellular water, ICW 
intracellular water, lit litres 
 
 
The difference of the mean ECW:ICW before liver transplant (0.79 +/- 0.085) and the mean 
ECW:ICW after liver transplant (0.70 +/- 0.116) did not reach statistical significance. 
In summary, the bromide dilution studies were the most challenging. From the results we have, 
ECW expressed as % per BW significantly reduced post liver transplant, but this was not 
reflected in a reduction of the ratio ECW: ICW. 
 
3.1.4 Air displacement plethysmography (BOD POD) 
According to the protocol, all children healthy and patients, were to have the BOD POD if they 
were over 4 years of age. All children over 4 years of age attempted the BOD POD. Eleven of 
the patients were over 4 years of age, but one of them refused to enter the BOD POD. Of the 
remaining 10 patients, two of the younger ones were not able to yield consistent results. We 
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therefore have valid measurements from 8 of the older patients. Of the 14 healthy controls, 10 
were over 4 years of age and they all attempted the BOD POD with success. 
BOD POD gives us raw body volume measurements. Raw body volume was adjusted using 
age and sex appropriate predicted residual lung volume (Rosenthal et al., 1993, Zapletal et al., 
1976) and surface area artefact (Haycock et al., 1978) to calculate the actual body volume 
(ABV). Body weight (BW) divided by ABV gives total body density (TBD), which is then 
converted to fat mass percentage by using constants C1 and C2 from Wells et al (Wells et al., 
2010b). 
TBD = BW/ARV 
FM% = [(C1/BD)-C2]*100 
FM = BW * (FM%/100) 
FFM = BW – FM 
FM and FFM indices were converted to sd scores (z scores) using the previously mentioned 
reference population. 
By looking at the patients, we see 5 out of eight have a fat mass percentage of over 20% and 3 
of them over 30%. In spite of this their fat mass sd score for their age and sex is within normal 
limits. This could reflect a reduction in lean mass, which is really why proportionally the fat mass 
seems more. In fact 3 children have significantly low fat free mass sd scores.  
In healthy individuals, BMI tends to reflect fat mass and frequently fat mass correlates with fat 
free mass. In the patients, there was no significant correlation between BMI sd score and FM sd 
score, FM sd score and FFM sd score, FM percentage and BMI and FM percentage and BMI sd 
score for the patients. 
By looking at the healthy children, we see 7 out of ten have a fat mass percentage of over 20%, 
and 1 of them over 30%. Again FM sd scores are within normal limits, apart from one child with 
a very low FM sd score and also a very low BMI sd score. There is though now an important 
distinction. In the healthy children BMI sd score and FM sd score correlate strongly and have a 
Pearson’s correlation factor of 0.886 (p= 0.001). FM sd score and FFM sd score also correlate 
significantly (r= 0.678, p = 0.031). The correlation between FM percentage and BMI doesn’t 
quite reach significance (r=0.63, p=0.051), but between FM percentage and BMI sd score it 
does (r=0.765 and p=0.01). 










Table 3-21: Indices from the BOD POD for the patients 
 
ID Age Sex BMI sds FM FM% FFM TBD FM sds FFM sds TBD sds 
1 9.89 F -2.21 5.68 17.87 26.12 1.051 -0.87 0.14 0.95 
3 5.16 M 1.18 5.38 24.77 16.32 1.031 1.1 -0.15 -1.08 
11 10.54 F 0.86 8.09 24.27 25.23 1.038 -0.3 -0.58 0.11 
14 9.31 M -0.58 3.18 14.6 18.62 1.056 -1.14 -1.96 0.63 
15 17.17 M 0.27 18.63 34.34 35.63 1.022 0.91 -3.22 -1.63 
16 16.69 F 0.12 20.56 34.85 38.45 1.023 0.66 -0.88 -0.73 
17 8.7 F -0.44 8.03 32.72 16.5 1.02 0.12 -2.32 -0.89 
18 15.7 M -1.04 8.25 15.38 45.37 1.06 -0.2 -0.95 -0.08 
 












Table 3-22: Indices from the BOD POD for the healthy controls 
 
ID Age Sex BMI sds FM FM% FFM TBD FM sds FFM sds TBD sds 
C2 4.56 M 0.22 2.47 12.85 16.78 1.055 -0.33 0.68 -2.47 
C5 4.51 M -0.37 3.67 20.75 14.01 1.039 0.57 -0.72 -2.67 
C7 10.06 M -0.09 4.7 16.21 24.3 1.054 -0.48 -0.53 0.66 
C8 13.48 F 0.55 10.21 26.28 28.64 1.036 -0.21 -1.26 0.01 
C9 9.69 M 0.54 9.26 28.64 23.07 1.028 0.86 -0.66 -1.1 
C10 17.94 F 1.26 23.46 33.93 45.68 1.025 0.81 0.54 -0.62 
C11 15.84 M -2.69 2.32 5.98 36.44 1.081 -2.53 -2.45 1.43 
C12 4.32 F 1.09 4.96 25.06 14.82 1.031 0.65 0.73 -0.31 
C13 6.53 F 0.46 6.39 25.40 18.76 1.035 0.3 0.32 -0.07 
C14 9.6 F -0.61 7.19 27.26 19.17 1.032 -0.32 -1.86 -0.27 
 
 








Figure 3.8: Relationship between FM% and TBD 
FM fat mass, TBD total body density 
 
As expected there was a strong negative correlation between total body density and fat mass 
percentage. Fat mass has a stable density of 0.9094 gr/cm3 and fat free mass has a higher 
density than fat mass, therefore the more fat in the tissue the lower the density. This 
relationship remained strong when we looked at the participants all together, and when we 
looked at them separately (healthy controls and patients). 
Four of the patients had BOD POD measurements post liver transplant as well. One of them, 
who was not transplanted, but was treated for HCV and was 1 year post sustained viral 
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5.16 3M  17.18 1.18 5.38 24.77 16.32 1.031 1.1 -0.15 -1.08 
6.96  1.66 17.3 1.08 7.65 29.27 18.48 1.025 1.18 -0.55 -1.59 
10.54 11F  19.35 0.86 8.09 24.27 25.23 1.038 -0.3 -0.58 0.11 
12.24  1.45 19.53 0.49 9.17 22.14 32.23 1.045 -0.39 -0.23 0.56 
17.17 15M  21.3 0.27 18.63 34.34 35.63 1.022 0.91 -3.22 -1.63 
18.3  0.57 20.37 -0.35 19.47 34.07 37.68 1.022 0.86 -3.18 -1.55 
8.7 17F  15.45 -0.44 8.03 32.72 16.5 1.020 0.12 -2.32 -0.89 
9.6  0.56 15.24 -0.78 8.02 31.7 17.27 1.022 -0.10 -2.59 -0.77 
16.69 16F  21.06 0.12 20.56 34.85 38.45 1.023 0.66 -0.88 -0.73 
17.86  1.0 24.99 1.2 28.03 39.93 42.17 1.012 1.24 -0.16 -1.29 
In light blue the measurements before liver transplant and in white the measurements after liver transplant. 
The last 2 lines are the patient with the HCV infection, before and after treatment. 
Age in years, M male, F female, TpTx time from transplant, BMI body mass index, sds standard deviation 
score, FN fat mass, FFM fat free mass, TBD total body density 
 
 
By performing a paired t-test for the 4 patients that had a liver transplant, we found no statistical 
significant difference between any on the indices before and after liver transplantation.  
There was significant correlation between FM (r= 0.987, p<0.05), FFM (r=0.965, p<0.05), FM sd 
score (r=0.993. p<0.01) and FFM sd score (r=0.026, p<0.05) before and after liver 
transplantation. There was significant correlation between BMI (r=0.983, p<0.05) and BMI sd 
score (r=0.966, p<0.05) before and after liver transplantation for these 4 patients. 
FM% post-transplant significantly correlated with TBD sd score before transplant (r= -0.951, 
p<0.05) and TBD post-transplant (r=-0.96, p<0.05). FFM post-transplant correlated with BMI 
before transplant (r=0.967, p<0.05) and FFM sd score post-transplant correlated with FM5 
before transplant (r=-0.998, p<0.01). Overall there were no significant correlations between FM, 
FFM and BMI before transplant and equally none after liver transplantation. 
In summary, the BODPOD could only be done by the older patients.  Looking at 8 of these 
patients they all had a FM% of over 10% and their FM sd score was within normal limits. In 
regards to FFM through, 3 of them (in spite of the organomegaly) had a low FFM sd score < 
1.96. From the 10 healthy children, only one had a very low FM and FFM sd score; he was the 
one identified by the deuterium studies with a FM < 10%. The four patients with FM and FFM sd 
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scores before and after liver transplant showed no significant difference in these scores after 
liver transplant. The one patient that had the HCV infection treated, but remained cirrhotic, had 
a noticeable increase in FM sd score. As expected total body density had a strong negative 
correlation with FM%. 
 
3.1.5 Dual-energy X-ray absorptiometry (DXA) 
According to the study protocol only patients over the age 4 years were to have a DXA scan. 
Eleven of the 17 patients fitted this requirement and had their whole body DXA scan. Of these 
11 patients, 6 were female. Their age varied from 4.7 to 17.2 years (mean 10.69, median 9.89 
and SD 4.78 years). 
DXA allows for total and regional body composition data. For each patient, DXA will give values 
of total FM, bone free FFM (LM) and BMC. The FM and LM was expressed in sd scores to allow 
comparisons between the patients, using data from the reference populations previously 
mentioned (Wells et al., 2012, Wells et al., 2010b). FM and LM can also be expressed as fat 
mass index (FMI) and lean mass index (LMI) and then again in sd scores. FMI and LMI are 
calculated by a method analogous to BMI (FM and LM divided by Ht2 respectively). In addition it 
will give values of arm, leg and trunk FM, LM, which can then be converted to the relevant 
indices and subsequent sd scores. This helps remove the effect of height, which is of particular 
relevance in children that may be stunted (Wells et al., 2002). 
Table 3-24 and Table 3-25 show the sd scores for the FM and FMI measurements for the 
children before liver transplantation. One child had a BMI sd score below -2, but no sd scores 
for the FM related indices was below 2. In addition when running a paired t-test comparing 
these FM sd scores to 0, this population differed from 0 significantly only for the arm FM sd 





























1f 2.67 -0.02 -2.21 -1.36 -1.57 -1.51 -1.16 
3m 0.38 1.06 1.18 0.31 -0.25 0.30 0.61 
6m -1.77 -1.66 -0.52 -0.48 -0.06 -0.12 -0.44 
7f -1.70 -0.88 0.34 -0.15 -1.13 -0.46 0.39 
11f -1.55 -0.14 0.88 -0.79 -0.85 -0.99 -0.61 
13f -3.88 -1.61 0.80 -0.28 -0.09 -0.61 -0.16 
14m -2.54 -2.16 -0.57 -0.45 -1.13 -0.52 -0.28 
15m -2.32 -1.20 0.37 0.10 0.21 0.25 -0.15 
16f 0.65 0.44 0.28 0.00 -0.15 -0.15 0.13 
17f -0.88 -0.77 -0.41 -0.79 -1.05 -0.85 -0.64 
18m -0.04 -0.48 -0.61 -1.07 -1.67 -1.05 -1.01 
Sds standard deviation score, BMI body mass index, FM fat mass, f female, m male 


















1f 2.67 -0.02 -2.21 -1.68 -1.79 -1.86 -1.38 
3m 0.38 1.06 1.18 0.36 -0.35 0.26 0.51 
6m -1.77 -1.66 -0.52 0.04 0.08 0.14 -0.15 
7f -1.70 -0.88 0.34 -0.13 -1.16 -0.34 0.34 
11f -1.55 -0.14 0.88 -0.39 -0.54 -0.56 -0.22 
13f -3.88 -1.61 0.80 0.41 0.49 0.22 0.45 
14m -2.54 -2.16 -0.57 0.04 -0.66 0.00 0.12 
15m -2.32 -1.20 0.37 0.39 0.39 0.60 0.25 
16f 0.65 0.44 0.28 -0.11 -0.24 -0.23 0.02 
17f -0.88 -0.77 -0.41 -0.52 -0.86 -0.62 -0.36 
18m -0.04 -0.48 -0.61 -1.16 -1.82 -1.20 -0.96 




Table 3-26: Correlation between FM and FMI from the DXA 
 
 
*p<0.05, **p<0.01, ***p<0.001, NS not significant correlation, N/A not applicable 
BMI body mass index, FM fat mass, FMI fat mass index, z standard deviation score 
 
 
In Table 3-26 we can see the correlations between the FM and FMI sd scores derived from DXA 
for the patients prior to liver transplantation. In addition to the values shown in the table, arm FM 
sd score also correlated with weight (r= 0.611, p< 0.05) and as expected, total FMI sd score had 
a negative correlation with height (r= -0.709, p<0.05), as did arm FMI sd score (r=-0.646, 
p<0.05), leg FMI sd score (r= -0.700, p<0.05) and trunk FMI sd score (=-0.662, p<0.05). 
BMI sd score correlated strongly with all sd scores of variables: total FM (r= 0.754, p<0.01), arm 
FM (r=0.604, p<0.05), leg FM (r=0.619, p<0.05), trunk FM (r=0.736, p<0.05), total FMI (r=0.782, 
p<0.05), arm FMI (r=0.624, p<0.05), leg FMI (r= 0.719, p<0.05) and trunk FMI (0.833, p<0.01). 






























































































1f 2.67 -0.02 -2.21 -0.47 -2.18 -1.57 0.84 
3m 0.38 1.06 1.18 0.54 -1.29 -0.80 2.23 
6m -1.77 -1.66 -0.52 -2.53 -0.90 -2.32 -2.24 
7f -1.70 -0.88 0.34 -1.15 -1.12 -1.94 -0.26 
11f -1.55 -0.14 0.88 -0.16 -1.71 -0.92 0.94 
13f -3.88 -1.61 0.80 -2.51 -2.87 -2.78 -1.84 
14m -2.54 -2.16 -0.57 -2.62 -2.54 -2.61 -2.08 
15m -2.32 -1.20 0.37 -1.88 -4.11 -3.00 -0.41 
16f 0.65 0.44 0.28 0.13 -0.15 -0.28 0.67 
17f -0.88 -0.77 -0.41 -0.85 -2.97 -2.43 -0.20 
18m -0.04 -0.48 -0.61 -0.23 -0.69 -0.41 0.11 





































1f 2.67 -0.02 -2.21 -2.34 -4.05 -3.51 0.01 
3m 0.38 1.06 1.18 1.04 -1.75 -1.21 3.92 
6m -1.77 -1.66 -0.52 -1.79 0.03 -2.00 -1.39 
7f -1.70 -0.88 0.34 0.28 -0.43 -1.42 1.42 
11f -1.55 -0.14 0.88 1.92 -0.89 0.33 3.30 
13f -3.88 -1.61 0.80 0.14 -0.98 -0.77 0.93 
14m -2.54 -2.16 -0.57 -1.52 -1.69 -1.84 -0.62 
15m -2.32 -1.20 0.37 -0.82 -4.42 -2.53 1.40 
16f 0.65 0.44 0.28 0.06 -0.29 -0.49 0.70 
17f -0.88 -0.77 -0.41 -1.00 -3.41 -2.66 0.94 
18m -0.04 -0.48 -0.61 -0.42 -0.95 -0.62 0.10 
Sds standard deviation score, BMI body mass index, LMI lean mass index, f female, m male 
 
In contrast to the FM and FMI sd scores, many more LM and LMI sd scores are below -1.96. 
When this data was compared with a paired t-test to 0, total LM sd score (-1.07 +/- 1.15, 
p<0.05), arm LM sd score (-1.87 +/- 1.18, p<0.001), leg LM sd score (-1.73 +/- 0.99, p<0.001, 
arm LMI sd score (-1.71 +/- 1.55, p<0.01) and leg LMI sd score (-1.52 +/- 1.12, p<0.01) differed 















































































NS NS NS 0.736** 0.843** NS NS N/A 
*correlation was statistically significant with a p<0.05, ** correlation was statistically significant with a 
p<0.01,  
*** correlation was statistically significant with a p<0.001, NS not significant, N/A not applicable 
BMI body mass index, LM lean mass, LMI lean mass index, z standard deviation score 
 
 
Table 3-29 shows the correlations between the LM and LMI sd scores. In addition to the ones 
shown in the table, Height sd score correlated significantly with total LM sd score (r=0.744, 
p<0.01), leg LM sd score (r= 0.651, p<0.05) and trunk LM sd score (r=0.702, p<0.05). Weight sd 
score correlated significantly with total LM sd score (r=0.958, p<0.001), leg LM sd score 
(r=0.802, P<0.01), trunk LM sd score (r=0.959, p<0.001) and trunk LMI sd score (r=0.64, 
p<0.05). BMI sd score correlated significantly with the following sd scores: total LMI (r=0.853, 
p<0.01), leg LMI (r=0.68, p<0.05) and trunk LMI (r=0.706, p<0.05). 
None of the FM or FMI sd scores, either regional or total correlated significantly with any of the 
LM or LMI sd scores either regional or total. 
Four children had a whole body DXA before and after liver transplantation. The two children that 
were removed for the liver transplantation list also had repeat whole body DXA scans. In Table 
3-30 and in Table 3-31 we can see the FM sd scores and the FMI sd scores before and after 
liver transplantation for the 4 children that had liver transplants. 
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Pre Tx         
5.16 3M 0.38 1.06 1.18 0.31 -0.25 0.30 0.61 
10.54 11F -1.55 -0.14 0.88 -0.79 -0.85 -0.99 -0.61 
17.17 15M -2.32 -1.20 0.37 0.10 0.21 0.25 -0.15 
8.66 17F -0.88 -0.77 -0.41 -0.79 -1.05 -0.85 -0.64 
Post 
Tx  
       
6.91 3M 0.30 1.07 1.25 1.20 0.83 0.58 1.25 
12.24 11F -0.78 -0.02 0.48 -0.94 -0.63 -1.11 -0.91 
18.42 15M -2.07 -1.27 0.16 0.56 0.79 0.60 0.40 
9.58 17F -1.18 -1.15 -0.70 -0.62 -0.45 -0.62 -0.49 
Age in years, Pre Tx before transplantation, Post Tx after transplantation, M male, F female, sds standard 

























Pre Tx         
5.16 3M 0.38 1.06 1.18 0.36 -0.35 0.26 0.51 
10.54 11F -1.55 -0.14 0.88 -0.39 -0.54 -0.56 -0.22 
17.17 15M -2.32 -1.20 0.37 0.39 0.39 0.60 0.25 
8.66 17F -0.88 -0.77 -0.41 -0.52 -0.86 -0.62 -0.36 
Post 
Tx  
       
6.91 3M 0.30 1.07 1.25 1.11 0.87 0.67 1.20 
12.24 11F -0.78 -0.02 0.48 -0.80 -0.51 -0.91 -0.76 
18.42 15M -2.07 -1.27 0.16 0.83 0.96 1.00 0.66 
9.58 17F -1.18 -1.15 -0.70 -0.17 -0.18 -0.27 -0.15 
Age in years, Pre Tx before transplantation, Post Tx after transplantation, M male, F female, sds standard 




When the mean difference in sd score for the FM and FMI measurements was compared 
between the 2 groups with a paired t-test, only the difference in arm FM z score before and after 
transplant achieved statistical significance at p<0.05. 
BMI sd score before transplant correlated significantly with BMI sd score after transplant (r= 
0.975, p<0.05), as did total FM sd score (r=0.985, p<0.05), Leg FM sd score (r=0.988, p<0.05) 
and trunk FM sd score (r=0.963, p<0.05), but not arm FM sd score. These correlations were not 
significant for total FMI, arm FMI, leg FMI and trunk FMI sd scores before and after liver 
transplant. 
In Table 3-32 and Table 3-33, the LM sd scores and the LMI sd scores before and after liver 
transplantation for the 4 children that had liver transplants are shown. Two of these children had 
significantly low arm and leg LM and LMI sd scores before their liver transplant and these 
remained low after their liver transplant.  
 
 




















Pre Tx         
5.16 3M 0.38 1.06 1.18 0.54 -1.29 -0.80 2.23 
10.54 11F -1.55 -0.14 0.88 -0.16 -1.71 -0.92 0.94 
17.17 15M -2.32 -1.20 0.37 -1.88 -4.11 -3.00 -0.41 
8.66 17F -0.88 -0.77 -0.41 -0.85 -2.97 -2.43 -0.20 
Post 
Tx  
       
6.91 3M 0.30 1.07 1.25 -0.13 -0.41 -0.49 0.58 
12.24 11F -0.78 -0.02 0.48 0.30 0.32 -0.14 0.66 
18.42 15M -2.07 -1.27 0.16 -2.66 -3.18 -2.92 -2.05 
9.58 17F -1.18 -1.15 -0.70 -2.51 -3.29 -2.91 -2.00 
Age in years, Pre Tx before transplantation, Post Tx after transplantation, M male, F female, sds standard 





























Pre Tx         
5.16 3M 0.38 1.06 1.18 1.04 -1.75 -1.21 3.92 
10.54 11F -1.55 -0.14 0.88 1.92 -0.89 0.33 3.30 
17.17 15M -2.32 -1.20 0.37 -0.82 -4.42 -2.53 1.40 
8.66 17F -0.88 -0.77 -0.41 -1.00 -3.41 -2.66 0.94 
Post 
Tx  
       
6.91 3M 0.30 1.07 1.25 -0.40 -0.57 -0.79 0.93 
12.24 11F -0.78 -0.02 0.48 1.58 1.13 0.81 2.18 
18.42 15M -2.07 -1.27 0.16 -2.11 -3.10 -2.39 -1.36 
9.58 17F -1.18 -1.15 -0.70 -2.66 -3.52 -3.09 -1.74 
Age in years, Pre Tx before transplantation, Post Tx after transplantation, M male, F female, sds standard 
deviation score, BMI body mass index, LMI lean mass index 
 
When the mean difference in sd score for the LM and LMI measurements was compared 
between the 2 groups with a paired t-test, there was a statistically significant difference (p 
<0.05) between trunk LM sd score, total LMI sd score and trunk LMI sd score. All three 
decreased post liver transplantation. 
Leg LM sd score, LMI sd score and leg LMI sd score pre transplant had a strong positive 
correlation with the corresponding measurements post-transplant (r= 0.968, 0.981 and 0.989 
respectively, p<0.05). 
There were no statistically significant correlations between the FM and FMI sd scores and the 
LM or LMI sd scores either before or after liver transplantation. 
Two of the children were taken off the liver transplant waiting list. One was a 16 year old girl 
with HCV related cirrhosis. She was treated successfully for the HCV infection and she 
remained stable from a cirrhosis point of view. At the time of the second DXA scan she was not 
taking any diuretics. The second child was a child already transplanted because of biliary 
atresia, but with significant graft function. He was taken off the list, because it was felt, the 
dysfunction was improving and it was a matter of lapsed compliance with his 
immunosuppression. Table 3-34 and Table 3-35 show the sd scores for these 2 children at the 
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time they were considered for liver transplantation and 15 and 13 months later respectively. 
One can see that the girl has increased fat mass, whilst the boy has further reduced lean mass. 
 


















16.66 16f 0.65 0.44 0.28 0.00 -0.15 -0.15 0.13 
17.86 16f 0.67 1.38 1.24 1.03 1.02 0.71 1.22 
9.25 14m -2.54 -2.16 -0.57 -0.45 -1.13 -0.52 -0.28 
10.44 14m -1.51 -0.55 0.44 0.89 0.70 0.84 1.03 
In light green the measurements for the girl and in light orange the measurements for the boy. Age in 
years, f female, m male, sds standard deviation score, BMI body mass index, FM fat mass 
 







































-0.11 -0.24 -0.23 0.02 0.13 -0.15 -0.28 0.67 0.06 -0.29 -0.49 0.70 
1.03 1.03 0.66 1.18 0.08 0.84 -0.09 0.48 0.09 0.90 -0.18 0.58 
0.04 -0.66 0.00 0.12 -2.62 -2.54 -2.61 -2.08 -1.52 -1.69 -1.84 -0.62 
1.25 0.99 1.20 1.28 -2.60 -2.69 -2.47 -2.27 -2.81 -2.54 -2.50 -2.25 
In light green the measurements for the girl and in light orange the measurements for the boy. Age in 
years, f female, m male, sds standard deviation score, BMI body mass index, FM fat mass 
 
3.1.5.1 Bone mineral density (BMD). 
The eleven children with ESCLD who had a whole body DXA also had their BMD measured by 
the machine. By convention the sd score reported for BMD is the one for the whole body without 
the head (TBLH). Two of these children were under the age of 5 years and there is not enough 
reference data to generate an sd score, but the BMD of these 2 children was less than the BMD 
of some of the under 5 years of age in the database. 
The nine older children had a mean sd score for their BMD of -1.43 (SD 1.09, median of -0.8 
and a range of -0.3 to -3.2). When compared to an sd score of 0, this was significantly less 
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(p<0.01). There was no significant correlation between TBD sd score and vitamin D levels of the 
patients. 
Four of these 9 patients have had a post liver transplant whole body DXA scan. Their mean 
BMD sd score prior to liver transplant was -1.28 (+/- 1.14) and after the liver transplant -0.95 (+/- 
1.56). There was no statistical difference detected between these two means. The correlation of 
BMD sd score before and after liver transplant, almost reached statistical significance at 
p=0.055. 
The two children that had repeat whole body DXA scans, but who had not had a liver transplant 
showed some improvement in their BMD sd scores. One of them was the girl with HCV related 
cirrhosis who received treatment for the HCV infection. Her BMD sd score improved from -0.8 to 
-0.2 in 15 months. The other child was a boy, already transplanted for biliary atresia who was 
considered for a second liver transplant. His original BMD z score was -3.2 and this had 
improved to -2.2 13 months later, but remained considerably low. 
In summary, the DXA could only be done by the older patients. Eleven patients had their DXA. 
All indices related to FM were within the normal range. This was not the same for the indices 
related to LM. Six of the eleven patients had LM sd score, either total or regional, well below the 
normal range. When this was corrected for height, four had regional LMI sd scores well below 
the normal range. For the patients were BMD could be referenced it was found to be lower than 
the normal population. 
Four patients had measurements before and after transplant; FM remained within the normal 
range and LM remained low where it was low before transplant. 
 
3.1.6 Bioelectrical Impedance (BIA) 
All the patients and the healthy controls had BIA. Phase angle (PA) was significantly lower in 
the patients (mean 4.3) compared to the healthy controls (5.3) (two tailed t-test with a p value of 
0.0115 (ΔX= -1.0918, CI 95% -1.9181 to -0.2655). There was no statistically significant 
difference of PA between the patients before (mean 4.5) and after transplantation (mean 4.27) 
(p value 0.6391, two-tailed paired t-test). There was no statistically significant difference 
between the healthy controls and the patients post liver transplant. 
The mean PA before liver transplant (4.7 +/- 1.06) and the mean PA after liver transplant (4.07 





Figure 3.9 Phase angle of patients versus healthy controls 
PA phase angle 
 
Furthermore, the difference of the mean illness marker (IM) of the patients prior to liver 
transplantation (0.867 ± 0.057) and the mean IM of the healthy controls (0.842 ± 0.089) did not 
achieve statistical significance. In a similar way the mean difference of the mean IM of the 
patients before (0.854 ± 0.045) and after (0.851 ± 0.029) did not achieve statistical significance. 
In summary, phase angle as previously described was lower in the patients in comparison to 
the controls, but a significant increase was not demonstrated post liver transplant. Illness 
marker was not significantly different between the two groups. 
 
3.1.7 Indirect Calorimetry 
3.1.7.1 REE before liver transplant 
Seventeen children had their REE measured (mREE) prior to having a liver transplant with 
indirect calorimetry. Valid results were obtained in sixteen of them. mREE was recorded in 
Kcal/day and also expressed as Kcal/day/kg of body weight. In addition their predicted REE 
(pREE) was calculated from the Henry 2005 equations (Henry, 2005). Subsequently (REE-
pREE)/pREE *100% was calculated. The children with a percentage of over +20% would be 
considered hypermetabolic and with a percentage of less than -20% would be considered 




















1 9.88 F 31.8 1572 1179 33.3 49.43 
2 1.76 M 11.04 802 629 27.5 72.64 
3 5.16 M 21.7 1166 717 62.6 53.73 
4 0.63 F 7.14 488 408 19.6 68.35 
7 4.74 F 15.45 906 803 12.8 58.64 
8 0.81 M 8.08 489 441 10.9 60.52 
9 3.02 F 11.4 705 719 -0.02 61.84 
10 0.66 F 6.98 622 388 60.3 89.11 
11 10.54 F 33.3 1455 1102 32 43.69 
12 0.99 F 7.06 455 406 12.1 64.44 
13 15.06 F 42.4 1646 1204 36.7 38.82 
14 9.31 M 21.8 1284 724 77.3 58.90 
15 17.17 M 54.26 1702 1570 8.4 31.37 
16 16.7 F 59.01 1503 1434 4.8 25.47 
17 8.7 F 24.53 1229 1004 18.3 50.10 
18 15.7 M 53.62 1848 1599 15.6 34.46 
F female, M male, kg kilograms, cm centimetres, kcal kilocalorie, mREE measured resting energy 
expenditure, pREE predicted resting energy expenditure, BW body weight, in bold the measurements of 
REE that over 20% the predicted REE. 
 
 
Seven of the 16 children (44%) would qualify as hypermetabolic when using the predictive 
equations to compare their REE, the rest were all normometabolic 9/16 (56%) and none were 
hypometabolic. 
Table 3-37: Comparisons between hypermetabolic and normometabolic patients 
 
 No of patients Mean Wt sds Mean Ht sds Mean BMI sds 
Hypermetabolic 7 -0.63 -1.1243 0.0671 
Normometabolic 9 -0.98 -1.1022 -0.3967 




None of the differences of the mean z scores for weight, height or BMI between the 
hypermetabolic and normometabolic group achieved statistical significance using an unpaired 
independent t-test. Mean RQ between the 2 groups was identical at 0.77. The diagnoses of the 
children in the hypermetabolic group were neonatal sclerosing cholangitis, biliary atresia (3 of 
them), Alagille syndrome and one already transplanted for biliary atresia, being considered for a 
second transplant. The hypermetabolic patients in comparison to the normometabolic ones 
were not different in any of the liver function tests, including bilirubin levels. 
In addition we measured REE for thirteen healthy children and calculated for the predicted REE 
from the Henry 2005 equations. Only for twelve were the results valid and can be seen below:  















C2 4.58 M 19.25 1388 678 105 72.10 
C6 0.79 F 9.2 738 527 40 80.21 
C5 4.5 M 17.68 1125 653 72.3 63.63 
C7 10 M 29 1256 1106 13.6 43.31 
C8 13.5 F 38.85 1560 1176 32.6 40.15 
C9 9.67 M 32.33 1269 896 41.6 39.25 
C10 18 F 69.14 1447 1524 -0.05 20.93 
C11 15.83 M 38.76 1313 1326 -0.01 33.88 
C12 4.33 F 19.78 1180 888 32.9 59.66 
C13 6.5 F 25.15 1177 1009 16.7 46.8 
C14 9.58 F 26.36 1174 1042 12.7 44.54 
C15 2.67 F 18.2 949 963 -0.02 52.14 
F female, M male, kg kilograms, cm centimetres, kcal kilocalorie, mREE measured resting energy 
expenditure, pREE predicted resting energy expenditure, BW body weight, in bold the measurements of 
REE that over 20% the predicted REE. 
 
 
As one can see, with the previous definitions applied to the patients, 6 of the 12 (50%) healthy 




Table 3-39: Comparisons between hypermetabolic and normometabolic healthy controls 
 
 No of patients Mean Wt sds  Mean Ht sds Mean BMI sds 
Hypermetabolic 6 0.44 0.41 0.25 
Normometabolic 6 0.06 -0.06 0.06 
Wt weight, Ht height, BMI body mass index, sds standard deviation score 
 
None of the differences of the mean sd scores for weight, height or BMI between the 
hypermetabolic and normometabolic group achieved statistical significance using an unpaired 
independent t-test. The mean RQ for the hypermetabolic healthy children was 0.75 and for the 
normometabolic it was 0.79- this difference did not achieve statistical significance. 
When comparing the two groups, patients and healthy controls, as whole groups there was no 
significant difference between mean age, mean mREE/kg or RQ between the two groups. 
 
Table 3-40: Mean Age, mREE/kg and RQ between patients and healthy controls 
 
 Age (years) mREE/kg RQ 
Patients 7.55 (SD +6.16) 53.85 (SD +16.58) 0.77 (SD +0.036) 
Controls 8.33 (SD +5.39) 49.72 (SD +16.75) 0.77 (SD +0.051) 
mREE measured resting energy expenditure, kg kilograms, RQ respiratory quotient 
 
Seven of the patients could be matched for sex and age and so for them REE and RQ was 












Table 3-41: Mean Age, REE/kg, RQ, Weight, Height and BMI sd scores of patients and 
paired controls 
 Mean SD SE mean 
Age of patient 8.45 6.07 1.62 
Age of control 8.27 6.03 1.61 
REE/kg patient 52.03 16.83 4.50 
REE/kg control 52.17 19.34 5.17 
RQ patient 0.78 0.03 0.01 
RQ control 0.79 0.06 0.02 
Weight sd patient -0.84 0.91 0.24 
Weight sd control -0.10 1.53 0.41 
Height sd patient -0.99 1.66 0.44 
Height sd control 0.09 1.59 0.43 
BMI sd patient -0.31 0.92 0.25 
BMI sd control -0.27 1.32 0.35 
SD standard deviation, SE standard error, REE/kg resting energy expenditure per kilogram, RQ respiratory 
quotient, sd standard deviation score, BMI body mass index 
 
None of the above differences in mean between the various groups reached statistical 
significance using a paired t-test. As one can see, the mean REE/kg for the patients and their 
paired controls was almost identical. The mean difference between REE/kg of patient – REE/kg 
of paired control was -0.1621 kcal/kg (median: -0.1350 kcal/kg, min -18.37 kcal/kg and 
maximum +15.59 kcal/kg, SD 9.72 kcal/kg).  
There was a strong negative correlation between age and REE/kg for the patients (Pearson’s 
correlation -0.92, p <0.01) and the controls (Pearson’s correlation -0.938, p<0.01). 
 
3.1.7.2 REE after liver transplant 
For nine of the patients that have had their liver transplant we have indirect calorimetry results 
post liver transplant. The repeat measurements were done on average 15.6 months after the 
first body composition assessment (median 15.9 months, minimum 10.8 months and maximum 
21.6 months) and on average 11.4 months after the liver transplant (median 10.8 months, 




Table 3-42: Mean REE/kg and mean RQ before and after liver transplantation 
 
 Mean SD SE mean 
REE/kg pre 58.13 16.33 5.44 
REE/kg post 58.58 18.70 6.23 
RQ pre 0.77 0.04 0.01 
RQ post 0.76 0.05 0.02 
SD standard deviation, SE standard error, REE/kg resting energy expenditure per kilogram, RQ respiratory 
quotient, pre- before transplant, post- after transplant 
 
The difference in mean REE/kg before and after liver transplantation was not statistically 
significant (paired t-test, p= 0.899). The difference in mean RQ before and after liver 
transplantation was also not significant (paired t-test, p=0.645). 
REE/kg pre transplant correlated significantly with REE/kg post-transplant (Pearson’s 
correlation factor 0.832, p= 0.005). 
 
Figure 3.10: Correlation between REE/kg in kcal/kg before and after liver transplantation 
REE_kg_post resting energy expenditure per kilogram of body weight after transplantation, REE_kg_pre 
resting energy expenditure per kilogram of body weight before transplantation 
 
RQ before liver transplant did not correlate significantly with RQ after liver transplant. 
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From these 9 patients, we see that 3 of them would be classified as hypermetabolic when 
comparing to prediction equations. These 3 remained hypermetabolic after the liver transplant, 
but an additional 3 would now also classified as hypermetabolic after the transplant, making a 
total of 6 out of 9. 
 















3M 5.30 53.73 59.36 62.6 95.8 
4F 0.65 68.35 55.53 19.6 4.1 
8M 1.09 60.52 71.78 10.9 28.9 
9F 3.14 61.84 70.81 -0.02 44.5 
10F 1.11 89.11 78.04 60.3 34.5 
11F 10.79 43.69 36.6 32 24.8 
12F 1.90 64.45 80.79 12.1 38.2 
17F 9.04 50.1 47.01 18.3 16.6 
15M 17.73 31.37 27.35 8.4 -3.8 
mREE measured resting energy expenditure, pREE predicted resting energy expenditure, kg kilogram, 
pre- before liver transplant, post-after liver transplant 
 
In summary, prediction of REE with equations underestimates REE for patients and healthy 
controls.  The main determinant of REE/kg after transplant is the REE/kg before transplant. 
REE/kg reduces with increasing age. 
In summary, whereas 44% of the patients were demonstrated to be hypermetabolic when 
using the predictive equations to compare their REE, so were 50% of the healthy children. Nine 
patients were measured post liver transplant and 67% were hypermetabolic. REE/kg of BW 
before transplant correlated strongly to REE/kg after liver transplantation. 
 
3.1.8 3D Photonic Scanning (3D-PS) 
Three of the patients had 3D photonic scanning before and after liver transplantation and the 
child with HCV related cirrhosis also had 3D-PS before and after treatment. Apart from the 
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images, 3D-PS generates anthropometric measurements and the pairs for these 4 patients are 
shown in the table below. 
 
Figure 3.11: Image generated by 3D-PS of a child with ESCLD 
3D-PS 3 dimensional photonic scanning, ESCLD end stage chronic liver disease 
 
Figure 3.12: 3D-PS image of the child in Figure 3-11 after liver transplantation 
3D-PS 3 dimensional photonic scanning 
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Table 3-44: 3D-PS measurements of children before and after liver transplantation 
 







17-pre 64.2 67.3 20.6 30.7 108.1 24.2 
17-post 62.5 70.8 21.5 34.1 107.9 27.6 
16-pre   25.3 44.0 155.2 34.9 
16-post 93.1 103.4 33.3 54.4 145.7 37.8 
11-pre 70.0 75.4 22.1 38.2 123.2 28.0 
11-post 69.3 77.1 24.5 48.1 114.7 34.9 
13-pre 81.3 90.0 26.3 43.4 150.1 33.6 
13-post 81.9 96.5 31.0 44.5 155.5 34.5 




There was a strong correlation between the thigh and the calf circumference (Pearson’s 
correlation factor 0.963, p< 0.001). The hips circumference correlated with the centre trunk 
(0.918, p<0.05) and the waist (0.979, p<0.001). Correlations were tested with FM, FMI, LM and 
LMI sd scores from the whole body DXA measurements. Only waist circumference correlated 
with the trunk FM sd score and the trunk FMI sd score significantly (Pearson’s correlation factor 
0.763 with p< 0.05 and 0.827 with P <0.05 respectively). All 3 measurements though correlated 
significantly with total FM sd score and total FMI sd score; waist (Pearson correlation 0.93 
p<0.05 and 0.86 p<0.01 respectively), hips (Pearson correlation 0.949 p<0.01 and 0.910 at 
p<0.01 respectively) and centre trunk circumference (0.814 p<0.05 and 0.741 p<0.05). Waist, 
centre trunk, thigh and calf circumference did not correlate significantly with any of the LM or 
LMI sd scores. 
The upper arm circumference by 3D-PS correlated strongly with MUAC and also had a strong 
correlation with arm LM sd score (Pearson correlation 0.887 p<0.05) and arm LMI sd score 







Figure 3.13: Correlation between upper arm circumference by 3D-PS and MUAC by 
anthropometry 
3D-PS 3 dimensional photonic scanning, MUAC mid upper arm circumference, all 
measurements in centimetres 
 
In summary, 3D photonic scanning was well received by the children that tried it. It is not an 
established method of body composition, but it did show some promising correlations with basic 
anthropometry and DXA derived data. 
 
Results by 3C and 4C model of body composition 
3.1.9 3C model of body composition 
Eight patients and 9 healthy controls have body composition results from the 3C model, i.e. they 
were old enough to have the BOD POD and their deuterium samples have been analysed. 
Using the methodology described in the methods section, FM and FFM was calculated for each 








Table 3-45: Comparison of FM and FFM of patients and healthy controls with the 3C 
model 
 
 Mean Median SD  Range 
FM sd patients -0.06 -0.43 1.03 -1.45 to 1.97 
FM sd controls -0.094 0.06 1.26 -3.15 to 1.3 
FFM sd patients -0.85 -0.54 0.99 -2.25 to 0.45 
FFM sd 
controls 
-0.74 -1.09 1.24 -2.25 to 1.31 
FM fat mass, FFM free fat mass, sd standard deviation score, SD standard deviation 
 
The mean difference between the FM sd score of the patients and the controls and the mean 
difference between the FFM sd score of the patients and the controls did not achieve statistical 
significance. When the above sd scores were compared with an sd of zero using a paired t-test, 
then the only measurement that was significantly different from zero was the FFM sd score of 
the patients (mean difference -0.85, p< 0.05). 
Three of the patients had results from before and after their liver transplant. The mean 
difference between these sd scores did not achieve statistical significance. 
 
Table 3-46: FM and FFM before and after liver transplantation using the 3C model 
 
 Before Transplant After Transplant 
Mean FM sd score (SD) 0.34 (± 1.41) 0.63 (± 0.36) 
Mean FFM sd score (SD) -1.32 (± 0.88) -1.43 (± 1.11) 
3C 3 component, FM fat mass, FFM free fat mass, sd standard deviation score, SD standard deviation 
 
 
In summary the 3C model where applied, showed that FM sd scores were within the normal 
range and FFM sd scores were lower than the FM sd scores.  FM and FFM sd scores did not 
differ significantly between the patients and the healthy controls, but the FFM sd scores did 
differ significantly from the normal distribution. There was no significant difference between FM 




3.1.10 4C model of body composition 
Seven patients have had a 4C model of body composition i.e. they have deuterium dilution 
studies (with results available), BOD POD and whole body DXA. One of these patients though 
had a problematic deuterium study and therefore had to be excluded from the 4C analysis. 
Their FM and FFM was calculated as described in the methods section and subsequently 
appropriate sd scores were assigned. For these measurements we do not have healthy controls 
to compare them, but as we have sd scores we can compare them against a value of zero with 
a paired t-test. 
 
Table 3-47: FM and FFM sd scores using the 4C model 
 
4C Model Mean (± SD) Median Range 
FM sd score -0.15 (± 1.04) -0.48 -1.53 to 1.82 
FFM sd score -1.09 (± 1.0) -1.13 -2.24 to 0.45 
4C 4 component, FM fat mass, FFM fat free mass, sd standard deviation score, SD standard deviation 
 
When comparing with an sd of zero, only the FFM sd scores of the patients reached statistical 
significance (difference of the mean -1.09, p< 0.05). 
For 2 patients with 4C body composition results expressed as sd scores, before and after liver 
transplantation, we can see the results in the table below.  
 
Table 3-48: FM and FFM before and after liver transplantation using the 4C model 
 
 Before transplant After transplant 
FM sd score (SD) 0.26 (± 1.36) 0.42 (± 0.61) 
FFM sd score (SD) -1.22 (± 0.83) -1.38 (±1.1) 
4C 4 component, FM fat mass, FFM fat free mass, sd standard deviation score, SD standard deviation 
 
In summary, the 4C model where applied, showed that FM sd scores were within normal range 





Comparison between 2C, 3C and 4C models of body composition 
The 4C model can give us estimates of FM and FFM without relying on the assumptions made 
by the various 2C models. By comparing the individual results from DXA, BOD POD and 
deuterium dilution studies one can easily see, if one method has been problematic. Expression 
of fat mass as % can make these discrepancies more obvious. 
 
Table 3-49: Comparison between 2C models 
 
ID Whole Body 
DXA 
 Deuterium  BOD POD  4CM  
 FM %FM FM %FM FM %FM FM %FM 
1 5.36 16.84 4.66 14.65 5.68 17.87 4.53 14.26 
3 3.38 15.56 10.75 49.52 5.38 24.77 8.13 37.48 
11 6.69 20.10 7.18 21.57 8.09 24.27 6.94 20.83 
14 3.97 18.20 5.46 25.05 3.18 14.60 3.94 18.05 
15 11.74 21.63 11.08 20.42 18.63 34.34 13.68 25.20 
16 16.84 28.54 18.00 30.50 20.56 34.85 18.76 31.79 
17 5.16 21.03 5.87 23.93 8.03 32.72 6.50 26.49 
3p 6.09 23.31 6.55 25.05 7.65 29.27 7.05 27.00 
17p 6.75 26.69 7.31 28.90 8.02 31.70 7.67 30.33 
DXA dual energy absorptiometry, BOD POD air displacement plethysmography, 4CM 4 component model, 
FM fat mass in kilograms, %FM is percentage of fat in body weight, p post liver transplant 
 
By plotting the average percent body fat by 2 methods against the difference of percent body fat 
between the same 2 methods, we can see the agreement between the 2 methods. Looking at 
the tables we can see that DXA and BOD POD don’t have good agreement, whereas DXA does 






Figure 3.14: Agreement between DXA and BOD POD 
DXA dual energy absorptiometry, BOD POD air displacement plethysmography, %BF 




Figure 3.15: Agreement between DXA and Deuterium 















































































Chapter 4 RESULTS- “TISSUE STUDIES” 
Introduction 
In this chapter are presented the results from the study of expression of metabolic related 
molecular pathways in the tissue of the children that had a liver transplant. Fourteen of the 
patients recruited have had their liver transplant and liver, muscle and fat tissue has been 
collected as previously described in 13 of them. The analysis presented in this thesis includes 
the tissue studies of 11 of these patients. The remaining 2 together with the tissue to be 
collected from the last patient waiting to be transplanted will be analysed as a second batch. 
The analysis presented in this thesis also includes tissue from 2 patients with Crigler-Najjar type 
1 syndrome. Therefore in total we analysed muscle, liver and fat tissue from 13 children. 
Total RNA was extracted from this tissue and amplified cDNA was made, this was then used for 
the microarray studies, as described in the methods section (p58-60). Two of the patient liver 
samples were too small to yield enough RNA and unfortunately had to be excluded from the 
analysis.  
To summarise, 11 liver samples, 13 muscle and 13 fat tissue samples were studied. Nine of the 
liver samples and 11 of the muscle and 11 of the fat samples were from patients with ESCLD 
and 2 of the liver, muscle and fat samples were from the 2 patients with Crigler-Najjar type 1 
syndrome. A list of the tissue sample IDs with the corresponding characteristics of the patient 
they were taken from can be seen in Table 4-1. 
The microarray data was submitted to the software Qlucore Omics Explorer version 3.2. This 
software can represent the data by principal component analysis (PCA) plot (Figure 4.1). PCA is 
a “mathematical algorithm that reduces the dimensionality of the data while retaining most of the 
variation in the data set” (Ringner, 2008). It does this along 3 axes of maximal variability and 
allows in this way for the samples to be grouped in a visually meaningful way. The PCA plot 
shows 3 distinct clusters of tissue representing the 3 different tissues. Perhaps unsurprisingly 
the liver tissue shows a higher scatter, probably representing the variety of diseases affecting 






Table 4-1: Characteristics of the patients corresponding to the tissue sample IDs. 
 
Sample ID Diagnosis Age (years) Sex Ethnicity Samples 
1 NSC 10.4 f Greek M, F 
3 BA 5.3 m Caucasian M, F 
4 BA 0.7 f Caucasian L, M, F 
6 Alagille  5.6 m Caucasian L, M, F 
8 BA 1.1 m Caucasian L, M, F 
9 A1AT 3.1 f Caucasian L, M, F 
10 BA 1.1 f Caucasian L, M, F 
11 BA 10.8 f Caucasian L, M, F 
12 BA 1.9 f Black African L, M, F 
15 PSC 17.7 m Caucasian L, M, F 
17 BA 9 f Caucasian L, M, F 
CN1 Crigler-Najjar 7.3 m Middle East L, M, F 
CN2 Crigler-Najjar 5.5 m Middle East L, M, F 
NSC neonatal sclerosing cholangitis, BA biliary atresia, A1AT alapha 1 antitrypsin deficiency, 




Figure 4.1: Microarray PCA plot of all samples 
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Muscle tissue analysis 
As previously mentioned, Qlucore Omics Explorer version 3.2 software was used to detect 
variability between the tissue samples and the samples were studied separately for each tissue. 
Starting with the muscle tissue, a list of the top most variable genes was first generated. This list 
included 403 gene transcript IDs. The software was then asked to separate the samples 
according to variability, a process known as unsupervised clustering (Boutros and Okey, 2005). 
A q value of 0.2 and a p value of ≤ 0.05 was applied and the muscle tissue samples were 
separated by unsupervised clustering into 2 clusters. The first cluster included samples 3, 8, 9, 
11, and 12 whereas the second cluster included samples 1, 4, 6, 10, 15, 17 and CN1 and CN2 
(Figure 4.2). A two group comparison of the 2 clusters then generated a list of gene transcript 
IDs and their difference in expression between the 2 clusters. The “q” value in this comparison 
is the smallest false discovery rate for which a particular gene would remain on this list of 
differentially expressed genes (Storey and Tibshirani, 2003). 
 
 

















Table 4-2: List of genes with a fold expression >3 between cluster 1 and cluster 2 in 
muscle tissue 
 
Gene Symbol p-value Fold change 
MT1A 0.0008 15.53 
MIR21 0.0000 10.31 
THBS1 0.0001 9.60 
ANKRD1 0.0071 8.65 
PLA2G2A 0.0010 8.17 
MYH3 0.0128 6.66 
MT1M 0.0003 6.55 
SELE 0.0004 6.20 
EGR1 0.0306 5.83 
SFRP2 0.0077 5.17 
EGR1 0.0306 5.83 
SFRP2 0.0077 5.17 
CCL2 0.0009 5.04 
CH25H 0.0043 4.79 
ATP1B3-AS1 0.0249 4.73 
SAA1 0.0001 4.71 
CTGF 0.0014 4.52 
PTX3 0.0013 4.49 
PRUNE2 0.0006 4.44 
MYBPH 0.0007 4.40 
JUNB 0.0482 4.35 
PRG4 0.0292 4.25 
IL6 0.0097 4.24 
C13orf33 0.0005 4.22 
MLLT11 0.0010 4.07 
TNC 0.0070 4.07 
CYR61 0.0008 4.06 
ZFP36 0.0282 3.93 
NAMPT 0.0008 3.82 
DDN 0.0135 3.78 
RGS2 0.0007 3.74 
GADD45B 0.0158 3.63 
CD163 0.0007 3.60 
STEAP1 0.0054 3.53 
SOCS3 0.0110 3.52 
PRG2 0.0442 3.52 
STEAP2 0.0135 3.33 
RNU4ATAC 0.0447 3.26 
SNORD3C 0.0469 3.24 
C14orf57 0.0079 3.19 
FMOD 0.0249 3.17 
C7 0.0244 3.13 
MYC 0.0075 3.09 
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F13A1 0.0064 3.08 
COMP 0.0040 3.07 
SCL2A3 0.0182 3.04 
 
 
Table 4-3: List of genes with a fold expression <0.5 between cluster 1 and cluster 2 in 
muscle tissue  
 
Gene Symbol p-value Fold change 
KCNQ5-IT1 0.0400 0.42 
COL4A3 0.0248 0.39 
SIM1 0.0367 0.38 
MYLK4 0.0246 0.33 
DHRS7C 0.0017 0.30 
KCNQ5-AS2 0.0125 0.29 
MYLK3 0.0018 0.28 
C3orf43 0.0088 0.28 
AQP4 0.0012 0.15 
 
In Figure 4.3, we can see a heatmap representing the muscle samples and the gene transcript 





Figure 4.3: Heatmap of muscle tissue samples 
Disease legend: Blue- biliary atresia, pink- a1 antitrypsin deficiency, red- Crigler-Najjar 
syndrome type 1, green– neonatal sclerosing cholangitis, yellow- Alagille syndrome, white- 
primary sclerosing cholangitis 
  
Using GeneGo MetacoreTM software we were able to analyse which molecular networks were 
significantly different between the two clusters. To do this we submitted the top most variable 
genes between the two clusters when applying cut offs of a q ≤ 0.2 and p ≤ 0.05 to the software. 
This software uses an algorithm that recognises co-regulated components of pathways or 
biological processed that are affected by these differentially expressed genes and then is able, 
based on known target gene regulation, to generate networks that include as many of the above 
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components possible. The 3 most significant networks generated in this way are seen in Table 
4-4 and Figure 4.4 is a representation of the first pathway.  
 
Table 4-4: Three most significant networks for cluster 1 of the muscle samples 
 
Network p- Value zScore gScore 
Il-6, SAA1, SOCS3, STAT3, gp130 3.15e -06 17.88 101.63 
Aggrecanase-1, collagen IV, miR-21-
5p, MLCK, MHH3 
4.75e -32 78 81.30 
c-myc, SFRP2, FKBP11, CH25H, 
RPL9 
1.06e -15 42.35 73.60 
 
 
Figure 4.4: Network involving SOCS3, IL-6 and STAT3 in muscle samples of cluster 1. 
 
Because of the interest in the AMPK and related metabolic pathways, these 2 clusters of 
muscle samples were also tested against a list of genes related to the AMPK pathway (see 
Appendix A). For this a p value ≤0.05 was used as a cut-off and the q value was not 
manipulated. As can be seen in Table 4-5, there was an increase in the α1 subunit of AMPK 
123 
 
(PRKAA1), but a reduction in PGC-1a (PPARGC1a), muscle glycogen phosphorylase (PYGM), 
myostatin (MSTN) and glucose transporter 4 (GLUT4- SLC2A4). Further to this in addition to the 
increase in IL6 and SOCS3, there was an increase in serum amyloid (SAA1), plasminogen 
activator inhibitor-1 (SERPINE1), as well fatty acid synthase (FAS) and transcription factor 
NFκB2. 
 
Table 4-5: Top variable genes of the AMPK pathway in muscle with a p<0.05 (cluster 1 
versus cluster 2) 
 
Gene Symbol p-value Fold change 
SAA1 0.000 4.71 
IL6 0.010 4.24 
RGS2 0.001 3.74 
SOCS3 0.011 3.52 
SERPINE1 0.001 3.43 
FAS 0.008 1.43 
NFKB2 0.009 1.36 
STAT4 0.044 1.30 
PRKAA1 0.034 1.21 
SLC2A4 0.000 0.66 
PYGM 0.016 0.64 
PPARGC1A 0.011 0.61 
MSTN 0.047 0.45 
 
The two graphs depict the real time PCR results for the fold change in the expression of IL6 and 
SOCS3 confirming the microarray data. 
 
Figure 4.5: IL6 expression in muscle with PCR 
































Figure 4.6: SOCS3 expression in muscle with PCR 
CN: the average of the 2 samples from the subjects with Crigler-Najjar type 1 
In summary, unsupervised clustering of the muscle tissue generated 2 groups with over 400 
gene transcripts significantly different between the 2 groups. Based on these gene transcripts 
one of the most significantly different networks involved IL6- SAA1- SOCS3-STAT3-gp130, a 
pathway of inflammatory mediated insulin resistance, this was upregulated in group 1 (patients 
3,8,9,11 and 12). The genes related to the AMPK pathway did not come up as highly variable 




Going on to analyse the fat tissue, first a list of the top most variable genes in the fat samples 
was generated. This list included 543 gene transcript IDs. Then by applying a q value of 0.2 and 
p value of ≤ 0.05 with unsupervised clustering the Qlucore Omics Explorer version 3.2 software 
separated the fat tissue samples into 2 clusters. The first cluster included samples 3, 8, 9, 11, 






















































Table 4-6: List of genes with a fold expression >2 between cluster 1 and cluster 2 in fat 
tissue 
 
Gene Symbol p-value Fold change 
FOSB 0.0024 10.28 
MT1A 0.0008 9.85 
EGR1 0.0002 6.73 
IL6 0.0002 6.44 
SELE 0.0000 6.27 
JUNB 0.0001 5.89 
HSPA1A/HSPA1B 0.0006 5.39 
HSPA1A /HSPA1B 0.0007 5.05 
HSPA1A /HSPA1B 0.0007 5.05 
HSPA1A /HSPA1B 0.0007 5.05 
HSPA1A /HSPA1B 0.0008 4.98 
DNAJB1 0.0008 4.96 
HSPA1A /HSPA1B 0.0009 4.90 
CYR61 0.0000 4.88 
FOSB 0.0083 4.84 
FOS 0.0214 4.80 
SNORD14E 0.0150 4.79 
NR4A3 0.0002 4.70 
SOCS3 0.0001 4.55 
HSPH1 0.0021 4.48 
ATP1B3-AS1 0.0000 4.45 
HSPA1A /HSPA1B 0.0010 4.36 
HSPA1A /HSPA1B 0.0010 4.32 
HSPA1A /HSPA1B 0.0010 4.32 
MT1E 0.0021 4.10 
FABP9 0.0003 4.10 
TNFAIP3 0.0025 4.04 
NAMPT 0.0026 4.01 
HSPA1A /HSPA1B 0.0010 3.95 
RNY4P20 0.0061 3.89 
CCL2 0.0022 3.81 
AREG 0.0334 3.81 
NFKBIZ 0.0002 3.60 
AREG 0.0369 3.52 
TNFAIP6 0.0205 3.49 
ZFP36 0.0003 3.44 
CH25H 0.0345 3.42 
GADD45B 0.0078 3.38 
PPBP 0.0026 3.27 
S100A9 0.0165 3.18 
DUSP1 0.0044 3.17 
NR4A2 0.0017 3.07 
NR4A1 0.0030 3.05 
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OR52N1 0.0293 3.03 
MIR21 0.0404 2.94 
SERPINE1 0.0303 2.80 
RNU5E-1 0.0050 2.78 
IL8 0.0197 2.75 
S100A8 0.0083 2.70 
 
 
Using GeneGo MetacoreTM software we were able to analyse which molecular networks were 
significantly different between the two clusters. To do this we submitted the top most variable 
genes between the two clusters when applying cut offs of a q ≤ 0.2 and p ≤ 0.05 to the software. 







Table 4-7: Three most significant networks for cluster 1 of the fat samples 
 
Network p- Value zScore gScore 
Calgranulin B, A20, FosB, IKBZ, 
HSPA1B 
1.66e -38 110.29 111.54 
EGR1, c-Fos, ZFP36(Tristetraprolin), 
HSPA1A, AP-1 
4.34e -23 70.85 70.85 
NOR1, CCL2, Metallothionein-I, IL-8, 
IL-6 










Figure 4.9: The third most significant network from the fat tissue involving IL6, IL8 and 
CCL2 
 
The following three graphs depict the real-time PCR results for the fold change in the 
expression of IL6, SOCS3 and IL8 in the fat tissue confirming the microarray data. 
 
 
Figure 4.10: IL6 expression in fat tissue with PCR 

































Figure 4.11: SOCS3 expression in fat with PCR 





Figure 4.12: IL8 expression in fat with PCR 
CN: the average of the 2 samples from the subjects with Crigler-Najjar type 1 
 
In summary, unsupervised clustering of the fat tissue generated 2 groups with over 500 gene 
transcripts significantly different between the 2 groups. Based on these gene transcripts one of 




















































pathway involving IL6-IL8-CCL2 via NFkB, which was upregulated in group 1 (patients 3,8,9,11 
and 17). 
 
4.1.1 Liver tissue 
A similar process was followed for the liver tissue.  First a list of the top most variable genes in 
the liver samples was generated with Qlucore Omics Explorer version 3.2 software. In these 
samples the variability was much bigger (compared to the muscle or fat samples), so even more 
stringent cut offs were applied. This list included 675 gene transcript IDs. By applying a q value 
of 0.1 and p value of ≤ 0.002 with unsupervised clustering the software separated the liver 
tissue samples into 2 clusters. The first cluster included samples 4, 8, 9, 10, 11, 12, 15 and 17 
whereas the second cluster included samples 6, CN1 and CN2 (Figure 4.13). 
 





Figure 4.14: Heatmap of liver tissue showing only gene transcripts with a fold change of 
more than 4. 
Disease legend: Blue- biliary atresia, pink- a1 antitrypsin deficiency, red- Crigler-Najjar 
syndrome type 1, green– neonatal sclerosing cholangitis, yellow- Alagille syndrome, white- 
primary sclerosing cholangitis 
 
 
Table 4-8: List of known genes with a fold increase of over 4 in the liver between the 2 
groups 
 
Gene Symbol p-value Fold change 
IL8 0.0005 9.78 
VCAN 0.0009 8.90 
ACSL4 0.0007 7.91 
TIMP1 0.0001 5.34 
CTGF 0.0007 5.08 
EFEMP1 0.0006 4.88 
 
GeneGo MetacoreTM software analysed which molecular networks were significantly different 
between the two clusters. For this process the top most variable genes between the two 








Table 4-9: Three most significant networks for cluster 1 of the liver tissue 
 
Network p- Value zScore gScore 
Cyclophilin C, DOC1, MUNC18-3, 
EIF5A2, CHMP4B 
 
9.6e -45 58.39 58.39 
PIGT, XPR1, ELTD1, TMEM32, 
WBP5 
 
6.9e -40 53.28 53.28 
Kif2a, Cathepsin C, Beta-adaptin 2, 
N4BP1, Sac2 
 
2.9e -36 50.82 52.07 
 
 









Table 4-10: Top variable genes of the AMPK pathway in liver with a p<0.05 (cluster 1 
versus cluster 2) 
 
Gene Symbol p-value Fold change 
IL8 0.0005 9.78 
SOCS3 0.0020 3.33 
PFKFB3 0.0125 2.48 
SERPINE1 0.0363 2.42 
SAA1 0.0009 2.23 
PRKAA2 0.0022 1.76 
STAT3 0.0141 1.62 
NFKB1 0.0079 1.40 
SMAD2 0.0318 1.35 
ATG13 0.0232 1.33 
GYS1 0.0114 0.70 
MSTN 0.0316 0.59 
PRKAB2 0.0438 0.56 
IL6R 0.0404 0.50 
 
 
In summary, the variation of gene expression in the liver was obviously more varied than in the 
muscle and fat tissue, as that is the primarily diseased tissue in children with ESCLD. For this 
reason, unsupervised clustering for the liver tissue was applied with more stringent cut offs to 
the muscle and fat tissue. As perhaps expected the gene transcripts that were significantly 
increased in group 1 versus group 2 (group 2 included patients 6 and the 2 CN patients) were 
related to inflammation and fibrosis. The expression of genes related to the AMPK pathway was 
not in the top most variable list and there was no clear evidence to support up- or down- 
regulation of the AMPK pathway in the liver. 
 
Supervised clustering 
It became clear from the previous analysis that samples from subjects 3, 8, 9 and 11 were most 
likely different from the rest, as far as their muscle and fat tissue was concerned. This 
observation was tested by going back to Qlucore Omics Explorer version 3.2 and doing a 
supervised clustering i.e. by asking the software to treat subjects 3, 8, 9, 11 as cluster 1 and the 
rest as cluster 2. By setting the q value to 0.2, these 2 groups differed in 222 gene transcript 
IDs, all with a p value < 0.0082. 
When this list was submitted to GeneGo the 3 most significant networks were generated by the 




Table 4-11: Three most significant networks for cluster 1 of the muscle samples, where 
cluster 1 is supervised to include subjects 3, 8, 9 and 11. 
 
Networks p- Value zScore gScore 
IL-6, c-Myc, CCL2, p21, SOCS3 4.68e -19 43.27 194.52 
A20, Pim-1, CCL2, MafF, 
Aggrecanase-1 
3.02e -52 102.27 103.52 
ETS2, NURR1, KLF6, MKP-1, CCL2 7.38e -32 66.76 68.01 
 
 





Figure 4.17: Heatmap of muscle samples after supervised clustering focusing on gene 
transcripts with a fold change ≥ 3. 
Disease legend: Blue- biliary atresia, pink- a1 antitrypsin deficiency, red- Crigler-Najjar 
syndrome type 1, green– neonatal sclerosing cholangitis, yellow- Alagille syndrome, white- 












Table 4-12: List of gene transcripts from the muscle tissue of subjects 3,8,9 and 11 
against the rest of the muscle tissue with a fold change ≥ 3. 
 
Gene Symbol p-value q-value Fold change 
MT1A 0.0000 0.01 29.27 
MIR21 0.0002 0.04 9.42 
ATP1B3-AS1 0.0005 0.06 8.94 
SELE 0.0000 0.01 8.42 
MT1M 0.0001 0.04 7.70 
IL6 0.0001 0.04 6.79 
PTX3 0.0001 0.04 5.77 
CH25H 0.0021 0.12 5.66 
ZFP36 0.0061 0.17 5.47 
CCL2 0.0022 0.12 5.06 
NR4A3 0.0010 0.08 4.96 
RASD1 0.0001 0.04 4.89 
CTGF 0.0023 0.12 4.70 
C13orf33 0.0004 0.06 4.66 
GADD45B 0.0040 0.14 4.65 
NAMPT 0.0001 0.04 4.64 
RGS2 0.0001 0.04 4.37 
SOCS3 0.0034 0.13 4.32 
SAA1 0.0018 0.11 4.29 
ERRFI1 0.0005 0.06 4.16 
MYC 0.0003 0.06 4.15 
CYR61 0.0020 0.12 4.08 
SLC2A3 0.0037 0.14 3.88 
DUSP1 0.0033 0.13 3.84 
AREG 0.0000 0.01 3.83 
ADAMTS4 0.0006 0.07 3.79 
ATP1B3 0.0005 0.06 3.72 
CD163 0.0016 0.10 3.67 
NR4A1 0.0025 0.12 3.65 
SNORD56B 0.0004 0.06 3.60 
NR4A2 0.0036 0.14 3.54 
ACTC1 0.0007 0.07 3.52 
AREG 0.0000 0.01 3.47 
MMP19 0.0002 0.04 3.46 
NFKBIZ 0.0054 0.17 3.41 
CSRNP1 0.0001 0.04 3.37 
TNFAIP6 0.0011 0.08 3.32 
ADAMTS1 0.0014 0.10 3.27 
ELL2 0.0005 0.06 3.25 
SERPINE1 0.0033 0.13 3.25 
ATF3 0.0021 0.12 3.10 
MRC1 0.0013 0.09 3.07 
SERPINA3 0.0009 0.08 3.07 
RGS1 0.0070 0.18 3.06 
ICAM1 0.0003 0.06 3.06 
MT1F 0.0024 0.12 3.06 
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Table 4-13: Top variable genes of the AMPK pathway in muscle with a p<0.05 (supervised 
cluster 1 versus cluster 2) 
 
Gene Symbol p-value Fold change 
IL6 0.0001 6.79 
RGS2 0.0001 4.37 
SOCS3 0.0034 4.32 
SAA1 0.0018 4.29 
SERPINE1 0.0033 3.25 
RGS1 0.0070 3.06 
STAT4 0.0244 1.35 
NFKB2 0.0168 1.35 
SREBF1 0.0271 0.70 
SLC2A4 0.0004 0.67 
 
The same process was repeated with the fat tissue. The fat samples were analysed with 
Qlucore after submitting samples 3, 8, 9 and 11 of the fat tissue as cluster 1 and the other 
samples as cluster 2. This gave a list of 134 gene transcript IDs significantly different between 
the 2 groups at a q value of 0.2 and a p value < 0.03. 
 
Figure 4.18: PCA of supervised clustering of fat tissue, where cluster 1 includes subjects 











Figure 4.19: Heatmap of fat samples after supervised clustering. 
Disease legend: Blue- biliary atresia, pink- a1 antitrypsin deficiency, red- Crigler-Najjar 
syndrome type 1, green– neonatal sclerosing cholangitis, yellow- Alagille syndrome, white- 


















Table 4-14: List of genes in fat tissue expressed >2.5 fold in supervised cluster 1 in 
comparison to cluster 2 
 
Gene Symbol p-value Fold change 
MT1A 0.0001 13.56 
PTX3 0.0070 9.51 
IL6 0.0005 6.75 
SELE 0.0001 6.47 
HP 0.0066 5.23 
TNFAIP3 0.0003 5.13 
EGR1 0.0091 5.05 
ATP1B3-AS1 0.0001 4.81 
AREG 0.0152 4.76 
DNAJB1 0.0039 4.68 
TNFAIP6 0.0049 4.56 
HSPA1A /HSPA1B 0.0092 4.43 
OR52N1 0.0024 4.40 
CH25H 0.0125 4.36 
AREG 0.0194 4.27 
JUNB 0.0100 4.27 
SOCS3 0.0013 4.23 
HSPA1A /HSPA1B 0.0104 4.17 
HSPA1A /HSPA1B 0.0103 4.14 
FABP9 0.0011 4.10 
HSPA1A /HSPA1B 0.0114 4.07 
NR4A3 0.0040 4.06 
CYR61 0.0032 4.03 
HSPH1 0.0118 3.98 
GADD45B 0.0037 3.90 
SERPINE1 0.0056 3.67 
HSPA1A /HSPA1B 0.0134 3.62 
HSPA1A /HSPA1B 0.0128 3.61 
HSPA1A /HSPA1B 0.0132 3.60 
RNY4P20 0.0207 3.55 
CCL2 0.0103 3.50 
MIR21 0.0236 3.43 
NAMPT 0.0205 3.39 
HSPA1A /HSPA1B 0.0144 3.28 
CXCL2 0.0006 3.26 
THBS1 0.0014 3.18 
MT1M 0.0017 3.00 
NFKBIZ 0.0109 2.91 
ZFP36 0.0107 2.87 
IL8 0.0221 2.86 
IL1RL1 0.0033 2.77 
PDLIM3 0.0036 2.74 
PMP2 0.0120 2.74 
HSPA6 0.0026 2.72 
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MYC 0.0093 2.70 
NFIL3 0.0015 2.64 
ADAMTS4 0.0092 2.63 
UBC 0.0028 2.59 
MT1G 0.0050 2.58 
BAG3 0.0043 2.57 
ICAM1 0.0113 2.56 
C5AR1 0.0176 2.55 
SLC19A2 0.0050 2.53 
CTGF 0.0215 2.50 
 
The list was submitted to GeneGO MetacoreTM and this generated the 3 most significant 
networks, shown below. 
 
Table 4-15: Three most significant networks for supervised cluster 1 in the fat tissue 
 
Network p- Value zScore gScore 
PAI1, VMP1, p53, Shc, GAB1 2.3e -06 18.85 165.1 
ICAM1, ZFP36(Tristetraprolin), IL-6, 
JunB, Ubiquitin 
2.76e -39 99.81 99.81 
HSP70, HSC70, HSP40, IL-8, 
E4BP4 







Figure 4.20: Second most significant network in the fat tissue involving IL6 
 
 
Table 4-16: Top variable genes of the AMPK pathway in fat with a p<0.05 (supervised 
cluster 1 versus cluster 2) 
 
Gene Symbol p-value Fold change 
IL6 0.0005 6.75 
SOCS3 0.0013 4.23 
SERPINE1 0.0056 3.67 
IL8 0.0221 2.86 
RGS2 0.0021 2.32 
CAMKK2 0.0051 0.79 
IRS1 0.0240 0.70 
 
 
In summary, unsupervised clustering in the muscle tissue separated subjects 3,8,9,11 and 12 
to everyone else and subjects 3,8,9,11 and 17 in the fat tissue to everyone else. The clear 
overlap of these 2 groups was the group of subjects 3,8,9 and 11. When the group of subjects 
3,8,9 and 11 was defined as a separate group in the muscle tissue (supervised clustering), as 
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expected, the results were similar to the unsupervised clustering highlighting again the 
significance of the pathway related to IL6- SOCS3 and the upregulations of various chemokines 
and cytokines aside IL6, like selectin E, SAA1 and CCL2. In terms of the AMPK pathway, GLUT 
4 (SLC2A4) was downregulated, indirectly indication that AMPK was not activated. 
When the group of subjects 3,8,9 and 11 was separated in the fat tissue again as before 
pathways involving IL6 and IL8 were significantly upregulated. The AMPK was not 
demonstrated to be different between the 2 groups of subjects. Because GLUT4 was 
downregulated it is upregulated by AMPK) as was CAMKK2 (it upregulates AMPK), one could 
infer that it was downregulated in the group of subjects 3,8,9 and 11. 
 
4.1.2 Liver tissue 
If we separate our liver samples in a supervised way and cluster 1 includes samples 8, 9 and 11 
(there was no sample 3 liver tissue) the only gene trascripts that the two groups are significantly 
different by with a q of 0.2 are FOS and FOSB. 
 
 






Table 4-17: The three most significant gene transcripts for liver tissue between 
supervised cluster 1 and cluster 2 
 
Gene Symbol p-value Fold change 
FOSB 0.0006 11.04 
FOSB 0.0006 5.77 





Figure 4.22: Heatmap of liver tissue with supervised clustering- subjects 8, 9 and 11 
versus the rest. 
Disease legend: Yellow- cluster 1, subjects 8, 9 and 11; Blue- cluster 2, subjects 4, 6, 10, 12, 
15, 17, CN1 and CN2 
 
As these children had diseases affecting the liver we also looked into a comparison of the liver 
tissues of the children with biliary atresia versus the 2 children with Crigler-Najjar type 1 
syndrome. At a q value of 0.2 and a p value <0.05 the software generated a list of 274 gene 
transcript IDs. In the figure below we see a heatmap focusing on those with an over 10 fold 






Figure 4.23: Heatmap of liver tissue with tissue from the children with biliary atresia 
versus the children with Crigler-Najjar type 1 syndrome. The focus is on the genes with 
an over 10 fold increased expression in the children with biliary atresia. 



















Table 4-18: List of gene transcripts with an over 4 fold expression in the liver tissue of 
children with biliary atresia when compared to those with Crigler-Najjar type 1. 
 
Gene Symbol p-value Fold change 
TSIX 0.0280 34.41 
PLA2G2A 0.0288 17.68 
IL8 0.0085 10.79 
VCAN 0.0154 8.66 
ACSL4 0.0061 8.07 
CCL2 0.0137 7.89 
CTGF 0.0011 7.44 
SGIP1 0.0014 7.33 
EFEMP1 0.0004 6.73 
RN5S387 0.0098 6.70 
TIMP1 0.0011 6.36 
RASEF 0.0331 6.32 
ACSM3 0.0345 6.14 
MGP 0.0092 5.60 
MOXD1 0.0099 5.41 
BICC1 0.0297 5.18 
CCDC80 0.0057 5.16 
FGF7 0.0336 5.12 
CCL20 0.0192 5.05 
FAT1 0.0023 5.01 
SULF1 0.0178 4.77 
ANKRD1 0.0300 4.74 
BTG2 0.0073 4.72 
FAP 0.0278 4.71 
RGCC 0.0098 4.63 
LUM 0.0060 4.60 
COL4A1 0.0251 4.57 
RAB31 0.0012 4.57 



















Table 4-19: Three most significant networks in biliary atresia versus Crigler-Najjar 
syndrome type 1. 
 
Network p- Value zScore gScore 
G-protein alpha-i family, PAR1, 
SMCY, ABC50, ppl2/A4 
3.79e -43 69.32 71.82 
MMP-2, Fibrillin 1, SMCY, SART1, 
NTF2 
5.42e -34 59.35 60.60 
TMPS6, PRKX, MFGE8, CCL20, 
MGP 
1.39e -33 57.95 57.95 
 
Table 4-20: Top variable genes of the AMPK pathway in liver with a p<0.05 (biliary atresia 
versus Crigler-Najjar type 1) 
 
Gene Symbol p-value Fold change 
IL8 0.0085 10.79 
PFKFB3 0.0090 3.36 
SOCS3 0.0107 3.11 
SAA1 0.0084 1.86 
PRKAA2 0.0268 1.56 
SMAD2 0.0102 1.54 
NFKB2 0.0331 1.37 
NFKB1 0.0469 1.25 
PRKAB2 0.0370 0.43 




The following three graphs depict real-time PCR results for the fold change in expression of IL8, 




Figure 4.24: IL8 expression in the liver by PCR 




Figure 4.25: SOCS3 expression in the liver by PCR 
CN: the average of the 2 samples from the subjects with Crigler-Najjar type 1 
 
In summary, previously, with unsupervised clustering applied on the liver tissue it was only 
natural that gene transcripts related to the different disease processes would be the ones that 
would come up as the most variable between groups. When supervised clustering was applied 
though, and we asked the software to treat this group, which was different to the rest of the 
























































different in the liver tissue; they had FOSB isoforms and FOS gene transcripts significantly 
upregulated. 
An analysis was also performed focusing on the 2 more homogenous groups of patients with 
biliary atresia versus patients with CN type 1. This generated over 200 gene transcripts that 
were significantly upregulated in the liver of the children with biliary atresia; notably IL8 was one 
of them (fold change 10.79), but also other genes related to cell growth and fibrosis (e.g. 




Chapter 5 INTEGRATED RESULTS AND OUTCOMES 
General outcomes 
All the patients studied are currently alive. Sixteen of them have had their liver transplant whilst 
one patient is still awaiting his. The sixteen patients that have been transplanted stayed in 
hospital after transplantation for a mean of 31 days (SD ±28 days, median 17 days and range 
11 to 112 days). During their admission they were ventilated for a mean of 3 days (SD ± 5 days, 
median 2 days and range 1- 21 days). One of the children suffered repeated episodes of 
pneumothoraces bilaterally post liver transplant requiring bilateral pleurodesis. Two children 
suffered from a hepatic artery thrombosis (HAT). One of these children required re-
transplantation within a month of his first transplant and the second one required thrombectomy 
within 24 hours of her transplant. Both children have since made a good recovery. Another child 
developed post-transplant lymphoproliferative disease (PTLD) requiring treatment with rituximab 
and a period off immunosuppression. He has made an excellent recovery and he did not require 
chemotherapy. The table below (Table 5-1) shows the patient IDs and how these correspond 



















Table 5-1: Subject ID with the corresponding diagnosis and the complications noted post 
liver transplantation 
 
Patient ID Diagnosis Complications 
1 NSC Bilateral pneumothoraces 
2 BA No complications 
3 BA PTLD 
4 BA No complications 
(5)6 Alagille syndrome 2 admissions, one for diarrhoea and one for fever 
7 Re-transplantation No complications 
8 BA HAT- 2nd liver transplant 
ACR (2 episodes) 
9 A1AT deficiency No complications 
10 BA No complications 
11 BA HAT , ACR and ventricular bigeminy  
12 BA Biliary complications- required biliary reconstruction 
13 Alagille syndrome 1 admission for infection 
14 Re-transplantaion Off waiting list- 3 long bone fractures over 1 year 
15 PSC Stress cardiomyopathy, ACR 
16 HCV related cirrhosis Off waiting list 
17 BA Treatment for CMV reactivation, Leg pains 
18 Cryptogenic cirrhosis Waiting to be transplanted 
CN1 Crigler-Najjar type 1 No complications 
CN2 Crigler-Najjar type 1 CMV hepatitis 
NSC neonatal sclerosing cholangitis, BA biliary atresia, PTLD post-transplant 
lymphoproliferative disorder, HAT hepatic artery thrombosis, ACR acute cellular rejection, PSC 
primary sclerosing cholangitis, HCV hepatitis virus C, CMV cytomegalovirus. In bold are the 
patients whose tissue has been analysed. 
 
 
Children 1 and 2 live abroad and have not returned since transplant to have their follow up body 
composition. Patients 6, 7 and 13 are waiting to have their body composition assessment post 
liver transplant. Patients 14 and 16 are the 2 children that were removed from the waiting list. 
Patient 16 had a repeat body composition assessment after completing treatment for HCV and 
patient 14 had a repeat whole body DXA scan. Everyone else who has been transplanted has 
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had their post liver transplant body composition assessment. At the time of the repeat body 
composition assessments they were all well in themselves. They all had normal liver function, 
apart from one patient who subsequently was found to have acute cellular rejection on biopsy 
the next day. One patient is still waiting to be transplanted. 
 
5.1.1 Body composition and outcomes  
Looking at the more basic anthropometry, weight and height sd score did not correlate with 
days in hospital after liver transplantation, whilst BMI, MUAC and subscapular skinfold sd score 
had a significant negative correlation with days in hospital after liver transplantation (Pearson 
correlation factor -0.83 p<0.05, -0.76 p<0.01 and -0.703 p<0.05 respectively). 
 
Figure 5.1: Correlation between MUAC and days in hospital after liver transplantation. 
MUAC mid upper arm circumference 
 
From the measurements of the DXA scan, none of the FM or FMI were significantly low (i.e. sd 
score less than -1.96 which is less than the 5th centile). When the patients were separated 
according to LM and LMI sd scores being less than -1.96 or not, none of the groups were 
different in terms of length of stay in hospital for any of the indices. Nevertheless there was 
significant correlation between days spent in hospital after liver transplantation and FM and FMI 
sd scores for the 8 patients that these were available for. Specifically there were significant 
153 
 
negative correlations between days in hospital after liver transplantation and total FM (-0.78 
p<0.05), trunk FM (-0.75 p<0.05), total FMI (-0.859, p<0.01), leg FMI (-0.812, p<0.05), and trunk 
FMI (-0.907, p<0.01) sd scores. There was no significant correlation between length of stay in 
hospital and any of the LM or LMI sd scores derived from the whole body DXA scan. 
 
Figure 5.2: Correlation between total FMI sd score and days in hospital after liver 
transplantation. 
FMI fat mass index, sd standard deviation score 
The presence of hypermetabolism was not different between the children with ESCLD and the 
healthy controls. When the patients were separated into 2 groups depending on if they were 
hypermetabolic or not (when their measured REE was compared against predicted REE) there 
was no difference in outcomes between the 2 groups. 
 
5.1.2 Body composition and metabolic pathways 
The tissue studies highlighted a group of patients as different to the others. This group included 
patients 3, 8, 9 and 11. All four of these children were Caucasian. Two of them were boys and 
two were girls. Three of them had biliary atresia and one of the girls had alpha 1 antitrypsin 
deficiency. As a group their mean stay in hospital after the liver transplant (27.25 days ± 13.94 
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days) was not significantly different to the mean stay of the other children (38.22 days ± 34.85 
days). In regards to post liver transplant complications, the two children who suffered a HAT 
after their transplant, were both in this group. 
The children with the Crigler- Najjar type 1 syndrome were not part of the body composition arm 
of the study. For these children only weight, height, BMI and MUAC sd scores were available to 
allow comparisons with the rest of the children. The difference in mean sd score for weight, 
height and BMI between group 1 (subjects 3, 8, 9 and 11) and group 2 (subjects 1, 4, 6, 10, 12, 
15, 17 CN1 and CN2) did not reach statistical significance when tested with an independent t-
test. Only the difference in mean BMI sd score approached, but did not achieve, statistical 
significance with a p score of 0.051. 
Table 5-2: Mean weight, height and BMI sd scores for group 1 and group 2  
 
 Mean Weight sd 
score (±SD) 
Mean Height sd 
score (±SD) 
Mean BMI sd 
score (± SD) 
MUAC sd 
score (± SD) 
Group 1 -0.44 (1.09) -1.18 (1.09) 0.32 (0.98) -0.9 ( 0.6) 
Group 2 -0.83 (0.73) -0.54 (1.61) 0.69 (0.67) -1.3 ( 1) 
BMI body mass index, sd standard deviation score, SD standard deviation, Group 1 includes 
subjects 3, 8, 9 and 11 and Group 2 includes subject 1, 4, 6, 10, 12, 15, 17, CN1, CN2 
 
When looking at other parameters of body composition, there are no other complete sets of 
data, so we can only get an indication of what the relationships may be. Looking at the indices 
from the DXA scan, there are measurements for patients 3 and 11 from group 1 and there are 
measurements for patients 1, 6, 15 and 17 from Group 2. When the difference of mean sd 
scores for total FMI, arm FMI, leg FMI and trunk FMI are compared by t-test between these two 
groups, none of the differences achieve statistical significance. Whereas there are significant 
differences when comparing the LMI parameters. Group 1 has a higher mean total LMI sd score 
(1.48 versus -1.49, p<0.05), a higher arm LMI sd score (-1.3 versus -2.9, p NS), a higher leg 
LMI sd score (-0.44 versus -2.68, p< 0.05) and a higher trunk LMI sd score (3.61 versus 0.24, 
p< 0.05). There were no significant difference between mean phase angle and mean illness 




Chapter 6 Discussion 
 
The study presented in this thesis was a prospective pilot study and had two parts. The first part 
involved assessing the body composition of children with end stage chronic liver disease 
(ESCLD) with various methods before and after liver transplantation. The second part of the 
study involved studying molecular pathways that are implicated in metabolism in liver, muscle 
and fat tissue taken from these patients at the time of liver transplantation. The results will also 
be discussed in two parts in the first instance, with a discussion integrating the results in the 
end. 
Summary of results 
The basic anthropometry showed that the patients had a significantly lower weight and height 
than the healthy controls and this was particularly true for the younger patients. The MUAC was 
the measurement that was shown to be consistently significantly less for all the patients before 
transplantation and it showed significant increase after transplantation. The available results 
from the stable isotope studies showed that total body water of the patients was not different to 
that of the healthy children. After transplantation there was a reduction in the total body water of 
the patients, but this did not achieve statistical significance. FM as it can be calculated from 
TBW was not below 10% in any of the patients before transplantation. There are no available sd 
scores for values of extra cellular water, but the bromide studies did demonstrate a significant 
reduction in ECW after liver transplantation. 
Similar to the deuterium, the BOD POD also showed that FM was not under 10% of body weight 
for any of the patients and in fact FM sd scores were all within normal limits. Three of these 
children had significantly low FFM sd scores (< -1.96) in spite of the BOD POD not 
differentiating between muscle mass and organ mass. The children with before and after 
transplant measurements had sd scores for FM and FFM that did not change much and the 2 
that had low FFM sd scores before transplant had low scores afterwards as well.  
The whole body DXA measurements, done only by the patients as per protocol, showed again 
that FM and FMI sd scores were within the normal range either when referring to whole body or 
regional measurements. Six of the eleven patients had some measure of LM < -1.96 sd score 
either total or regional. When this was corrected for height, 4 of the children had a LMI < 1.96 sd 
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score. Sd scores tended to remain similar before and after transplantation. DXA correlated the 
best with the deuterium results. 
REE was higher than predicted in 44% of the patients, but also in 50% of the healthy children. 
RQ was not significantly different between patients and controls. REE/kg after liver 
transplantation correlated strongly with REE/kg before transplantation. 
Moving on to the tissue studies. Microarray analysis of the muscle and fat tissue separated a 
group of 4 patients from the rest of the patients. These 4 patients, 2 female and 2 male (3 with 
biliary atresia and one with alpha 1 antitrypsin deficiency) were significantly different to the other 
patients in regards to the levels of over 400 gene transcripts in their muscle and fat tissue. 
These gene transcripts included a variety of genes, many of them having to do with 
inflammation (IL6, CCL2, SELE, SAA1) and extracellular matrix/ tissue regeneration (THBS1, 
ANKRD1, FMOD) in muscle and also inflammation (IL6, FOS, FOSB, SELE) and protection 
from oxidative stress (MT1A, EGR1, NAMPT) in fat tissue. From a metabolism point of view the 
AMPK pathway did not feature in the significantly most variable pathways and, from the 
evidence we had, its expression in the muscle and fat tissue was not different between the 2 
groups of patients, if anything it was most likely down regulated. The metabolic pathway which 
was shown to be significantly upregulated in this group of 4 patients was the one that included 
IL6 and SOCS3 and is involved in inflammatory mediated insulin resistance (Wunderlich et al., 
2013). 
This group of 4 patients’ liver tissue (bar patient 3 for whom liver tissue mRNA yield was 
insufficient) was significantly different to the rest of the liver tissue (bar patient 1 for the same 
reason) in that FOSB and FOS gene transcripts were significantly upregulated (over 11 and 
over 4 fold increase respectively). The liver tissue of the children with biliary atresia also had 
over 200 gene transcripts upregulated in comparison to the 2 children with Crigler-Najjar 
syndrome type 1. Included in these gene transcripts was IL8 (over 10 fold increase) as well as 
genes to do with the extracellular matrix (VCAN, MGP, COL4A1). 
Overall BMI, MUAC and subscapular skinfold thickness had a significant negative correlation 
with days in hospital after liver transplantation, as did total and trunk FM and FMI as well as leg 
FMI, for the patients with DXA measurements. There was no difference in outcomes between 
the children that were hypermetabolic and those without. The group (patients 3,8,9 and 11) 
distinguished by the tissue studies as different to the rest of the children, in terms of body 
composition, had a higher mean BMI sd score which almost reached statistical significance and 
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significantly higher total, trunk and leg LMI sd scores. There was no difference in the days they 
spent in hospital after liver transplant in comparison to the other patients. 
Body Composition 
Body composition in children with ESCLD, as described in the Introduction, is known to be 
abnormal. In particular, it is known that these children suffer from weight loss, poor growth, 
muscle wasting, and fat loss and have been thought to be hypermetabolic. In addition, as 
previously mentioned, assessing these children accurately is challenging, because of the 
organomegaly and fluid retention. 
The results of the body composition studies in this study have confirmed some facts already 
known about children with ESCLD and have also highlighted some areas of new insight. It is 
useful to keep in mind that in the modern era children with ESCLD receive intensive dietetic and 
nutritional input (Henkel and Buchman, 2006). This implies that the changes in their body 
composition that we see today are in spite of this input. In addition, the group of children studied 
here were all children considered for liver transplantation. Poor growth and poor nutritional state 
are important indications for liver transplantation. Therefore these children are not 
representative of all children with chronic liver disease. They belong to a cohort of children 
where their chronic liver disease has reached its final stages and liver transplantation is the only 
means for survival. 
Basic anthropometry, weight, height, BMI and measurement of skinfold thickness remains the 
most accessible bedside means available to assess the nutritional status and progress of these 
children (Wells et al., 2012). These measurements need to follow certain standards in order for 
them to be of consistent good quality. Frequently skinfold thickness measurements are thought 
to be unreliable, because of the variability noted between different people taking the 
measurements. The advantage in this study was that all measurements were done by the same 
person.  
The anthropometry data presented here highlight that significant differences between the weight 
and height sd scores of the patients and the healthy controls exist and this was particularly true 
for the children under 4 years of age. This could be because younger children assessed for liver 
transplantation are more likely to have more aggressive disease influencing their 
anthropometry. In fact in spite of weight considered to overestimate the true weight in these 
patients, the weight sd score of the younger patients was significantly lower than that of the 
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healthy children. Height sd scores were also significantly lower highlighting the poor growth of 
these children. This is not an unusual finding in studies of children with chronic liver disease 
(Chin et al., 1992, van Mourik et al., 2000). MUAC was also shown to be significantly lower in all 
the patients compared to the healthy children and it increased significantly after liver 
transplantation. Arm anthropometry has been shown to correlate strongly with FM in healthy 
children and in children with cystic fibrosis (Chomtho et al., 2006). 
The dilution studies, in spite of the initial methodological problems, were able to indicate an 
increase in total body water through water retention in the patients with ESCLD. When 
compared to the healthy children the TBW was not different between the 2 groups. From 
various other methods though, we have seen that at least some of the patients had reduced 
lean mass. In health, total body water is found in fat free mass. Therefore, if two children have 
the same TBW, but one has reduced lean mass, this implies that this child has fluid retention. 
The dilution studies also demonstrated a reduction in the TBW and the ECW after liver 
transplantation as would be expected with disease related fluid retention. The study by Morgan 
et al (Morgan et al., 2006) in adults with stable cirrhosis and no overt oedema has shown that 
on the basis of deuterium dilution studies FM was well above 10% of BW and there was 
evidence of fluid retention even without obvious oedema. To my knowledge there are no 
deuterium dilution studies reported on children with liver disease. These results were in 
accordance with the DXA scan results which did not show a significant increase in lean mass 
post-transplant (expressed as sd score), and therefore an increase in the TBW post-transplant 
would not be expected (also expressed as sd score) as a result of increased lean mass. 
All patients and healthy controls over 4 years of age had the BOD POD. The BOD POD does 
require a high degree of co-operation from the children and care must be taken that the children 
are in the appropriate attire for the measurements to be accurate. All the BOD POD 
measurements were done following the same protocol and the measurements had to be within 
narrow limits of agreement, before they were accepted. Only one patient had a significantly low 
BMI sd score (sd. score below -1.96), but actually her FM and FFM sd scores based on the 
BOD POD were within the normal range. She was actually a very thin, but also tall girl. Based 
on the BOD POD, 3 other children were shown to have reduced FFM sd scores, below -1.96. 
This would be in spite of the presence of organomegaly. When compared to DXA and 
deuterium dilution studies, BOD POD tended to overestimate fat mass (Wells and Fewtrell, 
2006). As fat free mass is derived from the FM, this would lead to an underestimation of the 
159 
 
FFM. BOD POD is designed to measure body volume. BOD POD has been evaluated in 
healthy children with a variety of body shapes and it has been found accurate when done well 
(Wells et al., 2011, Wells and Fuller, 2001). Patients with ESCLD often have a particular body 
shape meaning that the same body volume between a patient with ESCLD and a healthy 
person does not imply the same composition and therefore the BOD POD equations used to 
derive the FM may not apply to these patients in the same way that they apply to the healthy 
children (Dewit et al., 2000). Again to my knowledge there are no air displacement 
plethysmography studies that have been reported on children with ESCLD. 
DXA is designed to measure BMC and BMD. It is clear that our patients had a low whole body 
bone mineral density. This is in accordance with other studies looking into bone health of 
children with chronic liver disease (Hogler et al., 2012, Kryskiewicz et al., 2012) and in fact the 
mean total body BMD of our patients (-1.43) was lower than the mean (-1.0) described in the 
study by Kryskiewicz et al which includes 18 children.  Both studies found vitamin D levels to be 
unrelated to the BMD. In this study lumbar region DXA was not performed, which is the 
essential criterion for the diagnosis of osteopenia. DXA measured BMC which was used for the 
4C model, but could also be used as a 2C body composition method. DXA had several 
advantages. It was a simple and quick technique that required minimal co-operation from the 
patient and with only minimal doses of radiation. It had the added advantage of giving regional 
data. Concerns have been raised about the accuracy of DXA soft tissue evaluation in the trunk 
as it involves substantial prediction rather than measurement (Wells and Fewtrell, 2006). This 
could be of particular relevance to the patients prior to liver transplantation, with relatively 
distended abdomens, where the measurements of total or trunk LM and FM would not be 
accurate. The measurements from DXA were also converted to indices in order to remove the 
effect of height, in a method analogous to that of BMI. The indexed variables were assigned the 
appropriate sd scores to allow comparisons. Some of these patients were stunted therefore 
correcting for height gave a more accurate representation of the extent of lean mass or fat loss 
mass they may have. DXA has not been used to report regional and whole body composition 
data on children with chronic liver disease, even though it has been used to study BMD. In adult 
studies, where DXA has been used, differences in FM between cirrhotic patients and controls 
have been reported mostly as not significant with the exception of trunk FM in females (Riggio 
et al., 1997), which has been reported reduced. 
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As with the dilution studies and the BOD POD, so with the DXA, FM remained remarkably within 
normal limits for the patients. This does not mean that these patients were not in the process of 
losing fat, but in spite of advanced disease their fat stores appeared preserved and this was 
true for regional FM (arm, leg and trunk) and remained true when FM was corrected for height 
as FMI. Even the children who had depleted LM and had very low sd scores for LMI, had FM 
indices in the normal range. To my knowledge this distinction has not been made before in 
children with ESCLD or chronic disease in general. Looking closely at the study of Greer et al 
(Greer et al., 2003) it reports a lower FM of 17% in the children with liver disease in comparison 
to the 20% of the healthy children, but with no statistical significance between the two means.  
As mentioned in the introduction, defining cachexia in adults has had its challenges, but some 
definitions do exist, whereas in children the situation is more obscure. Defining cachexia as a 
BMI < 5th centile would mean only one patient being cachectic from our cohort and if the 
definition was FM < 10% then none of the patients would qualify as cachectic. Cachexia though, 
as per its definition, is characterised by loss of muscle with or without loss of fat mass (Evans et 
al., 2008). This definition though applies mostly to patients with cancer, heart failure, COPD etc. 
and therefore not patients where organomegaly is common. For patients with ESCLD the 
method which most appropriately assesses appendicular lean mass loss is the whole body 
DXA. Weight overestimates ‘true’ weight, because of the water retention and the organomegaly, 
TBW for the same reasons overestimates lean mass and BOD POD cannot differentiate trunk 
lean mass from limbs, whereas DXA can provide this valuable differentiation. In fact looking at 
the DXA results, the trunk LMI indices were all normal or higher than normal most likely 
because of the organomegaly. If cachexia was defined in our patients as a LMI of either arm or 
leg below an sd score of -1.96 then 4 of the eleven children who had DXA scans would be 
cachectic. 
The REE results are interesting. When compared to the prediction equations, a significant 
number of children were hypermetabolic, but actually so were a significant number of the 
healthy children. The equations used are underestimating the REE. This could be due to 
differences in the study population and the cohorts used to generate the equations and because 
of differences in the methodology used to measure the REE. The Henry 2005 equations were 
based on 166 studies and include data on 10552 people. They are an improvement of the 
previous Schofield (Schofield, 1985) equations, because they are more contemporary and they 
have excluded the very large proportion of Italian data in the previous data set used by 
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Schofield. These equations predict BMR and BMR is measured after a 10-12 hour fast with the 
subject at rest. REE is any measurement done with a shorter interval of fasting, therefore one 
would expect REE to be higher than BMR. This also means that when studies report on REE 
and talk about hypermetabolism by comparing to BMR from prediction equations, one has to be 
wary of how the REE measured in the study. The advantage in this study was the 
measurements of the healthy controls. They were done following the same protocol and by the 
same person and therefore systematic error could be minimised. The study by Carpenter et al 
(Carpenter et al., 2017) looked into measured REE versus predicted REE in children with end 
stage liver disease and found that the equations were not suitable of accurate prediction of the 
children’s energy requirements. 
Expressing REE per kg of weight helps make comparisons between the different patients. None 
of the patients had overt ascites and only one was on diuretics, but of course weight is 
overestimated as there is a degree of fluid retention. Differences in REE/kg were not related to 
outcomes, but what was striking, was that REE/kg before liver transplant determined REE/kg 
after liver transplant. This has been shown in adult patients with cirrhosis and it implies that 
REE/kg depends more on idiosyncratic characteristics of the patients (age, genetics etc.) rather 
than the disease itself (Muller et al., 1994b). Some authors are in favour of expressing REE per 
kg weight of fat free mass, as fat free mass is considered the most active tissue from a 
metabolic point of view. If a patient and a healthy person had the same REE and the same 
weight, but the patient had a lower FFM, then the patient’s ratio of REE/kg of FFM would be 
higher than that of the healthy person, indicating they are hypermetabolic. There are though 
some inherent problems with this approach. Fat free mass includes bone, organs and muscle 
and these elements clearly have a very different metabolic profile and very different energy 
consumption e.g. muscle contributes 20% to REE whereas the organs 60%. Patients are likely 
to have a different composition of their FFM, which may not allow a direct comparison with 
someone healthy. The relationship between FFM and REE is not linear for the full range of FFM 
and the y-intercept of this relationship is very different to zero. In addition to this measuring FFM 
in patients frequently comes with its one challenges and inaccuracies. Focusing on a narrower 
age group of patients with more patients in that group and by including healthy controls, one 
would be able to make more representative observations for the REE of that age group of 
patients. Various studies have noted that the presence of hypermetabolism or not is not related 
to the severity of the liver disease (Ferreira et al., 2014, Prieto-Frias et al., 2016) and have 
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shown that hypermetabolism after transplantation is correlated to the presence of 
hypermetabolism before transplantation (Ferreira et al., 2013). 
Bioelectrical impedance in spite of being a very easy to use bedside technique did not add 
much value to the assessment of the patients. BIA machines use equations that are suitable for 
older patients and the normative data that was available applied to children over the age of 10 
years. For BIA to be used more extensively, normative data for the younger children are 
needed, as are studies of the children who are unwell, so that equations suitable for the latter 
are generated. Bioelectrical vector analysis (BIVA) would be more useful and could be used for 
the management of individual patients, but again normative data for children in the UK are 
required. 
3D photonic scanning is a technique that has only relatively recently been used for assessment 
of body composition. It is not a validated technique. It is though fairly simple for the children to 
follow and probably the most fun out of all the techniques used in this study. Once this method 
is validated, it could be easily used to establish more objective anthropometric measurements 
on the patients (Ng et al., 2016) and certainly the results from this study look promising. 
In terms of body composition before and after the liver transplant the mean follow up in this 
study was 11.4 months. The body composition indices after transplant were strongly influenced 
by the indices before transplant. There was an indication from the DXA scan that fat mass 
increased after liver transplantation with a small increase in lean mass. In fact one patient had 
worse LM indices after transplantation. It may be though that these children need to be studied 
5 and 10 years after their transplant or even later as adults in order for body composition 
changes to be more apparent. As mentioned in the introduction, adult studies confirm an 
increase in fat mass 1-2 years post liver transplantation. 
Looking at the comparison between the various methods, basic anthropometry still has a role, 
particularly in regards to BMI, MUAC and subscapular skinfold thickness and their correlation 
with length of stay in hospital after liver transplantation. The advantage in our study in using 
basic anthropometry was that all the measurement were done by the same person. This 
wouldn’t be feasible in every day practice. If more detailed studies are required then whole body 
DXA had a good agreement with the 4C model and is a fairly simple, safe and accessible 
technique to use. One does though need access to appropriate normative data to compare the 
measurements with. The biggest advantage of the DXA scan is the regional data it may provide. 
In this study it helped highlight some striking deficits in arm and leg lean mass in our patients. 
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Deuterium dilution studies are also a feasible option that can be applied for all ages and 
therefore may generate comparable results. In addition normative data exist. The disadvantage 
with deuterium dilution is that it is a multi-step procedure requiring precision and consistency 
throughout for it to be successful. Deuterium also had good agreement with DXA and the 4C 
model. 
Throughout the study fat mass was demonstrated to be in the normal range. Deuterium which 
was performed on all the children identified 3 children with a relatively low percentage of fat 
mass, less than 15%. None of the children with valid deuterium results, were had less than 10% 
fat mass, which would be considered abnormal. Two of these 3 children were old enough to 
have a DXA scan and their FM indices sd scores were not below -1.96 (< 5th centile), but they 
did have the lowest FM indices of the cohort. Only 2 of these 3 children with the relatively low 
fat mass have been transplanted and indeed they had the longest stay in hospital. 
Whereas the strength of this work is its prospective nature, the performance of studies not 
previously done with children with ESCLD and that the various measurements were done by 
one individual, there are also limitations. The first limitation has to do with the number of 
patients recruited. This was a pilot study, but there were difficulties in recruiting patients. 
ESCLD is a rare condition with a limited number of patients on the liver transplant waiting list 
eligible for recruitment and, in addition to this, the patients also had to live close enough to the 2 
sites where the study was done and also to be well enough for a fairly lengthy process of 
measurements. The most common indication for liver transplantation in children is biliary 
atresia. The relatively small number of patients studied meant that it was not possible to study 
patients of only one disease or to have many patients for each different disease. In order to 
make it possible to study more patients, the ages of the patients covered the whole range for 
transplantation for chronic liver disease. The relatively small number of patients means that 
generalisation of the results is limited. One way to address this issue in future studies would be 
to collaborate with other units and therefore increase the pool of patients. 
The patients were assessed once they were on the liver transplant waiting list and of course 
there was no control as to when their liver transplant would be. This meant that that the patients 
were assessed at varying stages of their disease journey and of course may have deteriorated 
further by the time the tissue was collected during transplantation. This is an inherent issue for 
studies of people on transplant waiting lists and their outcomes (Selberg et al., 1997) . After 
transplantation the minimum time for follow up body composition measurements was 6 months 
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and for some it went up to 2 years. This time scale is comparable to other studies that have 
looked at body composition before and after liver transplantation (Muller et al., 1992b). Again 
this variation in the timing of the post-transplant measurements hinders comparisons and of 
course the longer the time the more it allows for changes in height or even lean mass potentially 
to show. Nevertheless there are very few if any studies of children comparing pre and post liver 
transplant body composition measurements and one needs to work round the children, 
particularly the ones that suffer complications after the transplant. 
Another limitation of the study had to do with the varying number of children that had valid 
results for each method of body composition either because of protocol or because of 
methodological difficulties. This limits of course the comparisons between the various methods 
but considerable insight has been gained in identifying pitfalls and challenges in applying the 
various methods accurately and in identifying which methods are most suitable and well 
received by the patients. 
In summary, the findings of this study indicate that in this cohort of children with ESCLD fat 
mass was relatively preserved and body composition indices related to fat mass were the ones 
that correlated significantly to length of stay in hospital after liver transplantation. 
 
Tissue Studies 
In this thesis microarray validated by qPCR was used to study potential differences in metabolic 
pathways between patients with ESCLD. Microarray analysis of gene expression in tissue is 
helpful in identifying patterns that can subsequently guide further experiments. The results from 
the analysis of liver tissue from 9 children with ESCLD and 2 children with Crigler-Najjar type 1, 
as well as muscle and fat  tissue form 11 children with ESCLD and 2 children with Crigler-Najjar 
type 1 were summarised at the beginning of this chapter. 
In regards to the tissue studies, the obvious limitation is having suitable control tissue to 
compare the results. This was a unique part of the study that has been done for the first time. 
As the interest was in metabolic pathways, there had to be patients having similar operations so 
that systematic error introduced by the type of operation would be minimised. Patients with 
Crigler-Najjar type 1 are not of course entirely normal, but they are the closest to a normal child 
from a metabolism point of view having a liver transplant and without of course having ESCLD. 
We would not expect the Crigler-Najjar patients to be cachectic or to have abnormalities in their 
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body composition. They did not have their body composition measured, because their 
involvement in the study was to provide control tissue for the tissue studies. 
By using Qlucore Omics Explorer version 3.2 we were able to separate our cohort of children 
into 2 groups. These 2 groups had differences in the genes expression levels in their various 
tissue, muscle, fat and liver, and the software was able to help identify the genes that 
contributed most to this variability.  Subsequently the use of GeneGo MetacoreTM software 
helped build networks based on this gene expression variability. 
In the muscle tissue it was clear that a subset of the subjects showed an increase in expression 
levels of IL6 and SOCS3. IL6 is a cytokine with a role in regulating other cytokines with pro-
inflammatory and anti-inflammatory properties. IL6 has been described in promoting cachexia 
and muscle wasting (Chen et al., 2016, Munoz-Canoves et al., 2013), but IL6 is also known as a 
myokine- a cytokine that can be produced by contracting skeletal muscle after exercise 
(Pedersen and Febbraio, 2008). There is a lot of controversy round the role of IL6 in insulin 
resistance.  IL6 can be produced by many different types of cells most usually the monocytes 
and macrophages in response to acute and chronic inflammation (Kreutz et al., 1997), Exercise 
is accepted to be a way of increasing insulin sensitivity, whilst IL6 is also linked to obesity and 
insulin resistance (Piya et al., 2013). IL6 produced in skeletal muscle can be produced 
independently to systemic inflammation and has been linked to low muscle glycogen levels 
(Keller et al., 2001, Steensberg et al., 2001). IL6 via its receptor pg130, activates JAKs which in 
turn phosphorylate STAT3 (Xu and Neamati, 2013). This leads to an increased expression of 
SOCS3 (Starr et al., 1997), which has a role as a negative regulator of IL6 expression.  
SOCS3 has some interesting interactions. SOCS3 is implicated in leptin resistance. Leptin 
binds to a receptor similar, but not the same, to that of IL6 and induces SOCS3 via pSTAT3 
(Banks et al., 2000). Cells that overexpress SOCS3 develop leptin resistance and whereas 
leptin can normally activate the AMPK pathway, in cells where SOCS3 is overexpressed it 
cannot (Wolsk et al., 2011, Yang et al., 2012). Furthermore, SOCS3 is implicated in insulin 
resistance by inhibiting IR, IRS1 and IRS2 (Yang et al., 2012). 
It has been shown that e.g. after exercise IL6, in a similar way to leptin, mediates improved 
glucose uptake and insulin sensitivity by activating AMPK without requiring STAT3 (Carey et al., 
2006, Watt et al., 2006). It has been suggested that perhaps SOCS3 in conditions of chronic 
inflammation like in obesity, is able to blunt the ability of IL6 to activate AMPK (Sarvas et al., 
2013). In the data presented here, there was indication of increased inflammation. The patients 
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with the increased expression of IL6 in their skeletal muscle also had increased SAA1 (serum 
amyloid A1), CCL2, SELE (selectin E is a chemokine which is increased in cytokine stimulated 
endothelial cells) indicating an environment of inflammation. Perhaps the high levels of SOCS3 
in these conditions of inflammation were contributing to a blunted activation of the AMPK 
pathway by IL6 whereas also inducing insulin resistance with downregulation of the insulin 
receptors. 
Insulin resistance is very well described in patients with ESCLD (Selberg et al., 1993) and in 
patients with chronic disease in general (Gorjao et al., 2012). The mechanism though of how 
insulin resistance develops in cirrhosis is not known. Insulin resistance is known to be 
associated with cachexia (Evans et al., 2008).  It is far from clear if it is a coexisting 
characteristic or if it is actually involved in the mechanism of cachexia. Activation of the AMPK 
pathway, which is a catabolic pathway, leads to improved insulin sensitivity (Steinberg and 
Kemp, 2009); this is very well described. It may be that actually insulin resistance is a protective 
mechanism for the body, particularly in conditions of inflammation, by which it is trying to 
conserve energy for the inflammatory response.  
In regards to the AMPK pathway, in the muscle studied there was not much evidence to support 
activation of the AMPK pathway. When looking at the expression levels of some relevant genes 
there was a slight increase in AMPKα1, and a down regulation of GLUT4, PGC1a and an 
upregulation of FAS. These parameters indicate an overall down-regulation of AMPK. In 
regards to muscle atrophy, myostatin (MSTN) was down regulated and we found no evidence of 
increased expression of the atrogenes (MuRF-1 and MAFbx) and therefore no evidence to 
support increased muscle wasting. The functional studies that are to follow will shed more light 
on the actual protein expression of the AMPK and the IL6/STAT3/SOCS3 pathways and their 
potential interaction. 
The other highlighted significant networks that came up in the muscle (both with unsupervised 
and supervised clustering of the sub groups) were linked to pathways related to inflammation 
mainly through CCL2, cell adhesion interactions and connective tissue degradation. The focus 
was mainly on the IL6/SOCS3 network, as it is significantly related to metabolism which was the 
main focus of this study. 
In the fat tissue, a similar cytokine profile to the muscle was noted. IL6 remained highly 
expressed, as did SOCS3. SOCS3 is known to induce insulin resistance in adipose tissue as 
well (Shi et al., 2006, Yang et al., 2010a). The analysis of the fat tissue also indicated an 
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increase in PAI-1, a protein coded by the SERPINE1 gene. The primary role of PAI-1 is to 
inhibit fibrinolysis. PAI-1 is also an acute phase protein and increased levels have been linked 
to systemic inflammation, obesity, insulin resistance and the metabolic syndrome (Iwaki et al., 
2012). 
The other networks highlighted as most significant in the fat tissue (either by supervised or 
unsupervised clustering) involved the NFκB mediated increased expression of IL6, IL8 and 
CCL2, as well as the IL8 mediated inhibition of PI3K and the upregulation of micro RNA miR-21-
5p which has been linked to tumour growth, but is also considered as a marker of endothelial 
dysfunction and inflammation (Olivieri et al., 2015). Of interest is that IL8 has been associated 
with inhibition of insulin induced Akt phosphorylation and in this way has been implicated in 
insulin resistance in adipose tissue (Kobashi et al., 2009). 
In regards to the AMPK pathway in particular, the only finding of note was the possible reduced 
expression of CAMKK2, which is one of the key activators of AMPK. There was also a reduced 
expression of IRS-1, so again an indication of insulin resistance. Therefore in the fat tissue just 
like in the muscle, the data indicated an increase in IL6 and SOCS3 and possible insulin 
resistance, as well as an increase in IL8. 
In the liver tissue, when unsupervised clustering was applied, the software divided the subjects 
into 2 groups, where in one group the patients were the two with the Crigler-Najjar syndrome 
type 1 and the patient with the Alagille syndrome. All the other patients including the one with 
the alpha 1 antitrypsin deficiency clustered together in the second group. Of note in this analysis 
was the significantly increased expression of IL8 seen in the group that included the biliary 
atresia. The other highly expressed genes mainly had to do with the extracellular matrix and 
fibrosis (VCAN, TIMP1, CTGF and EFEMP1) except for ACSL4 (an isoform of acyl-coA 
synthetase that activates long chain fatty acids for either synthesis of lipids or for fatty acid 
oxidation). Looking at the genes potentially related to the AMPK pathway, AMPKα2 was slightly 
increased whereas AMPKβ2 was decreased. PFKFB3, a key modulator of glycolysis, was 
increased and glycogen synthase was reduced, but without knowing the functional state of the 
protein product of these genes it is not possible to know if the AMPK pathway was activated or 
not. 
When supervised clustering was performed and the patients were separated to those with 
biliary atresia and to those with Crigler-Najjar type 1 and everyone else was excluded, IL8 was 
highly expressed in the liver of the children with biliary atresia. This finding is in accordance with 
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previous reports that IL8 expression is increased in the liver of children with biliary atresia and it 
is associated with inflammation and fibrosis (Dong and Zheng, 2015). 
The muscle and fat data analysis identified the subgroup of subjects 3, 8, 9 and 11 as different 
to the other subjects. The next step was to see what differentiated this subgroup from the other 
subjects in regards to their liver, as the liver was the site of the primary disease process. This 
analysis only included subjects 8, 9, 11 in group 1, as the liver tissue from subject 3 was too 
small to yield enough RNA and subsequently cDNA to undergo the microarray analysis. The 
liver tissue from subject 1 had to be excluded for the same reason from group 2. This analysis 
showed that these 3 patients (subjects 3, 8 and 11) had a significantly higher expression of FOS 
(4.7 fold increase) and FOSB (2 isoforms 11.04 and 5.77 fold increase) in the liver. FOS and 
FOSB are 2 of four members of the FOS family. They dimerize with members of the JUN family 
(c-JUN, JunB and JunD) to form the transcription factor complex AP-1 (activator protein 1). 
JunB was also significantly increased in the muscle and fat tissue of this same subgroup of 
patients. AP-1 has a wide variety of roles and is implicated in cancer, fibrosis and inflammatory 
disorders- it is a known key regulator of hepatocyte differentiation (Stepniak et al., 2006) and it 
is also involved in inflammation induced insulin resistance (Olefsky and Glass, 2010). 
In summary, the results of the tissue studies show with strong statistical significance that the 
gene transcripts of IL6 and SOCS3 are increased in the muscle and fat tissue of a subgroup of 
patients in comparison to the rest. From a liver point of view these patients differ in that they 
express high levels of FOS and FOSB. Taking all the data together one could hypothesize that 
these children show evidence of inflammatory mediated insulin resistance at a gene expression 
level. One could hypothesize that the inflammation originates in their liver and then mediates 
the insulin resistance via cytokines and chemokines in the muscle and adipose tissue possibly 
via macrophages. 
As mentioned when the outcome of these patients was discussed, the tendency was for these 
four patients to have a higher BMI, more LM and have a shorter stay in hospital after liver 
transplantation, even though the difference was not statistically significant with the numbers of 
this study. This seems rather perplexing. The body composition arm of the study indicated a 
tendency for preservation of fat mass and fat mass was a predictor of stay in hospital after the 
transplant operation. The field of study where we see inflammation and insulin resistance 
commonly is in obesity. Of course these patients were not obese, but one could speculate that 
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in conditions of inflammation, where the body needs energy for the inflammatory response, the 
body tries to preserve its fat stores, as part of its adaptation mechanism to sickness.  
The sickness behaviour of reduced appetite, less movement and insulin resistance could be a 
way for the body to conserve energy. It is known that, in other situations of increased energy 
demand, the body has a tendency towards insulin resistance e.g. in puberty (Kelsey and Zeitler, 
2016) and in pregnancy (Baeyens et al., 2016). Adult studies in other fields of disease, like 
coronary heart disease, are reporting that the more obese patients have better outcomes, 
particularly when there is evidence of higher inflammation (De Schutter et al., 2016). The 
obesity paradox therefore may not be a paradox at all. It may be part of what the body would try 
to do anyway in conditions of chronic inflammation and that would be to conserve energy. The 
development of inflammation mediated insulin resistance may be linked to the conservation of 




Chapter 7 Conclusions and Future Work 
This study started with some clinical questions. The first question was asking what the body 
composition and REE of children with ESCLD was before and after liver transplantation. The 
children with ESCLD studied and reported in this thesis had poor growth, some of them had 
significant loss of lean mass, particularly in the limbs and they all had relatively preserved fat 
mass. In addition they had fluid retention and an increase in ECW. Their REE was not 
increased when compared to healthy children. REE/kg remained similar before and after liver 
transplant. In regards to body composition after liver transplant, the fluid retention resolved and 
even though growth parameters improved overall this was mostly due to gain in fat mass. 
The second question asked if the children with a higher REE/kg had more complications and 
worse outcomes post liver transplant and if this increase in REE/kg remained after liver 
transplantation. The results showed no correlation between REE/kg and length of stay in 
hospital after liver transplantation or REE/kg and complications post liver transplantation. There 
was though a significant correlation of pre liver transplant and post liver transplant REE/kg. So 
in this way REE/kg either higher or lower before transplant persisted after transplant.  
The last question asked how the metabolic pathways, that control cell energy metabolism, are 
affected in children with ESCLD and how do they relate to body composition, resting energy 
expenditure and outcomes. The analysis performed so far indicates that pathways implicated in 
inflammation related insulin resistance are upregulated in a subgroup of these patients. These 
pathways are similar to those implicated in obesity related insulin resistance and it may be that 
their upregulation is linked to the notable preservation of fat mass demonstrated in these 
patients. A link between these pathways and REE was not demonstrated. In regards to 
outcomes there were no clear differences between the two groups of patients. There was some 
indication that these patients had more lean mass and tended to be discharged home sooner. It 
is important to note that the only 2 episodes of hepatic artery thrombosis noted in this cohort 
were in this group of patients. 
In conclusion, the children with end stage liver disease of this study had evidence of fluid 
retention and loss of lean mass whilst their fat mass remained within the normal range. Body 
composition indices reflecting fat mass had a negative correlation with stay in hospital after liver 
transplantation i.e. less fat mass correlated with a longer stay in hospital. The children were not 
hypermetabolic. The tissue studies strongly indicated the higher expression of genes related to 
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inflammation mediated insulin resistance in a subgroup of these patients and to our knowledge 
this is the first time this has been shown in children with end stage chronic liver disease.  
Future work 
There is more work needed to complete this study. In regards to the body composition studies 
some more children are planned to have their body composition studies performed. Three of the 
children that have had their liver transplantation are planned to have their repeat post liver 
transplant body composition in the next 3 months. There is also a child still waiting to be 
transplanted, who will also need his body composition repeated after his transplant. In addition, 
three more controls need to have their body composition, they have also been scheduled for the 
next 3 months. 
In regards to the tissue studies, tissue has been collected from children who have had their liver 
transplants, but they were not in time for the tissue samples to be analysed with the ones 
presented in this thesis. One additional child with Crigler-Najjar type 1 has been recruited, who 
has yet to have his liver transplant. These samples, together with the ones from the child still 
waiting to be transplanted will be analysed in the same way as the ones presented here. 
So far from the tissue we have analysed gene expression with microarray and qPCR, but we 
also need to perform the functional assays. This will be a key point in delineating the pathways 
studied. E.g. STAT3 is a key regulator of the interaction between IL6 and SOCS3, but it is 
activated by phosphorylation, so it will be important to see if levels of phosphorylated STAT3 
protein are increased in line with the increase in IL6 and SOCS3. 
Insulin resistance has been clearly demonstrated in adults with cirrhosis (Selberg et al., 1993), 
but has not been actually demonstrated in children. The next step to take this work forward 
would be to measure insulin resistance in children with ESCLD, most likely with a 
hyperinsulinaemic euglycaemic clamp, whilst also assessing body composition (with whole body 
DXA and anthropometry) and combining this with tissue studies similar to this work with the 
addition of a cytokine profile from the children’s blood. In this way, one could document the 
degree of insulin resistance in children with ESCLD and its relationship with fat mass, cachexia 
and the IL6- SOCS3-IRS1 pathway. This study could then form a basis for longer term follow up 
of the children into adulthood. 
As previously discussed, chronic illness may trigger insulin resistance as a mechanism for the 
body to preserve energy and it is possible that certain individuals are more prone to this from a 
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genetic point of view. It is also possible that the individuals that develop insulin resistance 
during chronic illness may experience epigenetic changes that influence their insulin sensitivity 
and propensity to accumulate fat and therefore develop the metabolic syndrome increasingly 
described post transplantation in the future. This hypothesis would be in line with the capacity-
load theory for the development of insulin resistance and type 2 diabetes as described from 
populations that have previously experienced starvation and from children born at low birth 
weight (Wells, 2017). Being able to define these genetic or epigenetic changes in the future 
would be helpful in identifying the people at risk of developing metabolic syndrome in the 
context of chronic illness and this would pave the way in helping to improve their long term 
outcome particularly after transplantation. 
Finally, studying the role of the brain in the development of cachexia and/or inflammatory 
mediated insulin resistance would have a big impact in this field of research. The brain is likely 
to have a key role in affecting metabolism, but also is likely to be affected by these perturbations 
in metabolic profiles. We already know that liver disease at a young age impairs long term 
neurocognitive outcomes (Kyrana and Dhawan, 2017, Robertson et al., 2013, Lind et al., 2015). 
As the life expectancy of children with ESCLD has improved dramatically in the last few 
decades, we will need to gain a clearer understanding of how the brain is involved in this setting 
of liver dysfunction, chronic inflammation, cachexia and/ or insulin resistance and how these 
parameters may be manipulated to improve outcomes in a more holistic way for the children in 
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